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Abstract 
 
 
 Introduction: Mucosal human papillomavirus (HPV) infection is the most 
common sexually transmitted infection (STI) and is associated with genitals warts, 
anogenital cancers, and oropharyngeal cancers. Most sexually active persons will become 
infected with HPV at some point in their lives, however few will develop HPV-related 
diseases such as warts, lesions, or cancer as a result of the infection. It is unclear why a 
minority of individuals fail to clear HPV infection and develop clinical disease. Due to 
initial associations with cervical lesions, much research has focused on women. Th1 type 
immune responses have been associated with successful response to HPV infection. 
Factors such as psychological stress and sleep have been associated with immune 
function. Stress has been associated with cervical lesions, however no study has 
evaluated effects of stress or sleep on HPV infection. This research sought to examine the 
associations between perceived stress and sleep problems with HPV prevalence, 
incidence, and clearance among men.  
 Methods: Men were tested for 37 individual HPV genotypes every 6 months as 
part of a large natural history study. A total of 426 men were followed over 1 to 4 visits. 
Perceived stress was measured with a modified 4-item Perceived Stress Scale (PSS-4) 
assessing stress in the past six months and was dichotomized into high (scores in the 4th 
quartile) and low perceived stress. Self-reported sleep problems were measured by seven 
likert-scale items and categorized as high (4th quartile of sleep problems scores), 
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moderate (second and third quartiles; reference group), and low (first quartile). Three 
HPV classifications were examined; men were categorized as positive for 'Any HPV' if 
they tested positive for any of the 37 HPV genotypes in the study protocol, men were 
categorized as positive for 'Oncogenic HPV' if they tested positive for any oncogenic 
HPV type, and men were categorized as positive for 'Non-oncogenic HPV' if they tested 
positive for any non-oncogenic HPV genotype.  
 In the prevalence analysis, men who had no detectable HPV infection with any of 
the 37 types were the reference group in all analyses. Prevalence ratios and 95% 
confidence intervals (95% CI) were calculated using Poisson regression with robust 
variance. For HPV clearance and incidence, Cox regression with the robust sandwich 
estimator was used to calculated hazard ratios and 95% confidence intervals. 
 Results: A total of 424 men had genotyping results available for the prevalence 
analysis. High perceived stress was significantly associated with higher prevalence of any 
HPV infection [PR =1.33 (95% CI: 1.06-1.68)] and oncogenic HPV infection [PR=1.53 
(95% CI: 1.06-2.20)], adjusting for demographics, sexual behavior, and sleep problems. 
High self-reported sleep problems was significantly associated with higher prevalence of 
oncogenic HPV infection [PR=1.50 (95% CI:1.01-2.13)], adjusting for demographics, 
sexual behavior, and perceived stress. 
 Perceived stress and self-reported sleep problems were not associated with 
incidence of HPV infection. Perceived stress was not significantly associated with 
clearance of HPV infection overall. Among men 50 and older however, men with high 
stress were significantly less likely to clear any HPV infection than those with low stress 
adjusting for demographics, HR=0.09 (95% CI: 0.02-0.49). Compared to men with 
 ix 
moderate sleep problems, those with high sleep problems were significantly less likely to 
clear an infection with any HPV type, HR=0.68 (95% CI: 0.49-0.94), or an oncogenic 
HPV type, HR=0.51 (95% CI: 0.28-0.94), after adjustment for demographics and 
perceived stress. 
 Discussion: This is the first study to examine associations between HPV infection 
with perceived stress and self-reported sleep problems. It is also the largest study to 
examine associations between these exposures and an infection outcome. Results suggest 
that perceived stress and self-reported sleep problems have independent effects on HPV. 
Evaluation of perceived stress, biological indicators of stress, objective measures of 
sleep, and measurement of immune parameters may aid in further elucidating how stress 
and sleep disturbance are related to HPV infection. Determination of modifiable factors 
that can influence HPV infection may aid in the prevention of adverse disease outcomes 
related to infection with this virus. Examining the impact of factors such as perceived 
stress and sleep problems on HPV infection may aid in risk stratification of patients and 
allow more targeted interventions among those most at risk for developing disease. 
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Chapter 1: Introduction 
 
 
Background and Significance 
 
 Infection with one of the approximately 40 mucosal types of human 
papillomavirus (HPV) causes genital warts and is a necessary cause of cervical cancer1. 
These HPV types are also associated with 60-90% of other anogenital cancers and 25-
30% of oropharyngeal cancers2. Genital warts and lesions can be treated with medical 
procedures once they develop, however there is no antiviral treatment available that can 
cure HPV infection3. Although most individuals will be infected with HPV at some point 
in their lifetime, few will develop genital warts or cancer as a result of infection with 
HPV. It is persistent infection with an oncogenic strain of HPV which can lead to 
neoplastic lesions and eventually invasive cancers1. Few factors associated with HPV 
persistence have been identified thus far. Studies of HPV viral clearance and HPV-related 
diseases in women have found associations between smoking, oral contraceptive use, 
infection with other STIs, diet, and host factors with HPV persistence1. However, few 
studies have examined HPV persistence in men and factors that influence persistence in 
men remain to be elucidated4. Research is needed to advance the understanding of factors 
that influence HPV persistence in order to design interventions among men and women 
infected with HPV and decrease the risk of progression to clinical disease. Identification 
of factors associated with HPV persistence may also be beneficial in predicting patients 
at highest risk of progression. 
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Psychoneuroimmunology (PNI) is the study of the bidirectional links between the 
central nervous system (CNS), immune system, and endocrine system and the 
implications of these interactions for health and disease5,6. Psychological factors may 
play a role in the development and course of a range of diseases including infectious 
diseases and several cancers6,7. Psychosocial factors could effect HPV persistence 
through moderation of host immune responses8. Regression of genital warts and cervical 
lesions have been associated with increased cell-mediated or Th1 type immune 
responses9,10 and psychological stress has been associated with a decrease in Th1 type 
immune responses and a shift towards a Th2 type immune response11. Thus, stress may 
influence immunity and HPV persistence through this Th1 to Th2 shift. Sleep has also 
been shown to modify immune response, possibly through shared regulatory molecules12. 
Several studies have found an association between psychological stress and 
cervical lesions. While results of the small number of studies examining stress and 
cervical disease indicate an association, no study has examined the relationship between 
stress and HPV infection. A single study reported an association between sleep quality 
with number and percentage of helper T cells and percentage of cytotoxic T cells in 
women with cervical disease3, however the effect of sleep on HPV infection has not been 
evaluated.   
Specific Aims 
In order to further understand the possible role of stress and sleep on HPV 
infection, this research builds on two prospective cohort studies of HPV in men to 
examine the effect of self-reported perceived stress and sleep problems on HPV 
prevalence and clearance in men. HPV-positive men are compared to HPV-negative men 
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at the baseline visit to examine associations between perceived stress and self-reported 
sleep problems with prevalence of any HPV infection, oncogenic HPV infection, and 
non-oncogenic HPV infection. Among HPV-positive men, those who have the same HPV 
type detected at a following visit (type-specific persistent infection) are compared to men 
who test HPV-negative (HPV clearance) to examine associations between perceived 
stress and self-reported sleep problems with HPV clearance. Clearance of infection was 
defined as two consecutive negative visits following testing positive for a specific HPV 
type. Incidence of new type-specific HPV infection is also examined among HPV 
negative men. Whereas many previous studies used standard Cox proportional hazards 
models to evaluate HPV persistence, these methods do not allow all individual HPV 
types to be modeled simultaneously. This study utilized an extended Cox model13 to 
simultaneously model all HPV types individually, accounting for the correlation within 
individual subjects, and calculated a common HR across all HPV types, all oncogenic 
types, and all nononcogenic types.  
Perceived stress was measured with a modified version of the 4 item perceived 
stress scale (PSS-4)14 developed by Cohen et al. (1983)15. This scale attempts to measure 
the degree to which situations are appraised as stressful and determine how 
unpredictable, uncontrollable, and overloaded subjects consider their lives16. The three-
item version of the Jenkins Sleep Problems Scale (JSPS)17, which assess trouble falling 
asleep, trouble staying asleep, and waking up feeling tired was included as wells as 4 
items which assessed subjective sleep quality, sleep duration, ability to concentrate 
during the day, and sleep problem distress. 
The specific aims of this research were: 
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Aim 1: Examine associations between perceived stress and self-reported sleep problems 
in the past 6 months with prevalence of HPV among all participants. 
Aim 2: Evaluate the association between perceived stress and self-reported sleep 
problems with clearance of HPV infection in a cohort of HPV-positive men and 
incidence of HPV infection among HPV-negative men. 
This study is the largest to evaluate the effect of perceived stress or self-reported 
sleep problems with an infection outcome. Much of the previous research on perceived 
stress and sleep disturbance has focused on effects of certain immune system measures 
such as number and activity of NK cells and cytokines, however there is debate as to how 
these changes could affect clinical outcomes such as clearance of an infection. This study 
draws on multiple fields including epidemiology, biostatistics, PNI, and social science to 
contribute to further understanding factors associated with HPV infection. 
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Chapter 2: Self-reported perceived stress and sleep problems are associated with 
prevalence of Human Papillomavirus infection in U.S. men 
 
 
Abstract 
 Human Papillomavirus (HPV) is a common sexually transmitted infection 
associated with genital warts and ano-genital and oropharyngeal cancers. Th1 type 
immune responses are associated with successful response to HPV infection; however 
this does not occur for all people. Factors such as psychological stress and sleep have 
been associated with immune function. Stress has been associated with cervical disease; 
however no study has evaluated effects of stress or sleep on HPV infection. This study 
examined associations between perceived stress, self-reported sleep problems, and HPV 
prevalence in 426 men tested for 37 HPV genotypes. Perceived stress was measured with 
a modified 4-item Perceived Stress Scale (PSS-4) assessing stress in the past six months 
and was dichotomized into high (scores in the 4th quartile) and low perceived stress. 
Self-reported sleep problems were measured by seven likert-scale items and categorized 
as high (4th quartile of sleep problems scores), moderate (second and third quartiles; 
reference group), and low (first quartile). High perceived stress was significantly 
associated with higher prevalence of any HPV infection [PR =1.33 (95% CI: 1.06-1.68)] 
and oncogenic HPV infection [PR=1.53 (95% CI: 1.06-2.20)] adjusting for 
demographics, sexual behavior, and sleep problems. High self-reported sleep problems 
were significantly associated with higher prevalence of oncogenic HPV infection 
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[PR=1.50 (95% CI:1.01-2.13)] adjusting for demographics, sexual behavior, and 
perceived stress. Results suggest that perceived stress and self-reported sleep problems 
have independent effects on HPV. Further research is needed to examine whether 
perceived stress and sleep problems are associated with HPV acquisition or duration of 
infection. 
Introduction 
 Ano-genital Human Papillomavirus (HPV) infection is the most common sexually 
transmitted infection (STI). Most individuals who are sexually-active will become 
infected in their lifetime18 with an estimated 6.2 million incident infections annually in 
the US. There are approximately 40 HPV types which infect mucosal tissues such as the 
anogenital and aerodigestive tracts1. These types are classified as high-risk types, those 
associated with intraepithelial neoplasias and invasive carcinomas, or low-risk types, 
those associated with non-cancerous lesions such as genital warts19. Infection with 
multiple HPV types concurrently is common due to the shared route of sexual 
transmission1.  
 Despite the high prevalence of HPV, most of those infected with HPV will mount 
a successful immune response and clear the infection. Persistence of HPV infection 
increases the risk of intraepithelial lesions and invasive carcinoma. In women the average 
time to clearance of high risk types ranges from 8 to 14 months for oncogenic infection 
and 5 to 6 months for non-oncogenic infection20. Few studies have examined HPV 
incidence and clearance in men. In a large, longitudinal study conducted in Brazil, 
Mexico, and the US, oncogenic types had a slightly lower incidence per 1000 person 
months, 22.2 (95% CI: 19.8-24.9), compared to non-oncogenic types, 27.8 (95% CI: 
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24.8-31.0). Median time to clearance of oncogenic HPV was 7.2 months (95% CI: 6.7-
9.5) compared to 7.6 (95% CI: 6.8-9.3) for non-oncogenic HPV types4. 
Previous studies have found that stress can increase the severity and duration of 
infectious diseases, promote reactivation of latent viruses, and affect vaccine response21. 
Effects of stress on components of immunity including B and T cells, Natural Killer cells, 
and cytokines have been observed. The immune response may differ depending on the 
duration of the stress with brief stressors causing a shift from specific immunity to natural 
immunity and chronic stressors leading to a shift from a Th1 towards a Th2 weighted 
immune response7,11. Cytokines produced by these two subsets of T cells negatively 
regulate each other and the development of one can suppress the other subset. Th1 cells 
are involved in cell-mediated immunity, secreting interleukin (IL)-2, interferon (IFN)-γ, 
and tumor necrosis factor (TNF)-β and activating macrophages. Th2 cells support 
humoral immunity, activating B cell antibody responses and secreting IL-4, IL-5, IL-10, 
and IL-1322. Although the exact mechanism of a successful immune response to HPV 
infection is unknown Th1 immune responses have been associated with resolution of 
HPV infection10, genital warts9, and cervical intraepithelial lesions and cancer23-25. Thus, 
stress may impact HPV infection by suppressing Th1 immune responses. Although no 
studies examined the association between stress and HPV infection associations of stress 
with Herpes simplex virus type 2 (HSV-2), a viral STI, and cervical intraepithelial lesions 
and cancer have been studied. A meta-analysis of 11 prospective studies found a 
significant association between psychological stress and symptomatic genital HSV-2 
recurrence26. A more recent study also found significant associations between daily 
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distress and HSV-2 genital lesion frequency and onset27. Several studies report 
associations between measures of stress and cervical lesions in women28-32. 
Another factor which may be related to both stress and HPV infection is sleep 
disturbance. Short sleep duration (less than five hours per night) and poor sleep quality 
have been associated with increased risks of obesity, diabetes, hypertension, coronary 
heart disease, and mortality33,34. Previous research suggests that partial sleep deprivation 
(PSD) increases markers of systemic inflammation, TNF-α and IL-1β production, and 
secretion of IL-634. In several observational studies where participant's  regular sleep 
patterns were measured via self-report or electroencephalograph (EEG), significant 
associations with NK cell activity35,36 and NK cell number37 were found. In human 
experimental studies of exposure to rhino virus38,39 sleep efficacy and duration were 
associated with cold symptoms. The bi-directional communication between the brain and 
immune system suggests a route by which sleep has the ability to influence the immune 
system34. 
In addition, correlations between stress and sleep have been found40, and it has 
been suggested that sleep may mediate the relationship between stress and immunity37. If 
stress and sleep have an effect on immunity this could have implications for the host's 
ability to successfully respond to an HPV infection and subsequently influence disease 
development. No study has previously evaluated the association between stress and HPV 
infection or sleep and HPV infection. This study sought to examine the association 
between measures of perceived stress and self-reported sleep problems with prevalence 
of genital HPV infection among men. 
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Methods 
Participants 
 This research is part of two larger studies of HPV in men, The Natural History of 
HPV in Men (HIM) Study and the Cognitive and Emotional Responses (CER) Study. 
Details of the parent studies have been reported previously. In brief, the HIM study is a 
prospective natural history study of HPV in men from the Central Florida area, Sao 
Paulo, Brazil and Morelos, Mexico4,41. Men are followed for 10 visits scheduled every six 
months. At each visit a sexual history computer-assisted self interview (CASI) 
questionnaire is administered, a visual inspection of the skin and external genitalia is 
conducted, external genital skin samples are collected for HPV testing (current HPV 
status), and participants are told results of the HPV test of their study visit 6 months prior 
(previous HPV status). Men are recruited regardless of their HPV status and both HPV-
positive and HPV-negative men were enrolled in the study. Because of the transient 
nature of HPV infection men can transition from positive to negative and negative to 
positive throughout the study. 
 A subset of HIM study participants in the US were invited to also participate in 
the CER study. This is the behavioral arm of the larger HIM Study conducted among the 
US cohort of men42, and assesses men’s cognitive and emotional responses to receiving 
an HPV test result. At their first  HIM study follow-up visit men are invited to participate 
in the CER study. After providing informed consent men complete the CER CASI 
approximately two to four weeks after completing their follow-up HIM study visit 
(current HIM study visit). At the time men complete the CER questionnaire, they are 
aware of their previous HPV status from approximately 6 months ago, but do not know 
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their current HPV status collected at the HIM visit 2-4 weeks prior to the CER visit. 
Figure 1 presents a timeline of the HIM and CER studies. 
 As part of the CER study protocol men were followed over a total of 2 years and 
completed the CER survey after each of 4 HIM visits. Items concerning perceived stress 
and sleep problems were added to the CER CASI in June 2009. This was approximately 
midway through CER participant recruitment and 55 participants had already completed 
data collection of all 4 study visits. CER participants who completed the additional stress 
and sleep items at least one time and within 45 days of their corresponding current HIM 
visit were eligible for this analysis. Only data from participant’s first eligible CER visit 
are included in this cross-sectional analysis of HPV prevalence. The study was approved 
by the University of South Florida Institutional Review Board. 
Measures 
 
Perceived Stress 
 
 A modified version of the 4-item Perceived Stress Scale (PSS-4)16 was used to 
assess self-reported perceived stress on the CER questionnaire. The PSS-4 was designed 
to determine how unpredictable, uncontrollable, and overloaded individuals consider 
their lives. Response categories are on a 5-point likert scale ranging from never to very 
often16. Because participants in the HIM study are assessed every six months, yet the 
original scale assesses stress in the previous month, PSS-4 items were modified to assess 
stress in the past six months as reported in a comparison study of the 1-month and 6-
month PSS and a life events scale by43. Responses were summed to create a perceived 
stress score with higher scores indicating higher perceived stress. Cronbach's alpha was 
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0.65 for the stress scale. This is similar to 0.60, which was reported by the original 
authors for the 4 item version of the scale16. 
 A previous study of stress and HSV in women found that only high levels of 
stress were associated with lesion onset and stress was dichotomized as 'high' or 'low'27. 
In the present study continuous stress scale scores ranged from 0 to 15 and were divided 
into quartiles as follows; first quartile: 0 to 2, second quartile: 3 and 4, third quartile: 5 
and 6, fourth quartile: 7 to 15. Inspection of the association between HPV prevalence and 
perceived stress indicated that the relationship may not be linear. The highest prevalence 
of HPV was observed among men in the highest quartile of perceived stress; men in the 
lower three quartiles had a similar prevalence of HPV. Therefore, the perceived stress 
exposure variable was categorized as high if participants scored in the highest quartile of 
stress, and low if the perceived stress score was in the lower three quartiles. 
Self-reported Sleep Problems 
 
 Seven items concerning subjective sleep problems were added to the CER 
questionnaire. The three-item version of the Jenkins sleep problems scale (JSPS), a brief 
reliable scale17, assessed trouble falling asleep, trouble staying asleep, and waking up 
feeling tired. Four additional items assessed sleep duration, subjective sleep quality, 
daytime functioning, and sleep distress. The subjective sleep quality item asks 
participants to rate their sleep quality overall and is on a four point likert-scale ranging 
from very good to very bad. The sleep duration item asks participants how many hours 
and minutes of sleep they get at night. Duration of sleep time was divided into four 
categories;  ≥ 7 hours per night, 6 to <7 hours per night, 5 to <6 hours per night, and <5 
hours per night, as in the coding for the Pittsburg Sleep Quality Index (PSQI)44. Two 
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four-point likert items: “Does not sleeping affect your ability to concentrate or get things 
done during the day?”, and “How bothered are you by your sleep problems?” assessed 
daytime functioning and sleep distress. Responses to the seven sleep items were summed 
to create a sleep problems scale with higher scores indicating more sleep problems and 
shorter sleep duration. Sleep problems items had good internal consistency (Cronbach's 
alpha=0.79) and a factor analysis indicated all seven items loaded on a single factor. 
 Sleep problems scores demonstrated a different association with HPV prevalence 
than perceived stress; men with scores in the second and third quartiles of the sleep 
problems scale had the lowest prevalence of HPV. A follow-up study of weight gain and 
sleep problems measured via the four-item JSPS found a similar pattern with men who 
had the lowest summary sleep problems having the highest proportion of weight gain 
(27% gained 5 kg or more) followed by those with the highest sleep problems (26%), and 
men in the two middle categories (24% and 23%)45. Continuous sleep problems scale 
scores ranged from 0 to 21 and were divided into quartiles as follows; first quartile: 0 to 
4, second quartile: 5 and 6, third quartile: 7 to 10, fourth quartile: 11 to 21. The self-
reported sleep problems exposure variable was categorized as low if participants scored 
in the bottom 25% of sleep problems scores and high if participants scored in the top 25% 
of sleep problems scores.  Men in the middle 50% were categorized as moderate and 
were selected as the reference group in all analyses because this group had the lowest 
prevalence of HPV. Models using the four quartiles as separate groups were also 
examined; the second quartile was the reference group as this group had the lowest HPV 
prevalence. These models yielded the same results as the categorized sleep variable; 
therefore we only present results of the categorized models. 
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Demographics and Sexual Behaviors 
 
 Single items assessed race, ethnicity, marital status, education, and health 
insurance status. Age was calculated using the participant's date of birth and date of study 
visit. Consistent with research among HIV-positive individuals46,47, men aged 50 and 
older were categorized as 'older men.' Men younger than 50 were divided into four 
approximately equal groups. At each study visit, participants are asked whether they had 
sex in the past six months. Men who had sex were then asked about the number of 
vaginal sex partners they had in the past six months. Number of vaginal sex partners was 
categorized as zero (men who had not had sex in the past six months), one vaginal sex 
partner, and two or more vaginal sex partners. Lifetime number of sex partners was 
calculated by summing the number of female partners and male partners reported at each 
study visit. 
HPV Status 
 
 HPV status from participant's HIM study visit 2-4 weeks prior to assessing 
perceived stress and sleep problems was the outcome for this analysis. Exfoliated penile 
cell samples were tested for HPV DNA using polymerase chain reaction (PCR) 
amplification of a fragment of the HPV L1 gene. Samples were tested for 37 individual 
HPV genotypes41. Thirteen HPV types were categorized as oncogenic: 16, 18, 31, 33, 35, 
39, 45, 51, 52, 56, 58, 59, and 6848. The remaining HPV types were categorized as non-
oncogenic: 6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 67, 66, 69, 70, 71, 72, 73, 81, 82, 83, 
84, 89, and IS39.  
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Statistical Analysis 
 
 Three HPV classifications were examined. Men were categorized as positive for 
'Any HPV' if they tested positive for any of the 37 HPV genotypes in the study protocol. 
Men were categorized as positive for 'Oncogenic HPV' if they tested positive for any 
oncogenic HPV type, regardless of also testing positive for a non-oncogenic HPV type. 
Men were categorized as positive for 'Non-oncogenic HPV' if they only tested positive 
for one or more non-oncogenic HPV genotypes. Samples that were positive for HPV on 
PCR but failed to hybridize with a specific HPV type were considered unclassified. It is 
unclear whether these were true HPV infections or coamplification of other genes41. 
Among men in this sample those with only unclassified infections reported similar sexual 
behaviors to men with no detectable HPV infection, therefore men with unclassified 
infections were grouped with men who had no detectable HPV infection  and formed the 
reference group in all analyses. This approach has been used previously in the analysis of 
HPV infection data49 and if considering men with unclassified HPV types as negative 
were a misclassification of the outcome this would only attenuate associations.  
 A total of 426 men completed the study questionnaire; 425 completed all four of 
the stress items of which 423 had HPV genotyping available for data analysis and 418 
completed all of the sleep problems items of which 416 had HPV genotyping available. 
Prevalence ratios and 95% confidence intervals (95% CI) were calculated using Poisson 
regression with robust variance50 to examine associations between perceived stress, self-
reported sleep problems, and HPV prevalence.  
 The majority of men in this sample reported their race as white (68%), their 
ethnicity as non-Hispanic (82%), and were circumcised (79%) as determined by the study 
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clinician. These factors were not significantly associated with HPV status in this sample 
and were not included in multivariable models. Multivariable log-linear analyses for 
perceived stress were adjusted for age in years, health insurance status, education, marital 
status, and number of vaginal sex partners in the past six months. Smoking and alcohol 
were not adjusted for in the stress multivariable model as we hypothesized that these 
factors would likely be in the causal pathway from perceived stress to HPV status; i.e. 
stress can affect smoking and alcohol which can then affect HPV status. A second 
multivariable model also adjusted for sleep problems.  
 Multivariable analyses for self-reported sleep problems were adjusted for age in 
years, health insurance status, education, marital status, lifetime number of sex partners, 
smoking status, and alcohol consumption. A second multivariable model also adjusted for 
perceived stress. The genmod procedure in SAS version 9.3 (Cary, NC) was used to 
conduct statistical analyses. 
Results 
 
Characteristics of the Study Sample 
 
 Demographic variables by perceived stress and self-reported sleep problems can 
be found in Table 2.1 and by HPV status in Table 2.4. Study participants ranged in age 
from 18 to 70 (Mean = 31.2 ±13.4); 58 (14%) were aged 50 or older.  Most men had 
health insurance (74%), were single (59%), and had at least some college education 
(88%). Of the participants, 234 were HPV negative, 99 were positive for an oncogenic 
HPV type, and 91 men were positive for only a non-oncogenic HPV type (Table 2.1). 
Among men with an oncogenic HPV infection, 67 were also positive for a non-oncogenic 
type (data not shown). One hundred one men (24%) were categorized as having high 
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stress and 324 were categorized as low stress. One hundred eleven men (27%) were 
categorized as having low sleep problems, 208 as moderate sleep problems (50%), and 98 
as high sleep problems (24%).  
 Table 2.1 presents demographic characteristics by perceived stress and self-
reported sleep problems categories. There were significant differences in perceived stress 
only by education and smoking. Self-reported sleep problems differed significantly by 
age group, marital status, smoking status, and lifetime number of sexual partners. 
Associations between Perceived Stress and HPV Prevalence 
 
 The prevalence of any HPV, oncogenic HPV, and non-oncogenic HPV was 
higher among men with high stress compared to men with low stress (55% vs. 42% for 
any HPV; 39% vs. 27% for oncogenic HPV; and 36% vs. 26% for non-oncogenic HPV). 
High perceived stress was significantly associated with higher prevalence of any HPV 
type (PR=1.31, 95% CI: 1.05-1.63), and any oncogenic HPV type (PR=1.45, 95% CI: 
1.02-2.05). The association between perceived stress and prevalence of any HPV type 
and any oncogenic HPV type remained significant after adjusting for demographics 
(model 1: PR=1.37 (95% CI: 1.10-1.70) and PR=1.60 (95% CI: 1.14-2.24), respectively 
and sleep problems (model 2: PR=1.33 ( 95% CI: 1.06-1.68) and PR=1.53 ( 95% CI: 
1.06-2.20), respectively). Men with high perceived stress did not have a significantly 
higher prevalence of any non-oncogenic HPV type (Table 2.3). 
 Adjustment for smoking and alcohol attenuated estimates slightly, but 
associations between any HPV and oncogenic HPV remained significant (data not 
shown). When stratified by previous HPV status from the prior 6 month study visit (data 
not shown) the point estimates for high perceived stress were elevated for men who were 
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previously positive (PR=1.11 for any HPV type and PR=1.21 for oncogenic HPV), and 
for men who were previously negative (PR=1.73 for any HPV type and PR=2.07 for 
oncogenic HPV) after adjusting for demographic factors.  
Associations between Sleep Problems and HPV Prevalence 
 The prevalence of any HPV, oncogenic HPV, and non-oncogenic HPV was 
higher among men with high sleep problems vs. moderate sleep problems (55% vs. 48% 
for any HPV type; 43% vs. 33% for oncogenic HPV; and  32% vs. 28% for non-
oncogenic HPV). Corresponding prevalence ratios in univariate analysis were: any HPV 
PR=1.40, (95% CI= 1.09-1.79), oncogenic HPV PR=1.89 (95% CI: 1.29-2.77), and non-
oncogenic HPV PR=1.34 (95% CI: 0.72-2.49). In multivariable analyses significance 
persisted only for oncogenic HPV prevalence [model 1 PR=1.60 (95% CI:1.10-2.34) and 
model 2 PR=1.50 (95% CI: 1.01-2.13)]. Low sleep problems were significantly 
associated with prevalence of any HPV in model 1 [PR=1.27 (95% CI: 1.003-1.60)] and 
model 2 [PR=1.27 (95% CI: 1.01-1.60)]. Low sleep problems were also associated with 
oncogenic HPV in model 1 [PR=1.54 ( 95% CI: 1.04-2.26)] and Model 2  [PR=1.57 
(95% CI: 1.07-2.30)]. Non-oncogenic HPV was not significantly associated with sleep 
problems (Table 2.3).  
Discussion 
 
 This study found a significantly higher prevalence of HPV infection among men 
who reported high perceived stress and high self-reported sleep problems in the past 6 
months compared to those reporting low perceived stress or moderate sleep problems. 
The association with perceived stress and sleep problems was higher for oncogenic HPV 
types than non-oncogenic types. Although relatively small this is the largest study to 
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examine the association between perceived stress, self-reported sleep problems, and an 
infection outcome. 
 In the present study a higher prevalence of HPV was only apparent in men scoring 
in the upper quartile of PSS-4 scale scores. This is similar to a report by Strachan et al. 
(2011)27, which found a non-linear association between daily psychological distress and 
genital lesions due to HSV in a study of 19 women assessed daily. High stress predicted 
HSV lesion development five days later compared to low stress and was associated with 
frequency of lesion episodes in this group of women. 
 Associations with perceived stress were significant for any HPV infection and 
oncogenic HPV infection. Although the point estimate for non-oncogenic HPV was 
elevated (1.38 in the adjusted model) it did not reach statistical significance. Associations 
between sleep problems and non-oncogenic HPV were also lower than for oncogenic 
HPV types. Failure to achieve significance for perceived stress could be related to the 
smaller number of men who only had a non-oncogenic infection; 91 men compared to 99. 
It is also possible that the association with perceived stress and sleep problems is stronger 
for oncogenic HPV infection than for non-oncogenic HPV infection. Oncogenic and non-
oncogenic HPV types differ in rates of acquisition and duration, two factors that 
contribute to estimates of prevalence.  
 We hypothesized that smoking and alcohol were likely to lie in the causal 
pathway from stress to HPV status. Associations remained after including these factors, 
thus we do not believe the effect of perceived stress on HPV status is significantly 
mediated by these behavioral factors. Perceived stress remained significantly associated 
with any HPV infection and oncogenic HPV infection after adjusting for sleep problems. 
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Sleep remained significantly associated with oncogenic HPV infection after adjusting for 
stress. This suggests these exposures may independently influence HPV infection.  
 In this sample men with both low and high self-reported sleep problems were 
more likely to be HPV positive than those with moderate sleep problems. The low 
category included men who reported sleeping longer than 9 hours per night. Previous 
research has reported associations between both long and short sleep duration with all-
cause mortality51, body mass index, diabetes, hypertension, and heart disease33. PSD has 
been associated with lower antibody titers following administration of influenza 
vaccine52. Sleep satisfaction has been associated with number and percentage of helper T 
cells and percentage of cytotoxic T cells in women with cervical disease3. However this 
is the first study to examine the association between an STI and self-reported sleep 
problems. Research in this area is needed to further evaluate possible associations 
between measures of sleep and HPV infection. 
 There are several limitations to this research. The majority of participants reported 
their race as white. Additionally, men participating in a longitudinal study are a select 
group and results may not be representative of all men. The course of HPV infection and 
types of disease caused by HPV differ in men in women, and we cannot generalize these 
results to women. In a meta-analysis by Chida and Mao (2009)26, female populations 
showed a higher effect size between psychological stress and HSV-2 recurrence than the 
total sample. Perceived stress, sleep problems, demographic characteristics, and sexual 
behavior were self-reported and there is the possibility of misclassification bias and social 
desirability bias. Measures of immune parameters, biological indicators of stress, and 
drug/medication use were not collected. The PSS-4 is one of many ways to measure 
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stress and is an abbreviated version of the original 14 item PSS. Stress is a complex 
process and other measures of psychological stress such as coping style, social support, 
and emotional responses may also be relevant. Sleep was measured with 7 self-reported 
items. The use of full-length validated questionnaires or objective measurement of sleep 
such as EEG may be helpful in elucidating the relationship between sleep disturbance and 
HPV infection. 
 Participants were given results of their previous HPV test from genital samples 
collected approximately 6 months prior at each visit, however at the time of survey 
completion participants were unaware of their current HPV status. Men are told whether 
they were positive or negative for any HPV type, but are not given information on the 
type(s) of HPV for which they tested positive. If receipt of previous results affected 
perceived stress and sleep problems or the reporting of these factors, then we would 
expect self-reported previous HPV test results to be the most strongly associated with 
perceived stress and sleep problems as this is what men believe their HPV status to be. 
However, both previous laboratory HPV test result and self-reported previous HPV test 
result were not significantly associated with perceived stress (p=0.07 and 0.22, 
respectively) or self-reported sleep problems (p=0.48 and 0.85, respectively), and point 
estimates were elevated for men previously positive and previously negative. Therefore, 
we do not believe receipt of HPV test results affected reporting of perceived stress or 
sleep problems.  
This study found significant associations between high self-reported perceived 
stress and sleep problems in the prior six months and prevalence of HPV. The association 
between both stress and sleep problems with HPV was not linear, which may also be true 
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for other outcomes of interest. Results suggest that perceived stress and self-reported 
sleep problems may have independent effects on HPV prevalence. Evaluation of 
perceived stress, biological indicators of stress, and measures of immune parameters may 
aid in determining how stress and sleep are related to HPV infection. Determination of 
modifiable factors that can influence HPV infection may aid in the prevention of adverse 
disease outcomes related to infection with this virus. Future research is needed to 
evaluate whether perceived stress and sleep problems are associated with incidence or 
duration of HPV infection.  
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Table 2.1. Demographic characteristics of men tested for genital HPV infection 
who completed the first visit from the parent (CER) study and men who completed 
additional stress and sleep items and were eligible for inclusion into the present analysis. 
 
 
      CER Totala   
Eligible for 
Analysisa 
      n (%)   n (%) 
Age           
  18 to 20 149 (28%)   93 (22%) 
  21 to 22 94 (18%)   81 (19%) 
  23 to 31 107 (20%)   95 (22%) 
  32 to 49 119 (22%)   99 (23%) 
  ≥50 67 (13%)   58 (14%) 
Education           
  HS Diploma/GED or less 70 (13%)   49 (12%) 
  Some college, no degree 257 (48%)   195 (46%) 
  
2-yr/4-yr/Graduate 
degree   209 (39%)   182 (43%) 
Health Insurance           
  No 130 (25%)   109 (26%) 
  Yes 394 (75%)   312 (74%) 
Marital Status           
  Unmarried, Single 351 (66%)   250 (59%) 
  Unmarried, living with a partner 44 (8%)   51 (12%) 
  Married 80 (15%)   75 (18%) 
  Separated/ Divorced, widowed 59 (11%)   49 (12%) 
Smoking status           
  Never 295 (55%)   244 (57%) 
  Former 131 (24%)   94 (22%) 
  Current 109 (20%)   87 (20%) 
Alcohol           
  No alcohol 105 (20%)   76 (18%) 
  ≤1 drink per day 205 (40%)   172 (42%) 
  >1 drink per day 208 40%)   164 (40%) 
Number of vaginal sex partners in the past 6 months       
  0   146 (33%)   120 (29%) 
  1   182 (41%)   194 (47%) 
  ≥2 120 (27%)   103 (25%) 
Lifetime number of sex partners           
  0   27 (5%)   22 (5%) 
  1-3 129 (24%)   100 (23%) 
  4-9 122 (23%)   98 (23%) 
  10-20 131 (24%)   101 (24%) 
  ≥21 102 (19%)   88 (21%) 
  Decline to answer 25 (5%)   17 (4%) 
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Table 2.1 continued 
 
HPV Status           
  Negative for HPV 297 (55%)   234 (55%) 
  Positive for Any HPV type 239 (45%)   190 (45%) 
    Positive for Oncogenic HPVa       99 (30%) 
    Positive for Non-oncogenic HPV onlyb     91 (28%) 
Perceived Stress           
  1st quartile (0 to 2) NA   92 (22%) 
  2nd quartile (3 and 4) NA   124 (29%) 
  3rd quartile (5 and 6) NA   108 (25%) 
  4th quartile (7 to 15) NA   101 (24%) 
Sleep           
  1st quartile (0 to 4) NA   111 (27%) 
  2nd quartile (5 and 6) NA   92 (22%) 
  3rd quartile (7 to 10) NA   116 (28%) 
  4th quartile (11 to 21) NA   98 (24%) 
aTotal number of men who completed the first visit of the parent study (Cognitive and Emotional 
Responses Study), n=536 
bTotal number of men who completed additional perceived stress and sleep items and were eligible for 
inclusion into the present analysis, n=426 
NA: Not Applicable 
Note: Numbers may not add to 426 due to some participants' selecting "Decline to answer"; 
percentages calculated including those who did not decline to answer 
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Table 2.2. Demographic characteristics of men tested for HPV by self-reported perceived stress and sleep problems. 
 
      Perceived stress   Sleep problems 
      Low   High       Low   Moderate   High   
      n (%)   n (%)   p-value   n (%)   n (%)   n (%) p-value 
Age             0.22                   <0.01 
  18 to 20 75 (81%)   18 (19%)       25 (27%)   60 (65%)   8 (9%)   
  21 to 22 67 (83%)   14 (17%)       21 (26%)   41 (51%)   18 (23%)   
  23 to 31 71 (76%)   23 (24%)       24 (26%)   47 (51%)   22 (24%)   
  32 to 49 69 (70%)   30 (30%)       24 (25%)   38 (40%)   34 (35%)   
  ≥50 42 (72%)   16 (28%)       17 (31%)   22 (40%)   16 (29%)   
Education             <0.01                   0.10 
  HS Diploma/GED or less 28 (57%)   21 (43%)       13 (29%)   18 (40%)   14 (31%)   
  Some college, no degree 155 (79%)   40 (21%)       58 (30%)   98 (51%)   35 (18%)   
  2-yr/4-yr/Graduate degree 141 (78%)   40 (22%)       40 (22%)   92 (51%)   49 (27%)   
Health Insurance             0.89                   0.12 
  No 82 (76%)   26 (24%)       33 (31%)   44 (41%)   30 (28%)   
  Yes 239 (77%)   73 (73%)       76 (25%)   161 (53%)   68 (22%)   
Marital Status             0.06                   0.02 
  Unmarried, Single 197 (79%)   52 (21%)       62 (25%)   134 (54%)   50 (20%)   
  Unmarried, living with a partner 40 (78%)   11 (22%)       16 (32%)   26 (52%)   8 (16%)   
  Married 57 (76%)   18 (24%)       19 (26%)   34 (47%)   19 (26%)   
  Separated/ Divorced, widowed 30 (61%)   19 (39%)       14 (29%)   14 (29%)   20 (42%)   
Smoking status             0.04                   <0.01 
  Never 195 (80%)   48 (20%)       75 (32%)   120 (50%)   43 (18%)   
  Former 71 (76%)   23 (24%)       14 (15%)   52 (55%)   28 (30%)   
  Current 58 (67%)   29 (33%)       21 (25%)   36 (43%)   27 (32%)   
Alcohol             0.62                   0.07 
  No alcohol 59 (78%)   17 (22%)       26 (37%)   34 (49%)   10 (14%)   
  ≤1 drink per day 127 (74%)   44 (26%)       48 (28%)   84 (49%)   38 (22%)   
  >1 drink per day 129 (79%)   35 (21%)       35 (21%)   82 (50%)   46 (28%)   
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Table 2.2 continued 
 
Number of vaginal sex partners in the past 6 months 0.64                   0.50 
  0 90 (75%)   30 (25%)       32 (28%)   55 (48%)   28 (24%)   
  1 145 (75%)   48 (25%)       52 (27%)   100 (53%)   38 (20%)   
  ≥2 82 80%)   21 (20%)       25 (24%)   48 (47%)   30 (29%)   
Lifetime number of sex partners             0.10                   0.02 
  0 16 (73%)   6 (27%)       8 (38%)   11 (52%)   2 (10%)   
  1-3 83 (83%)   17 (17%)       30 (30%)   53 (53%)   17 (17%)   
  4-9 74 (78%)   21 (22%)       23 (24%)   55 (59%)   16 (17%)   
  10-20 79 (80%)   20 (20%)       27 (28%)   45 (46%)   26 (27%)   
  ≥21 58 (67%)   29 (33%)       16 19%)   35 (42%)   32 (39%)   
  Decline to answer 11 (65%)   6 (35%)       6 (38%)   8 (20%)   2 (13%)   
HPV Status                                   
  Negative for HPV 189 (81%)   45 (19%)       57 (25%)   126 (56%)   44 (19%)   
  Positive for Any HPV type 135 (71%)   54 (29%)   0.02c   53 (28%)   82 (43%)   54 (55%) 0.03c 
    Positive for Oncogenic HPVa 70 (71%)   29 (29%)   0.04c   28 (29%)   37 (38%)   33 (34%) 0.01c 
    Positive for Non-oncogenic HPV onlyb 65 (72%)   25 (28%)   0.09c   25 (27%)   45 (49%)   21 (23%) 0.60c 
aNumber and percentage of men positive for an oncogenic HPV type regardless whether they were also positive for a non-oncogenic type, percentage of men 
positive does not include participants with only an non-oncogenic HPV type 
bNumber and percentage for men only positive for a non-oncogenic HPV type, percentage of men positive does not include participants with an oncogenic HPV 
type 
cP-value calculated by comparing positive men to men negative for all HPV types                     
Note: Numbers may not add to 426 due to some participants' selecting "Decline to answer"; percentages calculated including those who did not decline to answer 
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Table 2.3. Associations between perceived stress, sleep problems, and prevalence of any 
HPV type, any oncogenic HPV type, and any non-oncogenic HPV type among men 
tested for HPV. 
 
 
    Any HPV Type 
    Prev. Univariate Multivariable 1 Multivariable 2 
    (%) PR (95% CI) PR (95% CI) PR (95% CI) 
Perceived Stressa           
  Low 41.7 1.00 1.00 1.00 
  High 54.6 1.31 (1.05-1.63) 1.37 (1.10-1.70) 1.33 (1.06-1.68) 
Sleep problemsb             
  Low 48.2 1.22 (0.95-1.58) 1.27 (1.003-1.60) 1.27 (1.01-1.60) 
  Moderate 39.4 1.00 1.00 1.00 
  High 55.1 1.40 (1.09-1.79) 1.21 (0.95-1.53) 1.16 (0.91-1.48) 
    Any Oncogenic HPV Type 
    Prev. Univariate Multivariable 1 Multivariable 2 
    (%) PR (95% CI) PR (95% CI) PR (95% CI) 
Perceived Stressa           
  Low 27.0 1.00 1.00 1.00 
  High 39.2 1.45 (1.02-2.05) 1.60 (1.14-2.24) 1.53 (1.06-2.20) 
Sleep problemsb             
  Low 32.9 1.45 (0.96-2.20) 1.54 (1.04-2.26) 1.57 (1.07-2.30) 
  Moderate 22.7 1.00 1.00     
  High 42.9 1.89 (1.29-2.77) 1.60 (1.10-2.34) 1.50 (1.01-2.13) 
    Any Non-oncogenic HPV Type 
    Prev. Univariate Multivariable 1 Multivariable 2 
    (%) PR (95% CI) PR (95% CI) PR (95% CI) 
Perceived Stressa           
  Low 25.6 1.00 1.00 1.00 
  High 35.7 1.40 (0.96-2.04) 1.40 (0.96-2.04) 1.38 (0.93-2.05) 
Sleep problemsb             
  Low 30.5 1.23 (0.69-2.19) 1.38 (0.68-2.80) 1.16 (0.77-1.75) 
  Moderate 26.3 1.00 1.00 1.00 
  High 32.3 1.34 (0.72-2.49) 1.01 (0.45-2.23) 1.23 (0.80-1.89) 
aMultivariable 1 model adjusted for age, insurance, education, marital status, and number of vaginal sex 
partners in the past 6 months, Multivariable 2 model additionally adjusted for sleep category 
bMultivariable 1 model adjusted for age, insurance, education, marital status, smoking status, alcohol 
consumption and lifetime number of sex partners, Multivariable 2 model additionally adjusted for 
perceived stress category 
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Table 2.4. Demographic characteristics of men tested for genital HPV infection by prevalence of any HPV type, oncogenic HPV type, 
and non-oncogenic HPV type. 
         Total Sample   Any HPVa p-valueb   Oncogenicc p-valueb   Non-oncogenicd p-valueb 
        n (%)   n (%)     n (%)     n (%)   
Age             0.01       0.03       0.14 
  18 to 20   93 (22%)   31 (33%)     15 (19%)     16 (21%)   
  21 to 22   81 (19%)   31 (38%)     17 (25%)     14 (22%)   
  23 to 31   95 (22%)   46 (48%)     25 (34%)     21 (30%)   
  32 to 49   99 (23%)   56 (57%)     31 (42%)     25 (37%)   
  ≥50   58 (14%)   26 (46%)     11 (26%)     15 (33%)   
Education             0.15       0.59       0.02 
  HS Diploma/GED or less   49 (12%)   27 (56%)     12 (36%)     15 (42%)   
  Some college, no degree   195 (46%)   80 (41%)     50 (30%)     30 (21%)   
  2-yr/4-yr/Graduate degree   182 (43%)   83 (46%)     37 (27%)     46 (32%)   
Health Insurance             0.05       0.13       0.09 
  No   109 (26%)   57 (53%)     29 (36%)     28 (35%)   
  Yes   312 (74%)   130 (42%)     68 (27%)     62 (26%)   
Marital Status             0.59       0.80       0.29 
  Unmarried, Single   250 (59%)   106 (42%)     59 (29%)     47 (25%)   
  Unmarried, living with a partner   51 (12%)   23 (45%)     11 (28%)     12 (30%)   
  Married   75 (18%)   37 (50%)     15 (29%)     22 (37%)   
  Separated/ Divorced, widowed   49 (12%)   24 (50%)     14 (37%)     10 (29%)   
Smoking status             <0.01       0.03       0.01 
  Never   244 (57%)   98 (40%)     49 (25%)     49 (25%)   
  Former   94 (22%)   40 (43%)     24 (31%)     16 (23%)   
  Current   87 (20%)   52 (60%)     26 (43%)     26 (43%)   
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Table 2.4 continued 
 
Alcohol             0.38       0.36       0.69 
  No alcohol   76 (18%)   29 (39%)     15 (25%)     14 (23%)   
  ≤1 drink per day   172 (42%)   76 (44%)     38 (28%)     38 (28%)   
  >1 drink per day   164 (40%)   79 (48%)     44 (34%)     35 (29%)   
Number of vaginal sex partners in the past 6 months       <0.01       <0.01       0.01 
  0     120 (29%)   39 (33%)     16 (16%)     23 (22%)   
  1     194 (47%)   77 (40%)     35 (23%)     42 (27%)   
  ≥2   103 (25%)   69 (67%)     43 (56%)     26 (43%)   
Lifetime number of sex partners             <0.01       <0.01       <0.01 
  0     22 (5%)   4 (18%)     2 (10%)     2 (10%)   
  1-3   100 (23%)   11 (11%)     4 (4%)     7 (7%)   
  4-9   98 (23%)   43 (44%)     26 (32%)     17 (24%)   
  10-20   101 (24%)   66 (65%)     31 (47%)     35 (50%)   
  ≥21   88 (21%)   56 (64%)     29 (48%)     27 (47%)   
  Decline to answer   17 (4%)   10 (63%)     7 (54%)     3 (33%)   
Perceived Stress             0.10       0.13       0.27 
  1st quartile (0 to 2)   92 (22%)   38 (41%)     23 (30%)     15 (22%)   
  2nd quartile (3 and 4)   124 (29%)   56 (45%)     28 (29%)     28 (29%)   
  3rd quartile (5 and 6)   108 (25%)   41 (38%)     19 (22%)     22 (25%)   
  4th quartile (7 to 15)   101 (24%)   54 (55%)     29 (39%)     25 (36%)   
Sleep             0.06       0.01       0.60 
  1st quartile (0 to 4)   111 (27%)   53 (48%)     28 (33%)     25 (30%)   
  2nd quartile (5 and 6)   92 (22%)   34 (37%)     17 (23%)     17 (23%)   
  3rd quartile (7 to 10)   116 (28%)   48 (41%)     20 (23%)     28 (29%)   
  4th quartile (11 to 21)   98 (24%)   54 (55%)     33 (43%)     21 (32%)   
aMen who were positive for any of the 37 HPV types, n=190 (45%) 
bChi-square test compared to men HPV negative 
cMen positive for an oncogenic HPV type regardless whether they were also positive for a non-oncogenic type, n=99 (30%); percentage of men positive does not 
include participants with only an non-oncogenic HPV type 
dMen only positive for a non-oncogenic HPV type, n=91 (28%); percentage of men positive does not include participants with an oncogenic HPV type 
Note: Numbers may not add to 426 due to some participants' selecting "Decline to answer"; percentages calculated including those who did not decline to answer 
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Figure 1.1. Timeline of HIM and CER study visits. 
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Chapter 3: Self-reported Perceived Stress and Sleep Problems: Associations with  
 
Incidence and Clearance of Human Papillomavirus Infection in U.S. Men 
 
 
Abstract 
 
 The 40 types of Human Papillomavirus (HPV) which can infect mucosal tissue 
are the most common sexually transmitted infection (STI) and are associated with ano-
genital warts and cancers. Most infected individuals will clear the infection and HPV 
DNA of a specific type will no be longer detected, however the virus will persist in some. 
We previously reported associations between perceived stress and self-reported sleep 
problems with prevalence of HPV infection in men. Here we examined the association 
between these factors and clearance and incidence of HPV infection. Cox regression 
using a robust sandwich estimator was used to calculate hazard ratios (HR) and 95% 
confidence intervals (95% CI). A total of 426 men completed 997 study visits. Neither 
perceived stress nor self-reported sleep problems was significantly associated with 
incidence of HPV infection. Perceived stress was not significantly associated with 
clearance of infection. However, among men 50 and older, those with high stress were 
significantly less likely to clear any HPV infection in adjusted models, HR=0.09 (95% 
CI: 0.02-0.49). Compared to men with moderate sleep problems, those with high sleep 
problems were significantly less likely to clear an infection with any HPV type, HR=0.68 
(95% CI: 0.49-0.94), or an oncogenic HPV type, HR=0.51 (95% CI: 0.28-0.94), after 
adjusting for demographics and perceived stress. Determining the impact of factors such 
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as perceived stress and sleep problems on HPV infection may aid in risk stratification and 
secondary prevention efforts among those HPV-positive. 
Introduction 
 Over 100 types of human papillomavirus (HPV) have been identified, of which 
approximately 40 can infect mucosal tissue such as the anogenital and aerodigestive 
tracts.  Together these mucosal HPV types are the most common sexually transmitted 
infection (STI). Low risk, or non-oncogenic, HPV types are associated with genital warts. 
High risk, or oncogenic, HPV types are a necessary, but insufficient cause of cervical 
cancer. Although much research has focused on cervical cancer, these types have also 
been associated with other anogenital cancers and cancers of the head and neck19.  
 The HPV virus has developed multiple strategies to evade the host's immune 
system such as confining viral protein expression to keratinocytes and downregulation of 
IFN-α gene expression. However, in most infected individuals HPV-specific immune 
responses will eventually clear the infection to where HPV DNA of a specific type can no 
longer be detected20,53. Although the exact mechanism remains to be elucidated54, a 
successful immune response has been characterized by strong, local, cell-mediated 
immune responses20.   
HPV persistence is generally defined as detection of the same HPV type at least 
two times over a specified time interval. However, there is no consensus on what time 
interval should be considered “meaningful” persistence1. It is uncertain whether the 
infection is entirely cleared by the host or the virus becomes latent and undetectable55. 
Although infection with oncogenic HPV is necessary in the progression of cervical 
cancer, studies of HPV viral clearance and HPV-related diseases in women have found 
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several factors associated with HPV persistence including smoking, oral contraceptive 
use, infection with other STIs, diet56, and host factors such as genes for HLA class I and 
II.  Viral factors such as HPV type, viral load, and viral integration are also associated 
with disease outcomes1.  
A few studies have examined HPV incidence and clearance in men. Factors 
previously associated with HPV clearance in men include circumcision status, lifetime 
number of sex partners, infection with multiple HPV types, age, and country of 
residence4,49,57-61. We previously reported significant associations between perceived 
stress and self-reported sleep problems with HPV prevalence in men.  
The purpose of this report is to examine associations between perceived stress and 
self-reported sleep problems with incidence and clearance of genital HPV infection in 
men. We hypothesized that clearance, rather than incidence, would be associated with 
perceived stress and self-reported sleep problems. Incidence of HPV infection in men has 
previously been associated with sexual behaviors4,57-59 and exposure to the virus is likely 
the most important factor in acquisition. Among men who become positive for HPV, 
stress and sleep may impact clearance via a negative impact on immune responses11,34. 
Methods 
Participants 
 Men participating in the Natural History of HPV in Men (HIM) Study complete 
study visits every 6 months where a sexual history computer-assisted self interview 
(CASI) questionnaire is administered, a visual inspection of the skin and external 
genitalia is conducted, and external genital skin samples are collected for HPV testing4. A 
subset of HIM study participants in the Central Florida area were invited to also 
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participate in The Cognitive and Emotional Responses (CER) Study42. This separate 
study assessed additional behavioral factors among HIM study participants. Men 
completed the CER CASI approximately 2-4 weeks after each HIM study visit. CER men 
were recruited into this study at their third HIM study visit and completed the CER 
questionnaire 4 times over approximately 2 years. Items concerning perceived stress and 
self-reported sleep problems were added to the CER CASI in June 2009 (midway through 
CER participant recruitment). All CER visits including the additional items which were 
completed within 45 days of the corresponding HIM visit were eligible for the present 
analysis. Additional details of this study can be found in the prevalence manuscript. This 
study was approved by the University of South Florida Institutional Review Board. 
Measures 
Perceived Stress 
 Self-reported perceived stress in the past 6-months was assessed via a modified 
version of the 4-item Perceived Stress Scale (PSS-4). This scale was designed to 
determine how unpredictable, uncontrollable, and overloaded individuals consider their 
lives with 5-point likert scale response categories ranging from never to very often for all 
4 items16. Participants completed this scale at each CER study visit. Stress was 
dichotomized and categorized as high if participants scored a 7 or above (top 25% of 
stress scores) and low if the perceived stress score was from 0 to 6 (bottom 75%). 
Self-reported Sleep Problems 
 Seven items assessed self- reported sleep problems with responses on a four-point 
likert-scale. The three-item version of the Jenkins sleep problems scale (JSPS) assessed 
trouble falling asleep, trouble staying asleep, and waking up feeling tired17.  Four 
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additional items assessed sleep duration, subjective sleep quality, daytime functioning, 
and sleep distress. Self-reported sleep problems were categorized as low if participants 
scored between 0 and 4 (bottom 25%), moderate if they scored from 5 to10 (middle 
50%), and high if they scored from 11 to 21 (top 25%). Men in the moderate category 
formed the reference group in all analyses. 
Demographics and Sexual Behaviors 
 Marital status, education, and health insurance status were assessed with single 
items. Age was calculated using the date of birth and date of study visit. Men aged 50 and 
older were categorized as 'older men' in this study. This categorization of men aged 50 
and older is consistent with research conducted among HIV-positive persons46,47. Men 
younger  than 50 were categorized as 18 to 29 or 30 to 49. Men who reported having had 
sex in the past 6 months were asked to report the number of vaginal sex partners during 
this time. Number of vaginal sex partners was divided into three categories: zero (men 
who had not had sex in the past six months), 1 vaginal sex partner, and 2 or more vaginal 
sex partners. Lifetime number of sex partners was calculated by summing the total 
number of female and male partners participants reported at each visit. 
HPV Status 
 Polymerase chain reaction (PCR) amplification of a fragment of the HPV L1 gene 
was used to test exfoliated penile cell samples for HPV DNA. Each penile sample was 
tested for 37 individual HPV genotypes41. Thirteen HPV types were categorized as 
oncogenic: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 6848. The remaining HPV 
types were categorized as non-oncogenic: 6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 67, 66, 
69, 70, 71, 72, 73, 81, 82, 83, 84, 89, and IS39.  
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Statistical Analysis 
 Men who tested positive for any of the 37 HPV genotypes in the study protocol 
were categorized as positive for 'Any HPV.' Men who tested positive for any oncogenic 
HPV type were categorized as positive for 'Oncogenic HPV' and men who tested positive 
for non-oncogenic HPV genotypes were categorized as positive for 'Non-oncogenic 
HPV.' Men could contribute to the oncogenic and non-oncogenic analyses if they were 
positive for both types of HPV. 
 Clearance of an HPV infection was defined as two consecutive negative tests 
following a positive test for a specific HPV type. Infections were considered prevalent if 
they had been detected at any previous visit or if it was detected at the first HIM study 
visit. If an infection was first detected at a participants final eligible visit it was not 
analyzed for clearance. Incidence of an HPV infection was defined as a positive test for 
an HPV type not detected at baseline or any previous follow-up visit.  
 Cox regression62 was used to calculate hazard ratios (HR) and 95% confidence 
intervals (CI). Because it is possible for men to be infected with multiple HPV types, 
type-specific HPV clearance and incidence was analyzed and all infections were included 
in the analysis. To account for within-subject correlations, the robust sandwich estimator 
was used for the covariance matrix13. Stratified analyses were conducted to assess 
possible effect modification. The phreg procedure in SAS version 9.3 (Cary, NC) was 
used to conduct statistical analyses. Schoenfeld residual plots did not indicate substantial 
violation of the proportional hazards assumption. 
 Demographic and sexual behaviors included in our analysis of HPV prevalence 
were also adjusted for in clearance and incidence multivariable models. Multivariable 
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analyses for perceived stress were adjusted for age in years, health insurance status, 
education, marital status, and number of vaginal sex partners in the past six months. A 
second multivariable model also adjusted for sleep problems. Multivariable analyses for 
self-reported sleep problems were adjusted for age in years, health insurance status, 
education, marital status, lifetime number of sex partners, smoking status, and alcohol 
consumption. A second multivariable model also adjusted for perceived stress. Most 
participants were white (68%), non-Hispanic (82%), and were circumcised as determined 
by a HIM study physician (79%). As in our previous analysis of HPV prevalence, these 
factors were not significantly associated with clearance or incidence of an HPV infection 
in this sample and were not included in multivariable models. 
Results 
Characteristics of the Study Sample 
 Data on perceived stress and self-reported sleep problems were collected from 
June 2009 to July 2011. There were a total of 997 eligible visits among 426 men. Total 
follow-up time per participant ranged from 4.4 to 32.1 months with a mean of 15.5 
(SD=6.6) months. The mean age of participants was 31.2 (SD=13.4) with a range of 18 to 
70. The majority of participants reported they had health insurance (74%), were single 
(59%), and had at least some college education (88%). There were a total of 336 incident 
infections detected among 163 men during follow-up (Table 3.1). Number of incident 
infections ranged from 1 to 9 with a mean of  2.1 infections per person. There were 554 
individual HPV infections detected at baseline or during follow-up among 222 men that 
were analyzed for clearance. Number of infections per person ranged from 1 to 10 with a 
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mean of 2.5 infections per person. Overall, 53% of HPV infections cleared during follow-
up (Table 3.1). 
Associations between Perceived Stress and HPV Incidence and Clearance 
 Perceived stress was not significantly associated with incidence of any HPV type, 
oncogenic HPV, or non-oncogenic HPV (data not shown). Perceived stress was not 
significantly associated with clearance of any HPV type (Table 3.2), oncogenic HPV 
(Table 3.3), or non-oncogenic HPV (Table 3.4). However, among men 50 and older, 
those with high stress were significantly less likely to clear any HPV infection, HR=0.09 
(95% CI: 0.02-0.49) after adjusting for demographics.  
Associations between Self-reported Sleep Problems and HPV Incidence and Clearance 
 Self-reported sleep problems were not significantly associated with incidence of 
any HPV type, oncogenic HPV, or non-oncogenic HPV (data not shown). Men with high 
sleep problems were significantly less likely to clear an infection with any HPV type 
compared to men with moderate sleep problems, HR=0.68 (95% CI: 0.49-0.94) (Table 
3.2), and significantly less likely to clear an oncogenic HPV infection compared to men 
with moderate sleep problems after adjusting for demographics, HR=0.59 (95% CI: 0.36-
0.98) (Table 3.3),  and after additional adjustment for stress, HR=0.51 (95% CI: 0.28-
0.94). New infections were more likely to clear among men with low or high self-
reported sleep problems compared to men with moderate sleep problems with this 
difference reaching statistical significance among men with low self-reported sleep 
problems for non-oncogenic HPV infection, HR=1.89 (95% CI: 1.06-3.38). Among men 
with prevalent infections, those with low or high sleep problems were less likely to clear 
HPV however, these differences did not reach statistical significance. 
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Discussion 
 
 We found significant associations between self-reported sleep problems and 
clearance of HPV infection in this cohort of men. Perceived stress was only significantly 
associated with reduced clearance of any HPV infection among men aged 50 and older. 
Neither perceived stress or self-reported sleep problems were significantly associated 
with incidence of HPV infection.  
 Associations between perceived stress and self-reported sleep problems could 
differ by age group and prevalence of HPV infection. It is possible that the effects of 
stress and sleep disturbance could differ depending on where a person is in the course of 
HPV infection. Perceived stress and self-reported sleep problems many not affect HPV 
clearance among those with new infections. If stress and sleep disturbance have a 
negative impact on HPV clearance among prevalent infections then these factors may 
also be associated with HPV-related diseases as it is persistent infection with oncogenic 
HPV types that has been associated with cervical cancer in women1. A retrospective 
cohort study conducted using national registers in Sweden found significant associations 
between loss of a child and subsequent development of infection related cancers in 
parents . Associations were particularly elevated for HPV-related and possibly HPV-
related cancers with the highest significant relative risk estimates obtained for cancers of 
the cervix, larynx, and eye63. Future studies which include longer follow-up of HPV-
infected persons may aid in determining how stress and sleep disturbance can effect HPV 
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clearance among recently detected infection and infections of longer duration as well as 
possible associations with HPV-related diseases.  
 Most men in this study were younger and the number of men in the 50 and older 
age group was limited. Despite the small sample of older men, significance was reached 
for any HPV infection. Among older men, participants with high stress were significantly 
less likely to clear an HPV infection compared to those with low stress. Although there 
has been little research which examined differences in the association between stress and 
measures of immunity or disease by age, Kiecolt-Glaser et al. (2001)64 postulated that 
ageing and stress could interact with the effect of stress on immunity greater among older 
adults. A study of immune response to influenza vaccine found that the effect of chronic 
stress in the form of caregiving for a spouse with dementia was more strongly associated 
with non-response post vaccination among participants >70 compared to those younger 
than 70 years of age65. A review of studies assessing associations between the stress of 
caregiving with measures of endocrinological and immunologic dysregulation reported 
more consistent findings among elderly populations than non-elderly caregivers66. 
 Although significant associations were observed, this study had several 
limitations. There was not an inadequate sample size to determine associations within all 
subgroups of age and prevalence of infection. Men participating in longitudinal studies 
such as the HIM Study are a select group and the majority of participants were white, 
therefore results may not be generalizable to all men with HPV infection. Immune 
parameters, biological indicators of stress, and drug or medication use was not collected 
and we cannot assess the impact of these factors. Measures of perceived stress, sleep 
problems, demographics, and sexual behaviors were all self-reported. There is no single 
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method for assessing patient reported stress or sleep disturbance. Stress is a complex 
factor and the PSS-4 is one of many methods for measuring the concept of stress. Sleep 
disturbance can also be measured through numerous aspects of sleep dysfunction. In the 
present study, sleep problems was measured subjectively using participant self-report. 
Objective measures of sleep such as electroencephalographic (EEG) assessment may aid 
in exploring the relationship between infection and sleep disturbance. 
 This is the largest study to examine associations between perceived stress and 
sleep problems with clearance of an infection. High self-reported sleep problems were 
significantly associated with decreased clearance of HPV among this sample of men. 
Stress may also be associated with clearance of HPV infection among certain groups of 
men. The direction of the associations differed by age group and prevalence of infection, 
which could be a consideration in future research to ensure adequate sample sizes of 
specific subgroups. Further research is needed to confirm associations of these factors 
with HPV infection among women. Future studies may examine associations of these 
factors with HPV-related diseases such as cervical, anal, or penile lesions in men and 
women. Determining modifiable behavioral factors associated with HPV clearance will 
be important in secondary prevention efforts to decrease the burden of HPV-related 
diseases among HPV-positive individuals. Examining the relationships between 
participant reported perceived stress and sleep disturbance, objective measures of sleep, 
salivary cortisol levels (widely used as a biomarker for psychological stress67), immune 
parameters such Natural Killer cells and cytokines, and HPV infection could provide a 
better understanding of the mechanisms by which these exposures influence HPV 
infection. Examining the impact of factors such as perceived stress and sleep problems on 
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HPV infection may aid in risk stratification of patients and allow more targeted efforts 
among those at greatest risk of developing clinical disease.   
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Table 3.1. Number of incident infections, total number of infections, and percent of 
infections that cleared during follow-up. 
 
    Incidence Clearance 
    
# Incident 
Infections 
Total # 
Infections 
# (%) Cleared 
Infections 
      n n (%) 
Any HPV 336 554 294 (53%) 
Oncogenic 136 212 135 (57%) 
  16 22 45 21 (47%) 
  18 8 12 7 (58%) 
  31 5 5 4 (80%) 
  33 1 3 2 (67%) 
  35 4 5 1 (20%) 
  39 20 27 15 (56%) 
  45 8 14 11 (79%) 
  51 23 30 18 (60%) 
  52 11 22 16 (73%) 
  56 6 7 5 (71%) 
  58 3 3 2 (67%) 
  59 21 29 15 (52%) 
  68 4 10 7 (70%) 
Non-oncogenic 200 342 159 (50%) 
  6 17 24 7 (29%) 
  11 2 4 2 (50%) 
  26 1 0 0% 
  40 8 7 6 (86%) 
  42 5 7 7 (100%) 
  53 14 31 13 (42%) 
  54 13 22 11 (50%) 
  55 7 9 5 (56%) 
  61 12 18 11 (61%) 
  62 21 38 17 (45%) 
  64 1 1 1 (100%) 
  66 24 35 18 (51%) 
  67 3 0 0% 
  69 2 0 0% 
  70 4 11 5 (45%) 
  71 1 3 3 (100%) 
  72 4 8 5 (63%) 
  73 10 10 7 (70%) 
  81 3 7 2 (29%) 
  82 4 8 3 (38%) 
  83 6 18 10 (56%) 
  84 21 40 19 (48%) 
  89 16 41 18 (44%) 
  139 1 0 0% 
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Table 3.2. Associations between HPV clearance, perceived stress, and self-reported sleep 
problems among men positive for any HPV type. 
 Any HPV Type 
    Univariate Multivariable 1 Multivariable 2 
    HR (95% CI) HR (95% CI) HR (95% CI) 
Perceived Stressa             
  Low 1.00   1.00   1.00   
  High 1.16 (0.86-1.56) 1.09 (0.76-1.57) 1.23 (0.86-1.77) 
Sleep problemsb             
  Low 0.85 (0.60-1.20) 0.97 (0.67-1.41) 0.99 (0.68-1.44) 
  Moderate 1.00   1.00   1.00   
  High 0.79 (0.59-1.05) 0.77 (0.56-1.07) 0.68 (0.49-0.94) 
Stratified Analyses 
Prevalence of Infection 
New infection             
Perceived Stressa             
  Low 1.00   1.00   1.00   
  High 1.45 (0.95-2.24) 1.04 (0.63-1.73) 1.23 (0.67-2.24) 
Sleep problemsb             
  Low 1.42 (0.89-2.28) NC   NC   
  Moderate 1.00   1.00   1.00   
  High 1.03 (0.64-1.65) NC   NC   
Prevalent infection             
Perceived Stressa             
  Low 1.00   1.00   1.00   
  High 0.83 (0.52-1.32) 0.85 (0.53-1.36) 0.90 (0.56-1.44) 
Sleep problemsb             
  Low 0.74 (0.43-1.27) 0.96 (0.49-1.88) 0.97 (0.50-1.90) 
  Moderate 1.00   1.00   1.00   
  High 0.73 (0.46-1.18) 0.78 (0.46-1.32) 0.79 (0.47-1.34) 
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Table 3.2 continued 
 
Age Category 
Aged 18 to 29             
Perceived Stressa             
  Low 1.00   1.00   1.00   
  High 1.16 (0.69-1.96) 1.22 (0.72-2.06) NC   
Sleep problemsb             
  Low 0.70 (0.43-1.13) 0.71 (0.35-1.41) 0.79 (0.40-1.56) 
  Moderate 1.00   1.00   1.00   
  High 0.73 (0.46-1.15) 0.56 (0.33-0.93) 0.48 (0.29-1.82) 
Aged 30 to 49             
Perceived Stressa             
  Low 1.00   1.00   1.00   
  High 1.41 (0.88-2.27) 1.00 (0.41-2.40) 1.40 (0.53-3.68) 
Sleep problemsb             
  Low 0.86 (0.45-1.65) 1.21 (0.58-2.50) 1.19 (0.59-2.41) 
  Moderate 1.00   1.00   1.00   
  High 0.77 (0.49-1.23) 0.92 (0.45-1.87) 0.65 (0.36-1.17) 
Aged ≥50             
Perceived Stressa             
  Low 1.00   1.00   1.00   
  High 0.28 (0.05-1.56) 0.09 (0.02-0.49) NC   
Sleep problemsb             
  Low NC   NC   NC   
  Moderate 1.00   1.00   1.00   
  High NC   NC   NC   
aMultivariable 1 model adjusted for age, insurance, education, marital status, number of 
vaginal sex partners in the past 6 months, and prevalence of HPV infection, Multivariable 
2 model additionally adjusted for sleep category 
bMultivariable 1 model adjusted for age, insurance, education, marital status, smoking 
status, alcohol consumption, lifetime number of sex partners, and prevalence of HPV 
infection, Multivariable 2 model additionally adjusted for perceived stress category 
  
 45 
Table 3.3. Associations between HPV clearance, perceived stress, and self-reported sleep 
problems among men positive for any oncogenic HPV type. 
 Any Oncogenic HPV Type 
    Univariate Multivariable 1 Multivariable 2 
    HR (95% CI) HR (95% CI) HR (95% CI) 
Perceived Stressa             
  Low 1.00   1.00   1.00   
  High 1.12 (0.75-1.68) 1.03 (0.62-1.71) 1.39 (0.79-2.42) 
Sleep problemsb             
  Low 0.74 (0.45-1.21) 0.77 (0.46-1.28) 0.78 (0.46-1.32) 
  Moderate 1.00   1.00   1.00   
  High 0.68 (0.45-1.02) 0.59 (0.36-0.98) 0.51 (0.28-0.94) 
Stratified Analyses 
Prevalence of Infection 
New infection             
Perceived Stressa             
  Low 1.00   1.00   1.00   
  High 1.52 (0.84-2.76) 1.44 (0.70-2.99) 2.09 (0.92-4.74) 
Sleep problemsb             
  Low 0.96 (0.48-1.95) NC   NC   
  Moderate 1.00   1.00   1.00   
  High 0.82 (0.43-1.56) NC   NC   
Prevalent infection             
Perceived Stressa             
  Low 1.00   1.00   1.00   
  High 0.54 (0.26-1.13) 0.59 (0.29-1.23) 0.74 (0.31-1.72) 
Sleep problemsb             
  Low 0.62 (0.27-1.42) 0.54 (0.22-1.35) 0.54 (0.22-1.36) 
  Moderate 1.00   1.00   1.00   
  High 0.50 (0.22-1.16) 0.43 (0.18-1.05) 0.62 (0.23-1.65) 
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Table 3.3 continued 
 
Age Category 
Aged 18 to 29             
Perceived Stressa             
  Low 1.00   1.00   1.00   
  High 1.76 (0.90-3.41) 1.81 (0.76-4.28) NC   
Sleep problemsb             
  Low 0.68 (0.33-1.39) 0.73 (0.26-2.07) NC   
  Moderate 1.00   1.00   1.00   
  High 0.91 (0.50-1.64) 0.55 (0.24-1.25) NC   
Aged 30 to 49             
Perceived Stressa             
  Low 1.00   1.00   1.00   
  High 0.97 (0.52-1.82) 0.55 (0.20-1.55) 0.51 (0.14-1.90) 
Sleep problemsb             
  Low 0.51 (0.17-1.54) 0.23 (0.03-1.88)     
  Moderate 1.00   1.00   1.00   
  High 0.42 (0.20-0.88) 0.47 (0.08-2.60)     
Aged ≥50             
Perceived Stressa             
  Low 1.00   1.00   1.00   
  High 0.81 (0.10-6.96) NC   NC   
Sleep problemsb             
  Low 1.25 (0.32-4.89) NC   NC   
  Moderate 1.00   1.00   1.00   
  High 2.84 (0.68-11.97) NC   NC   
aMultivariable 1 model adjusted for age, insurance, education, marital status, number of 
vaginal sex partners in the past 6 months, and prevalence of HPV infection, Multivariable 
2 model additionally adjusted for sleep category 
bMultivariable 1 model adjusted for age, insurance, education, marital status, smoking 
status, alcohol consumption, lifetime number of sex partners, and prevalence of HPV 
infection, Multivariable 2 model additionally adjusted for perceived stress category 
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Table 3.4. Associations between HPV clearance, perceived stress, and self-reported sleep 
problems among men positive for any non-oncogenic HPV type. 
 Any Non-oncogenic HPV Type 
    Univariate Multivariable 1 Multivariable 2 
    HR (95% CI) HR (95% CI) HR (95% CI) 
Perceived Stressa             
  Low 1.00   1.00   1.00   
  High 1.19 (0.79-1.79) 1.17 (0.76-1.81) 1.25 (0.79-1.97) 
Sleep problemsb             
  Low 0.94 (0.61-1.45) 1.08 (0.65-1.80) 1.10 (0.66-1.84) 
  Moderate 1.00   1.00   1.00   
  High 0.89 (0.61-1.29) 0.89 (0.59-1.35) 0.77 (0.49-1.21) 
Stratified Analyses 
Prevalence of Infection 
New infection             
Perceived Stressa             
  Low 1.00   1.00   1.00   
  High 1.41 (0.81-2.44) 1.07 (0.57-1.99) 1.28 (0.60-2.75) 
Sleep problemsb             
  Low 1.89 (1.06-3.38) 1.19 (0.56-2.51) 1.24 (0.59-2.60) 
  Moderate 1.00   1.00   1.00   
  High 1.25 (0.71-2.21) 0.85 (0.46-1.57) 0.63 (0.29-1.37) 
Prevalent infection             
Perceived Stressa             
  Low 1.00   1.00   1.00   
  High 1.04 (0.57-1.90) 1.00 (0.54-1.83) 0.99 (0.53-1.85) 
Sleep problemsb             
  Low 0.83 (0.44-1.54) 1.24 (0.52-2.91) 1.23 (0.52-2.93) 
  Moderate 1.00   1.00   1.00   
  High 0.96 (0.56-1.65) 1.09 (0.59-2.03) 1.08 (0.58-2.00) 
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Table 3.4 continued 
 
Age Category 
Aged 18 to 29             
Perceived Stressa             
  Low 1.00   1.00   1.00   
  High 0.82 (0.43-1.55) 0.82 (0.40-1.67) NC   
Sleep problemsb             
  Low 0.73 (0.38-1.38) 0.97 (0.37-2.52) NC   
  Moderate 1.00   1.00   1.00   
  High 0.57 (0.30-1.07) 0.57 (0.28-1.16) NC   
Aged 30 to 49             
Perceived Stressa             
  Low 1.00   1.00   1.00   
  High 1.78 (0.87-3.64) 1.13 (0.26-4.99) 1.53 (0.30-7.86) 
Sleep problemsb             
  Low 1.07 (0.45-2.57) 1.94 (0.76-4.93) NC   
  Moderate 1.00   1.00   1.00   
  High 1.11 (0.56-2.20) 1.07 (0.33-3.45) NC   
Aged ≥50             
Perceived Stressa             
  Low 1.00   1.00   1.00   
  High 0.17 (0.03-1.17) NC   NC   
Sleep problemsb             
  Low NC   NC   NC   
  Moderate 1.00   1.00   1.00   
  High NC   NC   NC   
aMultivariable 1 model adjusted for age, insurance, education, marital status, number of 
vaginal sex partners in the past 6 months, and prevalence of HPV infection, Multivariable 
2 model additionally adjusted for sleep category 
bMultivariable 1 model adjusted for age, insurance, education, marital status, smoking 
status, alcohol consumption, lifetime number of sex partners, and prevalence of HPV 
infection, Multivariable 2 model additionally adjusted for perceived stress category 
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Chapter 4: Discussion 
 
Conclusions 
 
 This research identified two new factors significantly associated with HPV 
infection in men. This is the largest study to measure perceived stress or self-reported 
sleep problems in relation to an infection outcome. Study findings support research on the 
association between stress and sleep disturbance with immunity, also contributing to the 
field of psychoneuroimmunology. Results suggest new avenues for further research, 
which could possibly lead to new prognostic factors or indicate a possible target for 
interventions among individuals HPV-positive. 
 Over the past 30 years, many studies have been conducted to examine the 
association between stress and the immune system. However, much of the previous 
research examining stress has looked at associations with measures of the immune system 
such as cytokines and Natural Killer cells. Whether these changes in immune function 
can have implications for disease in healthy populations remains unclear11. Studies which 
examine perceived stress, changes in immune parameters, and disease or infection 
outcomes are needed to determine the effect of changes in immune parameters on clinical 
outcomes and whether these changes in immune function are the mechanism by which 
stress can influence disease. 
 This study adds to the psychoneuroimmunology literature by reporting on 
associations between perceived stress and self-reported sleep problems with HPV 
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prevalence, clearance, and incidence. Few studies have examined associations between 
these factors and a clinical outcome such as HPV infection. This is also the largest study 
to date to examine associations between perceived stress, sleep disturbance, and an 
infection outcome. 
 Initial analyses examined the association between perceived stress and self-
reported sleep problems with HPV prevalence using data from the baseline visit. This 
analysis included a total of 426 men, although 2 did not have genotyping data available. 
Due to the high prevalence of HPV infection in this population (44.8%), prevalence ratios 
(PR) were calculated rather than odds ratios (OR). Logistic regression models have been 
widely used to estimate ORs adjusting for covariates, however the OR will only 
approximate the relative risk (RR) when the outcome of interest is rare (<10%). When the 
outcome is common the OR will overestimate the RR68. Because the outcome of interest 
in this study was common (45% of participants were HPV-positive), a Poisson regression 
model with robust error variance was used estimate the prevalence ratio50.  
 The association between perceived stress and self-reported sleep problems with 
HPV infection was not linear. A higher prevalence of HPV infection was only observed 
among men scoring in the highest quartile of perceived stress. For self-reported sleep 
problems, men in the middle 50% had the lowest prevalence of HPV and those with both 
low and high self-reported sleep problems had a higher prevalence. To further explore 
associations between HPV prevalence, marginal generalized estimating equation models 
with an autoregressive correlation structure were used to calculate ORs including all 
study visits when the full dataset was available69. Results of this analysis were formatted 
as a brief for potential publication and can be found in Appendix D. 
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 For HPV clearance and incidence, Cox regression62 was used to examine 
associations with perceived stress and self-reported sleep problems. There were several 
issues with this dataset which required consideration for analyses. Items to assess the 
exposures were added midway through the CER study, therefore participants could have 
received the additional items for the first time at their 1st, 2nd, 3rd, or 4th study visit. 
However, HPV test results were available for all visits, including those before the first 
time exposure items were asked. To avoid bias, time was calculated as the time from the 
first detection of an HPV type, not the first time participants tested positive after they 
came under observation by the additional survey items. Thus, the data were left truncated. 
Because men could be infected with multiple HPV types, there were multiple parallel 
events per subject. To address these issues, the data set was put into a counting process 
format. This format allows time-dependent covariates and strata, left truncation, and 
multiple events per subject70. The robust sandwich estimator was used for the covariance 
matrix 13 to account for with-in subject correlations. 
 In the baseline prevalence analyses, high perceived stress and both high and low 
self-reported sleep problems were significantly associated with a higher prevalence of 
any HPV infection and oncogenic HPV infection. Analyses using all study visits suggest 
effect modification of the relationship between HPV prevalence and perceived stress by 
age group and marital status and by age group, marital status, and education for self-
reported sleep problems. Men with high perceived stress were significantly more likely to 
be infected with oncogenic HPV in the total sample, among men 50 and older, and 
among single men. Compared to men with moderate self-reported sleep problems, men 
with low sleep problems were significantly more likely to be infected with any HPV type 
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among the total sample, men aged 30 to 49, men aged 50 and older, men with a college 
degree, and married men; significant associations with an oncogenic HPV type were 
found among the total sample and men with a college degree; and significant associations 
with a non-oncogenic HPV type were found among men aged 30 to 49 and married men. 
Compared to men with moderate self-reported sleep problems, men with high sleep 
problems were significantly more likely to be infected with oncogenic HPV among men 
with a college degree. 
 In the prevalence analysis, men reporting low or high sleep problems had a higher 
prevalence of HPV than men in the moderate category. In the clearance analysis, men 
with low sleep problems were less likely to clear any HPV infection or an oncogenic 
HPV infection compared to the moderate group although differences were not significant. 
Men in the low sleep problems group could have reported sleeping longer than 9 hours 
per night. Because both short and long sleep duration have been associated with other 
disease outcomes in previous studies, additional analyses were conducted to examine 
these associations. Table E.9 presents analyses of GEE prevalence and WLW clearance 
estimates for 5 categorizations of sleep duration with 7 to 9 hours as the reference group. 
Although only two point estimates were significant in all the analyses, it suggests that 
men with long sleep duration may also be more likely to be HPV positive. 
 Factors associated with HPV clearance in prior research studies conducted among 
men include circumcision status, lifetime number of sex partners, infection with multiple 
HPV types, age, and country of residence4,49,57-61. Analyses of the follow-up data 
examined perceived stress and self-reported sleep problems with incidence and clearance 
of HPV infection. In the total sample, men high self-reported sleep problems were 
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significantly less likely to clear any HPV type and oncogenic HPV types compared to 
men with moderate sleep problems. Perceived stress was not significantly associated with 
HPV clearance in the total sample. However among men aged 50 and older, those with 
high stress were significantly less likely to clear an HPV infection.  
 Clearance analyses were also stratified by whether the infection was newly 
detected or had been detected previously. Although results were not significant, among 
men with new infections those with high perceived stress were more likely to clear an 
infection compared to men with low perceived stress whereas among men with 
previously detected infections those with high perceived stress were less likely to clear 
and infection compared to men with low perceived stress. Due to the cross-sectional 
nature of the prevalence analysis, men with longer lasting infections would be more 
likely to be positive at the time of the study. If prevalent infections are negatively 
affected by high stress, but new infections are not, this could explain the significant 
results in the prevalence analysis that were not found in the overall sample in the 
clearance analysis. As expected based on the prevalence analysis, men with high and low 
sleep problems were less likely to clear HPV infections compared to men with moderate 
sleep problems. 
 In the prevalence analyses and clearance analysis, adjustment for demographic 
factors and sexual behavior increased the magnitude of associations between HPV 
infection and both perceived stress and self-reported sleep problems. The prevalence 
analysis of all study visits and the clearance analysis suggest that age may modify the 
association between perceived stress and HPV infection, with effects more prominent 
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among men 50 and older. Results of all analyses suggest that oncogenic HPV types are 
affected by stress and sleep disturbance, but non-oncogenic types may not be. 
Future Research 
This is a relatively small study, however results suggest that further investigation 
of these factors may prove useful. Although there is a vaccine to prevent infection and 
treatments are available for HPV-related diseases such as topically applied creams, 
surgical removal, cryotherapy, trichloroacetic acid, and 5-fluororacil, there is no antiviral 
treatment that can cure HPV infection among patients HPV-positive19. Determining 
modifiable behavioral factors associated with HPV clearance, such as perceived stress 
and sleep problems, could be important in secondary prevention efforts to decrease the 
burden of HPV-related diseases. Future studies could examine associations of these two 
exposures with HPV infection among women. Gender may be an effect modifier of the 
association between stress and immune function, thus these findings need to be 
confirmed in female populations.  
 There are many ways to measure stress and additional stress measurements as 
well as other psychosocial factors such as coping, social support, and emotional 
responses may be examined. This study only measured self-reported perceived stress and 
sleep problems. The use of full-length validated questionnaires or objective measures of 
sleep such as wrist actigraphy or EEG may be helpful in elucidating the relationship 
between sleep disturbance and HPV infection. Associations between both stress and sleep 
disturbance with immune parameters such as NK cells, cytokine levels and Th1 to Th2 
ratios could also be a focus of further studies. Salivary cortisol has been widely used as a 
biomarker for psycholocial stress67. Examining the relationships between cortisol levels, 
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participant reported perceived stress and sleep disturbance, objective measures of sleep, 
immune parameters, and HPV infection could provide a better understanding of the 
mechanisms by which these exposures influence HPV infection and biologic plausibility. 
This study looked at associations between perceived stress and sleep problems 
only with HPV infection. Many HPV infections are transient and do not result in clinical 
disease such as genital warts and lesions. Examining the associations of these factors with 
HPV-related diseases among both men and women may be useful. Results of this study 
suggest oncogenic, rather than non-oncogenic, HPV types may be affected by perceived 
stress and sleep disturbance. Thus, diseases caused by oncogenic types such as pre-
cancerous cervical, penile, and anal lesions, as well as ano-genital cancers could also be 
associated with these two behavioral factors. If these factors are associated with HPV-
related diseases, future research could examine behavioral interventions among these 
patients. 
Determining factors associated with HPV prevalence, clearance, and HPV-related 
diseases may also aid in risk stratification of HPV-positive patients. Although HPV 
infection is very common, most patients will not develop clinical disease due to the virus. 
Combining information on stress, sleep, and other factors may allow identification of 
patients at the highest risk of progressing to more severe disease and allow clinicians to 
target them for closer follow-up. Patients with the lowest risk of progression may not 
need to be followed closely, which could decrease the financial and psychological burden 
of being HPV-positive among these patients.  
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Appendix A. Literature Review 
 
 
HPV 
 
The Papillomaviridae are a family of DNA tumor viruses.  Included in this family 
are the human papillomaviruses (HPV) which comprise over 100 different types.  These 
viruses can cause genital warts and are a necessary cause of cervical cancer1.  HPV 
infections are also associated with other anogenital cancers and a portion of 
oropharyngeal cancers2. 
About 40 HPV types, members of the Alphapapillomaviruses1, can infect mucosal 
tissues such as the anogenital and aerodigestive tracts.  HPV types that infect the genital 
tract are classified as high-risk types, associated with intraepithelial neoplasias and 
invasive carcinomas, and low-risk types which are associated with condylomatas or 
genital warts19.  Specifically, HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 
73,and 82 have been identified as high-risk types71. 
Anogenital HPV infection is the most common sexually transmitted infection 
(STI).  Most individuals who are sexually-active will become infected in their lifetime18.  
There are an estimated 6.2 million incident infections annually in the United States. 
Infection with multiple HPV types is common due to the shared route of sexual  
transmission1.  Natural history studies find cumulative incidence rates of 13.6% to 41% 
after 12 months of follow-up, 34% to 39% after 24 months, and 55% after 5 years72.   
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HPV types 6 and 11 cause 90% of genital warts cases.  Though infection is 
common, only about 1% of adults have visible warts.  Most incident infections (74%) 
occur in individuals 15 to 24 years of age19.  The incidence of genital warts has been 
increasing in the US since the 1950s73.  In addition to genital warts, HPV can also cause 
papillomas in oral mucosa and recurrent respiratory papillomatosis (RRP), which can 
interfere with breathing and may require surgical or laser removal19.   
HPV Biology 
The HPV genome encodes for early (E) and late (L) viral proteins.  There are 
seven E proteins, of which E6 and E7 are oncogenic and can interfere with the host’s cell 
cycle control.  E6 binds the oncosuppressor p53 and E7 binds the RB protein74.  The 
genomes of high risk types have been found to integrate into the host’s DNA in cases of 
cervical neoplasia74.  Integration leads to disruption of the E2 gene, a repressor of E6 and 
E7, and upregulation of E6 and E753.  L1 and L2 encode the structural and viral capsid 
proteins74.  The L1 gene is the most conserved and has been used for identification of 
different HPV types.  Differences greater than 10% define a type, 2% to 10% a subtype, 
and less than 2% a variant75.   
Cervical Cancer 
The National Cancer Institute estimates that in 2010 there will be 12,200 incident 
cases of cervical cancer (age-adjusted incidence rate=8.1 per 100,000 per year based on 
2003-2007 SEER data) and 4,210 women will die of the disease (age-adjusted death 
rate=2.4 per 100,000 annually).  Cervical cancer affects women at younger ages then 
other forms of cancer.  From 2003 to 2007 the median age at diagnosis was 48 and the 
median age at death was 57.  Among incident cases, 14.5% were aged 20 to 34, 26.1% 
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were 35 to 44 and 23.7% were 45 to 54.  Of the deaths due to cervical cancer 5.1% were 
aged 20 to 34, 16.0% were 35 to 44, and 23.2% were 45 to 54.  Racial disparities exist, 
with black and Hispanic women having higher age-adjusted incidence and a death rates 
than white women76. 
Most cervical cancers are squamous cell carcinoma (SCC) (85 to 90%), with 
adenocarcinoma accounting for 10 to 15% of cases74.  The vast majority of cervical 
cancers (99%) occur within the cervical transformation zone where squamous metaplasia, 
the replacement of columnar epithelium by squamous epithelium, takes place56.  Nearly 
all carcinomas of the cervix are caused by high-risk HPV1; HPV is detected in >99% of 
cases72.  HPV carcinogenesis can also occur in similar tissue located in the anus56.   
Infection with HPV can lead to abnormal cervical cytology and histology.  
Papanicolaou (Pap) tests are used to screen for abnormal cytology.  The most common 
cytology is atypical squamous cells (ASC).  ASC includes two subcategories; ASC of 
undetermined significance (ASCUS) and ASC cannot exclude high-grade squamous 
intraepithelial lesions (ASC-H).  Cytological diagnoses also consist of low-grade 
squamous intraepithelial lesions (LSIL) and high-grade squamous intraepithelial lesions 
(HSIL)1.  The basis of Pap test guidelines are that lesions progress from low-grade 
dysplasia to moderate and severe dysplasias, followed by pre-invasive lesions and 
eventually develop into invasive cancers, although studies have shown that rapid 
progression to HSIL can occur77,78.  Having a low-grade pap smear (ASCUS or LSIL) is 
the main risk factor for a high-grade smear (HSIL and ASC-H)79.  
Histological diagnoses of biopsies include cervical intraepithelial neoplasia (CIN) 
1 though 3, squamous cell carcinoma in situ (CIS), adenocarcinoma in situ (AIS) and 
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invasive cancer.  An estimated 1 million women will be diagnosed with CIN 1 annually 
in the US and 500,000 will be diagnosed with high-grade lesions including CIN 2 and 3.  
Most cases of CIN 1 (70 to 90%) will regress.  There is debate about whether CIN 2 
constitutes a low-grade or high-grade lesion.  It is estimated that about 43% of untreated 
CIN 2 lesions regress, 35% will persist, and 22% progress to become carcinoma.  CIN 3 
is considered cervical pre-cancer and is used as a surrogate for invasive cervical cancer1.  
Most cases of cervical carcinomas (70%) are caused by HPV type 16 or 1819, with types 
31 and 45 accounting for an additional 10% of cases72.  Whereas HPV-16 is the most 
common type detected in SCC (50% of cases) HPV-18 is the most common type detected 
in cervical adenocarcinomas (55% of cases)72. 
Infection with a high-risk type of HPV is a necessary, but not sufficient, cause of 
nearly all cases of cervical cancer18.  Though infections are very common, only a few of 
those women who are infected will progress to cervical cancer.  Many women who 
become infected will clear the infection six to 12 months later.  It is still unclear whether 
the infection is entirely cleared by the host or the virus becomes latent and is not 
detectable55.  It remains unknown why in a minority of women HPV infections persist 
and progress to cervical lesions and cancer56.  Although infection with oncogenic HPV is 
necessary, other factors may be important in the development of cancer such as host cell-
mediated immunity, smoking, oral contraceptive use, infection with other STIs, 
inflammation, and parity56. 
Other Cancers 
 Though cervical disease is the most researched, HPV can cause neoplasias in 
several other anogenital sites including vulvar (VIN), vaginal (VAIN), anal (AIN), and 
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penile (PIN) intraepithelial neoplasias19.  About 60% to 90% of vaginal, anal and perianal 
cancers are positive for HPV.  Sexual practices, such as men having sex with men 
(MSM) increase the risk of anal cancer2.  The incidence of anal cancer and AIN is even 
higher among immunocompromised populations80.  The age adjusted incidence rate of 
anal cancer in the general population is estimated to be 1.4 to 2 per 100,000.  Studies of 
HIV+ men have shown an incidence of 70 per 100,00080.  Among established renal 
transplant patients, the prevalence of anal HPV infection is 47% and the relative risk for 
anal cancer is about 1080.  HPV, particularly HPV-16, is also found in 50% of vulvar 
cancers and 30% to 50% of penile cancers2.  
 More recently, HPV has also been implicated in causing carcinomas of the head 
and neck.  About 25% to 30% of these cancers have been associated with HPV infection.  
The annual incidence of these cancers have been increasing in the US since the 1970’s, 
possibly due to changes in sexual practices2. 
Burden of HPV 
 HPV infections cause a substantial burden to the health care system.  Women with 
cytological diagnoses of ASCUS or SILs require monitoring with additional Pap smear 
screenings and possible colposcopy and biopsy18.  The annual estimated direct medical 
costs of follow-up for abnormal cytology and treatment of neoplasias was $3.6 billion 
and $146.4 million for treatment of invasive cervical cancer in the US in the year 200081.   
 The direct medical costs of treating anogenital warts is difficult to estimate due to 
the wide range of incidence estimates.  Assuming an incidence of 500,000, the costs are 
approximated at $167.4 million annually81.  Treatment of genital warts can be difficult.  
No current treatment can offer a cure for the disease; removing genital warts, maintaining 
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clearance, and clearing the virus.  Warts may be removed via ablative therapies, however 
rates of recurrence can be high73.  The economic impact of non-cervical diseases due to 
HPV-6, -11, -16, and -18 including anogential warts, juvenile-onset recurrent respiratory 
papillomatosis (JORRP), and other genital cancers (anal, penile, vaginal, and vulval) and 
mouth and oropharyngeal cancers in the US was estimated at $418 million (range $160 
million to $1.6 billion)  in 200382. 
HPV infection also carries a psychlogical burden.  The most commonly reported 
emotions among HPV-positive women are depression, anxiety, and anger83.  Women 
with abnormal Pap smear results have reported feelings of stigma, fear, self-blame, anger, 
stress, confusion, and embarrassment84.  The emotional and psychological stress genital 
warts can cause can be worse than the morbidity of the disease including sex life 
impairments, fear of cancer, and negative affects on the emotional relationship with sex 
partners73.   
Brief Immunology Background 
 The human immune response can be divided into innate immunity and adaptive 
immunity.  Innate immune responses occur within minutes to hours of exposure to a 
pathogen.  The immune parameters of the innate immune system include; macrophages 
and neutrophils which ingest and destroy pathogens; complement, plasma proteins that 
induce inflammatory responses and mark pathogens for destruction by phagocytes; and 
natural killer (NK) cells which can destroy infected cells.  If a pathogen is able to breach 
these immediate immune defenses, then adaptive immune responses become activated.  
Adaptive immunity takes several days to develop, but can lead to long-lasting memory of 
specific pathogens. 
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 Antibody-mediated, or humoral, immunity responds to extracellular pathogens, 
clearing free virus particles and preventing reinfection.  Foreign substances (antigens) 
provoke the production of antibodies, proteins which combine with a specific antigen and 
accelerate its destruction.  Immunoglobulins (Ig) are the antigen recognition molecules on 
B cells.  There are five different types of Ig - IgM, IgD, IgG, IgA, and IgE - each with 
distinctive functions.  This immune response is the basis for the ability of vaccines to 
induce immunity.  Pathogens residing within the cell, such as viruses, do not encounter 
antibodies and cannot be destroyed by an antibody response.  Lymphocytes, cells that 
recognize and respond to antigens, destroy cells infected with intracellular pathogens in a 
process called cell-mediated immunity.  T lymphocytes are important in cell-mediated 
and humoral immunity.  Immune cells secrete proteins that mediate signaling between 
cells called cytokines.  The main classes of cytokines are interleukins (IL), interferons, 
(IFN), tumor necrosis factors (TNF), and chemokines22,85.   
The two classes of lymphocytes are B and T cells.  B cells originate within bone 
marrow whereas T cells develop within the thymus.  Lymphocytes carry clusters of 
differentiation (CD) molecules on the cell surface.  Two major subsets of T cells are 
those that carry CD4, a major histocompatibility complex (MHC) class II receptor and 
the receptor for HIV, and CD8, an MHC class I receptor.  Maturing T cells carry CD4, 
CD6, and CD8.  Mature T cells will become CD4+CD8- (helper T cells) which promote 
immune responses and CD4-CD8+ (cytotoxic T cells) which kill other cells and can 
suppress the immune response. T cells are divided into two subsets, T helper 1 (Th1) and 
T helper 2 (Th2), which are characterized by the lymphokines (cytokines released by 
lymphocytes) they secrete.  Th1 cells are involved in cell-mediated immunity and secrete 
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IL-2 (an activation factor for T, B, and NK cells), IFN-γ (enhances B cell production of 
Ig2a, production of MHC class I molecules, NK activity, and activates macrophages), and 
TNF-β (can induce apoptosis, activate neutrophils, and enhance leukocyte adhesion and 
procoagulant).  IL-12 stimulates Th1 cells.  Th2 cells support humoral immunity (aiding 
B lymphocytes in differentiating into plasma cells and secreting antibodies) and secrete 
IL-4, IL-5, IL-10, and IL-13.  The activities of Th1 lymphokines have a tendancy to 
counter the activities of Th2 lymphokines22,85.  CD4+ T cells are Th1 type while CD8+ 
are Th2.  Regulatory T cells (CD4+CD25+ Treg) secrete IL-10 and TGF-β and have been 
implicated in chronic and immunopathologic viral infections.  Antigen presenting cells 
(APC) activate naïve T cells and determine whether they become Th1, Th2, or Treg20.   
HPV and Immunity 
In most infected individuals, HPV-specific humoral and cell-mediated immune 
responses will eventually clear the infection to where HPV DNA of a specific type can no 
longer be detected20,53.  However, the exact mechanism of a successful immune response 
remains to be elucidated54.  HPV has evolved several mechanisms to avoid recognition by 
the host immune system including replicating without inducing cell death and 
suppression of proinflammatory cytokines, chemokines, and antiviral proteins54.  A 
suboptimal CD4+ T cell response along with induction of T reg cells may contribute to 
persistence of an HPV infection54.   
Despite the ability of HPV to evade immune response, a successful immune 
response characterized by strong, local cell-mediated immunity, is mounted in most 
individuals20.  Regressing genital warts display a Th1 type immune response with large 
infiltrates of CD4+, CD8+, macrophages in the stroma and epithelium and IL-12, TNF-α, 
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and IFN-γ cytokines9.  Though detailed prospective studies are not possible in humans, 
animal models of mucosal HPV infection demonstrate a cellular infiltrate similar to that 
seen in humans with regressing warts. In these animal models, systemic T cells responses 
to HPV E2 and E6 peak during wart regression20. 
HPV infection occurs in the lower genital tract in females, which is part of the 
mucosal immune system.  Therefore, local immunity may be significant in clearance or 
persistence of an HPV infection74.  Cervical anti-HPV immunoglobulin (Ig)A and IgG 
have been inversely correlated with HPV DNA and cervical lesions86,87.  In organ 
transplant patients on immunosuppressive drugs the prevalence of viral warts increases 
with increasing time since transplantation88. 
Women who are HIV+, even those on highly active antiretroviral therapy 
(HAART), clear HPV infections at a significantly lower rate than HIV- women89,90. CD4 
cell count has been associated with HPV persistence in HIV+ women90.  A study among 
men who have sex with men (MSM) found that HIV+ MSMs may clear certain types of 
HPV slower than HIV- MSMs.  This study had few HIV+ participants and may have 
been underpowered to detect differences for all HPV types91. 
Cervical Neoplasia and Immunity 
Host immune response plays a role in the development of cervical lesions and 
cancers as evidenced by higher rates of cervical lesions and anogenital cancers among 
HIV infected individuals89,92 and the immunocompromised.80,93  Use of HAART has been 
shown to affect lesion development among HIV+ women by decreasing the risk of 
progression and increasing regression92,94.  Cervical cancer is usually found among 
individuals who harbor HR-HPV infection for years or decades without an effective 
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immune response.  Cellular and humoral immune responses are necessary for clearance 
of HPV-associated cervical lesions and prevention of progression to more advanced 
disease states.  Although it has not been well characterized, the cervical mucosal immune 
response is thought to be important in viral clearance95. 
Th1 type immune responses have been shown to significantly correlate with 
regression of lesions in many studies.  Compared to normal tissue, HSIL has a 
significantly lower percentage of Th1 type cells and higher proportions of IL4+ and IL6+ 
cells95.  Consistent with a reduced th1 type immunity, de Gruijl et al. (1998)96 found the 
frequency of IFN-γ, IL-19, and IL-12 mRNA expression was significantly lower in 
cervical cancer biopsies compared to biopsies from normal or CIN 1-3 women.  In 30 
women with CIN III and 10 healthy controls, women with CIN III who had more 
extensive disease had lower production of IL-2 after mitogen stimulation and higher 
production of IL-4 and IL-10 after PHA-stimulation97.  Lymphoproliferative responses to 
HPV 16 E6 and E7 peptides have been associated with clearance of HPV infection and 
regression of CIN lesions98 and cell-mediated immune response to E7 peptides 
significantly correlates with regression and resolution of infection within 12 months10.   
HPV 16 E2 specific T-cell Th1 responses are associated with regression of 
LSIL23,25.  de Jong et al. (2004)99 found a strong CD4+ T-helper lymphoproliferative 
response along with  prominent IFN-γ and IL-5 secretion against HPV 16 antigens in 
healthy women, whereas women with cervical cancer had absent or impaired HPV 16 
specific immune responses.  They theorize that this lack of HPV 16 specific T-cell 
immunity could result in the development of cervical cancer.  In a study by Steele et al. 
(2005)100 the frequency of CD4+ T-cell response to HPV 16 proteins was higher in 
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normal women (50%) and women with cancer (60%) compared to those with CIN 1 
(37.5%) and CIN 2-3 (25%).  In patients with regressing CIN 1, CD4+ cells 
predominated within the stroma and epithelium.  These patients with regressing CIN 1 
had higher CD4/CD8 ratios than progressing CIN 1, CIN 3, and invasive cancer in the 
stroma, although this difference was significant only for invasive cancer.  Patients with 
invasive carcinoma had significantly higher CD8+ and CD45RO+ cells compared to 
regressing CIN 1101. 
Th1 type CD4+ T-cell reactivity to HPV18 E6 have been detected in 20% of 
healthy blood bank donors compared to 0% of patients with HPV 18+ CIN 3 or cervical 
cancer102.  In a follow-up study of 13 cervical cancer patients, production of IFN-γ by 
HPV-18 E6 specific CD4+ T cells, total number of CD4+ T cells, and T-bet+ lymphoid 
cells were significantly higher among those with a favorable outcome after surgery103. 
A cross-sectional analysis of 140 women showed that the proportion of women 
showing strong IL-2 production against HPV-16 peptides was greatest in women who 
were cytologically normal, but had previously tested HPV positive (35%) and decreased 
with increasing disease grade; 20% in LSIL, 17% in HSIL, and 7% in cancer patients104.  
In multivariate analysis of cross-sectional data, higher levels of IFN-γ and IL-10 were 
significantly associated with decreased odds of having CIN 2 or 3 compared to CIN 1 or 
normal histology.  Increased expression of Foxhead box P3 (Foxp3), a Treg transcription 
factor, was significantly associated with having CIN 2 or 3105. 
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Among women with cervical dysplasia followed for 7 to 52 months, cellular 
immunity to HPV 16 E7, assessed via delayed-type hypersensitivity skin test, was 
significantly associated with regression of CIN24.  Secretory IgA (SIgA), IgG, and SIgM 
contribute to mucosal immunity.  IgA and IgG have been associated with cervical 
lesions86,87. 
Genetic factors affecting some immune system components have been associated 
with clinical outcome of HPV infection.  Genetic variation in HLA genes may play a role 
in the immune response against HPV95.  Polymorphisms in the TNF-α, a pro-
inflammatory Th1 cytokine gene, have been associated with CIN 1 or invasive cervical 
cancer in case-control studies106,107.   
It is estimated that HIV+ women have a 2 to 12 folder higher risk of developing 
cervical lesions and a significantly lower mean age of invasive cervical cancer (ICC).  
ICC was added to the CDC list of AIDS-defining illnesses108.  Renal transplant patients 
have a significantly higher prevalence of cervical neoplasia than non-immunosuppressed 
controls109.  A prospective study that followed HIV+ and HIV- women for up to 5.5 years 
found that the risk of incident SIL was significantly higher among HPV+ women, rate 
ratio=4.5, 95% CI: 3.1 to 6.492.  The cumulative incidence of ASCUS among women 
normal at study entrance was 78% among HIV+ compared to 38% among HIV- women.  
Among women who had ASCUS diagnosed by Pap smear, significantly more HIV+ 
women progressed to SIL (60% of HIV+ and 25% of HIV-, p<0.01).  HIV+ women with 
lower CD4+ lymphocyte counts were more likely to develop SIL, OR=1.7, 95% CI: 0.8 
to 3.692.  Table A.1 presents a summary of immune parameters that have been associated 
with HPV-related disease outcomes. 
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Table A.1. Immune Parameters Associated with HPV Infection and Cervical Lesions 
 
Immune parameter   Increase associated with   Sources 
IgA   ↓ cervical disease and HPV DNA   Bierl (2005)86 
IgG   ↓ cervical disease and HPV DNA   Bierl (2005) 
HPV-specific cytotoxic T lymphocytes 
(CTL) 
  ↑ cervical disease   Sheu (2007)95 
lymphoproliferative response to HPV 16   clearance of HPV and regression 
cervical lesions 
  Sheu (2007) 
HPV 16 E2 specific T-cell response   ↑ regression of LSIL   Woo (2010)25 
INF-γ   ↓ prevalence of CIN 2 r 3   Scott (2009)105 
INF-γ transcripts   premalignant disease vs invasive 
carcinoma 
  de Gruijl (1998)96 
production of IFN-γ by HPV-18 E6 
specific CD4+ T cells 
  favorable clinical outcome after 
surgery 
  Seresini (2007)103  
IL-10   ↓ prevalence of CIN 2 or 3   Scott (2009) 
IL-10 transcripts   premalignant disease vs invasive 
carcinoma 
  de Gruijl (1998) 
IL-12 transcripts   premalignant disease vs invasive 
carcinoma 
  de Gruijl (1998) 
Foxp3 (T reg transcription factor)   ↑ prevalence of CIN 2 or 3   Scott (2009) 
T-lymphocytes   regression of genital warts   Coleman (1994)9 
macrophages   regression of genital warts   Coleman (1994) 
CD4+ T-cell reactivity to HPV 18 E6 and 
E7 
  healthy control status vs CIN 3 or 
cancer 
  Welters (2006)102 
CD4+ T-cell response to HPV 16    normal or cancer vs CIN 1-3   Steele (2005)100 
total number of CD4+ T cells   favorable clinical outcome after 
surgery 
  Seresini (2007) 
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Table A.1 continued 
 
total number of T-bet+ lymphoid cells   favorable clinical outcome after 
surgery 
  Seresini (2007) 
delayed-type hypersensitivity to HPV 16 
E7 
  regression of CIN   Hopfl (2000)24 
CD8+ cell count   invasive cancer   Monnier-Benoit 
(2006)101 
CD45RO+   invasive cancer   Monnier-Benoit 
(2006) 
CD4+/CD8+ ratio   regressing CIN 1 vs invasive cancer   Monnier-Benoit 
(2006) 
    regression of genital warts   Coleman (1994) 
HIV Positive Populations 
CD4+ cell count   ↑ HPV clearance   Moscicki (2004)90 
    ↓ SIL   Duerr (2006)92 
HAART use   ↑ lesion regression   Minkoff (2001)94 
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Treatment 
 
 There is no antiviral treatment available that can cure HPV infections.  
Podophyllotoxin and imiquimod can be applied by patients at home to treat genital warts.  
Podophyllotoxin arrests cell division and induces cell death.  Imiquimod induces 
production of a Th1 weighted immune response.  Other therapies include surgical 
removal of lesions,  cryotherapy, trichloroacetic acid, and 5-fluororacil19. 
 Recently, two vaccines have been developed using virus-like particles (VLPs) to 
prevent HPV infection.  Gardasil protects against types 6, 11, 16, and 18 while Cervarix 
protects against types 16 and 18.  Both vaccines are up to 100% effective and could 
prevent 70% of cervical cancers and 90% of genital warts (Gardasil only) in women and 
men not already infected with these types of HPV.  The high cost of these vaccines may 
be a barrier to vaccine uptake19. There has also been considerable controversy 
surrounding the HPV vaccine itself and enactment of compulsory vaccination for school 
attendance in the U.S., which has been shown to achieve high rates of vaccine 
coverage110.  
Factors Associated with HPV Clearance 
 HPV persistence is generally defined as detection of the same HPV type at least 
two times over a specified time interval.  There is no consensus on what time interval 
should be considered “meaningful” persistence.  Studies have shown that the longer an 
HPV infection persists the more likely it is to remain persistent.  Studies of HPV viral 
clearance and HPV-related diseases in women have found several factors which are 
associated with HPV persistence; smoking, oral contraceptive use, infection with other 
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STIs such as Chlamydia trachomatis, diet including fruit and vegetable and alcohol 
intake, and host factors such as genes for HLA class I and II.  Viral factors such as HPV 
type, viral load, and viral integration are also associated with disease outcomes1.  Few 
studies have examined HPV persistence in men.  Factors that influence HPV persistence 
in men remain to be elucidated.   
Kjaer et al. (2005)57 examined persistence of HPV in male soldiers aged 18 to 29 
years.  After a baseline visit, men were examined approximately 6.6 months later (range 
5.4 to 7.8 months).  Of the 374 men enrolled, 114 were HPV-positive at their baseline 
visit.  Data for 73 to 77 men were reported in the analysis of HPV persistence.  In 
univariate analysis, multiple HPV types at baseline, high risk type at baseline, and current 
smoking were associated with persistence.  Multiple HPV types at baseline was the only 
factor examined which was significant in multivariate analysis, adjusted OR=4.2, 95% 
CI: 1.3-12.7.  High-risk type, current smoking, Chlamydia DNA, age (≥21 versus ≤20) 
and number of sex partners (0-1 versus ≥2) were not significantly associated with HPV 
persistence in multivariate analysis.  
In this analysis HPV infection was considered to be persistent if any of the HPV 
types detected at baseline was subsequently detected at the follow-up visit.  Therefore, 
men with multiple HPV infections would need to clear all of them in order to be included 
in the clearance group.  Thus, the finding that multiple HPV types at baseline is related to 
clearance of HPV could be an artifact of the method of analysis. 
 Lajous et al. (2005)58 evaluated HPV persistence in male soldiers in Mexico.  
Three hundred thirty six men were sampled at a baseline visit and at a one year follow-
up.  There were 105 men who were HPV-positive at baseline and had a follow-up visit.  
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Higher median number of baseline infections was significantly associated with increased 
risk of persistence, adjusted OR=1.84, 95% CI:1.24-2.90, and men who self-reported they 
were circumcised had a significantly decreased risk of persistence, adjusted OR=0.12, 
95% CI: 0-0.87.  Age (<20, 21-25, and >25), religion (Catholic, Other, None), intercourse 
with prostitutes, and anal intercourse with females were not significantly associated with 
HPV persistence. 
 The definition of persistence in this analysis was defined as "having the same 
HPV type at both times; these participants were compared with those who were 
positive at baseline and negative at follow-up."  Thus, it appears that in this analysis men 
with multiple HPV types would have to clear all of them in order to be considered as 
having HPV clearance. 
 A prospective cohort study by Giuliano et al. (2008)49 examined 290 men every 6 
months for HPV infection; mean duration of follow-up of was 15.5 months.  Median time 
to clearance (the amount of time for 50% of infections to clear) was 5.9 months for any 
HPV infection, 5.8 months for oncogenic HPV types, and 6.0 months for nononcogenic 
types.  The percent of participants who remained HPV positive at 6 months was 44.5% 
for any HPV, 41.7% for oncogenic HPV, and 46.5% for nononcogenic HPV.  At 12 
months, 25.5%, 19.0%, and 29.3% remained positive for any HPV, oncogenic HPV, and 
nononcogenic HPV, respectively with 10.7%, 0%, and 14.4% remaining positive at 18 
months.  Age was not significantly associated with HPV persistence. 
 In another analysis of this cohort, Lu et al. (2009)59 examined HPV clearance in 
285 men followed for average of 18 months.  In univariate analyses, circumcision was 
positively significantly associated with HPV clearance for any HPV type and oncogenic 
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HPV, but not for nononcogenic HPV types.  Age, education, marital status, cigarette 
smoking, age at first sexual intercourse, lifetime number of sex partners, history of STI, 
having a steady sex partner in the past 3 months, having a sex partner with an STI in the 
past 3 months, having new a sex partner in the past 3 months, and condom use during the 
past 3 months were not associated with HPV clearance.  In multivariate analyses, 
clearance of any HPV infection was significantly higher in circumcised men (HR=3.1, 
95% CI: 1.2-8.2) adjusting for cigarette smoking and lifetime number of sex partners.  
For oncogenic HPV types, clearance of any HPV infection was significantly higher in 
circumcised men (HR=6.5, 95% CI: 2.1-19.7) and men with a higher lifetime number of 
sex partners (HR=4.9, 95% CI: 1.2-19.8 comparing >16 partners to 0-4 partners) 
adjusting for age at first sexual intercourse.  Nononcogenic HPV persistence was not 
associated with any sociodemographic and behavioral factors examined in univariate or 
multivariate analyses. 
 More recently, results of a clinical trial of circumcision among 650 HIV-negative 
men in Rakai, Uganda were reported60.  Men were randomized to an intervention group 
(immediate circumcision) or control group (circumcision at the end of the 24 month 
follow-up) and were assessed for HPV at enrollment, six months, 12 months, and 24 
months.  Men in the intervention group had a significantly higher rate of clearance 
compared to men in the control group, adjusted RR=1.39, 95% CI: 1.17-1.64.  Rates were 
adjusted for age, education, number of sex partners, and condom use, however the risk 
ratio for these variables was not reported.  
 Hernandez et al. (2010)61 followed 357 men for a mean of 431 days, range = 2 to 
9 visits.  Men were assessed every two months.  Adjusting for age, race/ethnicity, 
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birthplace, education, lifetime number of female sex partners, history of sex with men, 
condom use, and history of genital warts, uncircumcised men were significantly less 
likely to clear any HPV (HR=0.59, 95% CI: 0.36-0.98), oncogenic HPV (HR=0.36 95% 
CI: 0.14-0.91), and nononcogenic/undetermined risk status HPV (HR=0.50, 95%CI:0.25-
0.98).  Significant differences by circumcision status were only observed in samples from 
the glans/coronal sulcus of the penis and not from the penile shaft, scrotum, or all sites 
combined. 
 Finally, Giuliano et al. (2011)4 followed 1,159 men aged 18-70 residing in 
southern Florida, USA, São Paulo, Brazil, or Cuernavaca, Mexico.  Men underwent a 
clinical examination where samples of penile and scrotal cells were collected for HPV 
DNA testing at each study visit.  Participants returned for follow-up visits every 6 months 
over 4 years, for a total of up to 10 visits.  Increasing age was significantly associated 
with increased clearance of oncogenic HPV (AHR=1.02, 95% CI: 1.01-1.03).  Men from 
Brazil were significantly less likely to clear any HPV (AHR=0.69, 95% CI: 0.58-0.83), 
oncogenic HPV (AHR=0.71, 95% CI: 0.56-0.91) and non-oncogenic HPV (AHR=0.81, 
95% CI: 0.81-0.96) compared to men from the USA.  Men from Mexico were 
significantly less likely to clear oncogenic HPV (AHR=0.73, 95% CI: 0.57-0.94) 
compared to men from the USA.  Men with a higher number of lifetime female partners 
were less likely to clear oncogenic HPV (AHR for 2-9 partners=0.70, 95% CI: 0.55-0.90; 
AHR for 10-49 partners=0.64, 95% CI: 0.51-0.82; AHR for ≥ 50 partners=0.49, 95% CI: 
0.31-0.76) compared to men with 0 or 1 partner.  Men who were HPV-positive at 
baseline were less likely to clear any HPV (AHR=0.85, 95% CI: 0.76-0.96) and non-
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oncogenic HPV (AHR=0.81, 95% CI: 0.70-0.93) compared to men who were HPV-
negative at baseline.   
To date, the only factors associated with HPV clearance in men are circumcision 
status, lifetime number of sex partners, infection with multiple HPV types, age, and 
country of residence.  Other factors that influence HPV persistence remain to be 
identified.  Determining modifiable behavioral factors associated with HPV clearance 
will be important in secondary prevention efforts to decrease the burden of HPV-related 
diseases. 
Psychoneuroimmunology 
Psychoneuroimmunology (PNI) is the study of the bidirectional links between the 
central nervous system (CNS), immune system, and endocrine system and the 
implications of these interactions for health and disease.5,6  Psychological factors may 
play a role in the development and course of a range of diseases including infectious 
diseases and several cancers.6,7  The aim of psychoneuroimmunology is to discover how 
behaviors and health are related111.  One focus of this field is the influence of stress on 
immune function5. 
The theoretical model of how stress can affect immune function proposes that 
stress triggers cognitive, emotional, and affective responses which lead to the activation 
of the hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic-adrenalmedullary 
(SAM) axis inducing a release of hormones that can affect immune function7.  The 
nervous, endocrine, and immune systems are able to communicate by means of shared 
hormones, neuropeptides, and cytokines.  The brain is able to communicate with the 
immune system through the autonomic nervous system and from neuroendocrine outflow 
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from the pituitary112.  Both primary and secondary lymphoid organs are innervated with 
sympathetic nerves which release an array of neuropeptides and can influence the 
immune system112.  Release of corticotropin-releasing hormone (CRH) during stress may 
down regulate immune responses through it's effect on the secretion of glucocorticoids 
(GCs) and catecholamines (CAs)111,113.  In experiments on animals, stress has been 
associated with an increase in the susceptibility to a range of infectious diseases and 
experimental tumors112.  Subsequent research in patients with conjugal bereavement, 
severe life stress, and major depression found negative effects on immunity111.   
The effects of stress on immune function have varied in direction and magnitude 
in previous research. When examining the affects of stress and immune outcomes, host 
factors (e.g. age, sex, etc.), nature of the stimulus (e.g. intensity and duration), and the 
type of immune response measured are important factors which may interact and 
influence immune responses differentially.   
Of particular concern is the effect of stress on the balance between Th1 and Th2 
immune responses and neurogenic inflammation in peripheral tissues113.  GCs and CAs 
induce a shift towards Th2 immunity by up regulation of Th2 cytokine production and 
suppression of Th1 cytokine production. 
Stressful and uncontrollable life events, lack of social support, and having a 
passive or helpless coping style may have a negative impact on immune functioning, thus 
contributing to persistence of viral infections such as HPV.  Biobehavioral research such 
as psychoneuroimmunology may be important in furthering the understanding of HPV 
persistence and could “form the basis of interventions aimed at reducing the risk of HPV 
persistence” and subsequent malignancies8. 
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Stress 
Psychological stress is a factor that may play a role in the course of health and 
disease.  Stress can impact immune function; evidence suggests that stress can increase 
the severity and duration of infectious diseases, promote reactivation of latent viruses, 
and affect vaccine response.21  Effects are seen in numerous immune cells and substances 
including B and T cells, Natural Killer cells, and cytokines.  The immune response may 
differ depending on the duration of the stress, with brief stressors causing a shift from 
specific immunity to natural immunity and chronic stressors leading to broad immune 
impairment and a shift from a Th1 to a Th2 immune response 7,11 
Stress has been defined in a variety of ways14.  The classical definition of stress is 
when environmental demands exceed the perceived ability to meet those demands 
resulting in the perturbation of homeostasis7.  There is no universal definition of what 
constitutes psychological stress, however recent definitions focus on the cause (such as 
life events) or effect (appraisal and emotional responses)114.  Over 300 articles have been 
published examining the association of psychological stress and immune parameters in 
humans.  Overall, they have shown that stress is able to modify immune response11.   
Measurement of Stress 
 Several different approaches have been used to measure stress in humans.  Many 
studies have assessed major life events.  In these instruments, participants self-report life 
events which are assumed by the investigator to be stressful.  These life events checklists 
suffer from several limitations.  Studies comparing life event checklists with interview-
based measures have found that checklist methods are prone to errors in accurately 
measuring life events.  Self-reported events may be consistent with the life events 
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investigators are measuring less than 50% of the time.  Subjects may interpret questions 
in different ways, leading to reporting on events that do not correspond with the life 
events investigators are attempting to measure14.   
 Scales based on checklists may miss chronic stress due to other life 
circumstances, stress from the events in the lives of family or close friends, expectations 
of future events, or other events not listed in the checklist16.  There are also issues in how 
well subjects can recall past events and report them to investigators and defining what 
constitutes a life event14.  In studying the effect of stress in relation to health, illness may 
be affected by global stress level and not merely responses to particular events16.  
Assessing life events is best attained through interview-based methods with guidelines 
for defining life events14.   
 Other studies have compared immune outcomes among persons who are 
experiencing a severe chronic stressor, such as caregiving for a family member with a 
chronic illness, with controls who are not experiencing the stressor115,116.  These types of 
studies are measuring the effect of the stressor rather than the stress response on 
immunity.  Stressors are selected based on the researcher's belief that most people would 
consider the event as stressful.  However, the perception of an event as stressful and 
psychological reaction is moderated by individual differences7. 
 Perceived stress attempts to measure perceptions or appraisals of stress14.  The 
most common instrument used to measure perceived stress is the perceived stress scale 
(PSS)14 developed by Cohen et al. (1983)15.  This scale attempts to measure the degree to 
which situations are appraised as stressful and was designed to determine how 
unpredictable, uncontrollable, and overloaded subjects consider their lives16.  The scale 
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was designed for use in populations which possess at least a junior high school education 
level with questions that are easy to comprehend and response alternatives that are easy 
to understand16.  Response categories are a 5-point likert scale ranging from never to very 
often16.  Unlike check lists of life events, it is sensitive to nonoccurrence of events, 
ongoing life circumstances, stress in the lives of family or close friends, and expectations 
of future events16.  There are 14-item (PSS-14), 10-item (PSS-10), and four-item (PSS-4) 
versions of the scale.  All three versions have been shown to have satisfactory reliability 
and construct validity16,117.  The two shorter scales have been reported to be as reliable 
and valid as the original PSS-14, though the reported Cronbach's α for the PSS-4 is lower 
that for the longer versions117.  The PSS-4 is recommended for situations that require a 
very brief survey instrument16.  Construct validity of the PSS has been assessed by 
correlating scores with other measures of stress.  Correlation coefficients were higher for 
depressive symptoms (range 0.65-0.76), anxiety scores (0.48-0.81), and physical 
symptoms (0.52-0.70) than for life events (0.17-0.38).  Discriminate validity has been 
demonstrated by significantly different mean values in populations expected to 
experience different levels of stress114. 
 Cohen and Williamson 198816 assessed differences in PSS score by demographic 
characteristics among 2,387 U.S. residents 18 and older who completed a telephone 
interview.  There were significant differences in PSS scores by sex, age, household 
income, education, race, household composition, marital status, and employment status16.  
Cronbach’s alpha for each of the demographic groups was not reported. 
The items included in the original PSS inquire about stress in the past month.  
Because the scale is influenced by daily hassles, major life events, and changes in coping, 
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the predictive validity of the scale is expected to decline rapidly after approximately one 
to two months16.  The one month time frame is suitable for cross-sectional research or 
prospective designs which re-assess stress every one to two months.  However, in case-
control studies where the relevant etiologic time window includes time before the past 
month or in prospective studies where participants are not re-assessed every one to two 
months, the scale may miss important measures of stress.  For example, in a prospective 
study that re-assess participants annually, perceived stress will only be measured for the 
previous month, which may not accurately reflect perceived stress during the other 11 
months of the year. 
Pbert et al. (1992)43 assessed both perceived stress and psychosocial dysfunction 
in two clinical samples; 59 were participants in an employee health promotion program 
and 41 were participants in a 12-week outpatient cardiac rehabilitation program.  The 
original PSS-14 was administered as well as a version modified to ask about the previous 
six months.  Other measures included were the Life Experience Scale (LES) to assess 
events experienced in the past 6 months, the Inventory to Diagnose Depression (IDD) to 
assess the range of symptoms used to diagnose depression, the Sate Anxiety Inventory to 
assess feelings of apprehension, worry, tension, and nervousness, and the Cohen-
Hoberman Inventory of Physical Symptoms (CHIPS) to assess 39 common physical 
symptoms and how much each symptom bothered or distressed the participant in the past 
two weeks on a 5-point Likert scale.  No significant group differences in stress and 
dysfunction were found, therefore all participants were combined for analyses.   
The correlation between the 1-month PSS and 6-month PSS was 0.76.  Both 
versions of the PSS were moderately correlated (0.24 to 0.44) with the total number of 
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life events, number of negative life events, and impact scores on the LES; only the 6-
month PSS was correlated with the negative impact score.  Correlations with the LES 
scores were higher for the 6-month PSS than the 1-month PSS.  Both the 1-month PSS 
and the 6-month PSS were significantly correlated with the IDD, SAI, and CHIPS.  
Correlations between the 6-month PSS with symptom measures (IDD, SAI, and CHIPS) 
and the 1-month PSS with symptom measures were nearly identical. 
Levenstein et al. (1993)118 developed a 30-item scale to assess perceived stress, 
the Perceived Stress Questionairre (PSQ).  Responses to 30 items were collected among 
in-patients, outpatients, healthcare workers, and students with regard to both recent stress, 
'during the past month', and stress in general, 'in general, during the past year or two'.  
Both were correlated with the PSS; Spearman's r=0.56 with the General PSQ and 0.73 
with the Recent PSQ.  The correlation between the Recent and General forms 
administered in a single sitting was 0.71.  Ten ulcerative colitis patients completed the 
Recent form monthly four to six times at home and returned them at their next clinic 
visit.  The mean coefficient of variation within individuals was 0.22, confirming that 
there are temporal fluctuations in reporting of stress within the past month.   
Among students, a generally healthy population, both the General and Recent 
forms correlated with somatic symptoms assessed by Kellner's Symptom Questionnaire 
(r=0.50 and 0.58, respectively).  Among asymptomatic ulcerative colitis patients, visible 
mucosal inflammation of the rectum was associated with scores on the General and 
Recent PSQs (p=0.005 and 0.03 respectively).  While the Recent scale had a higher 
correlation with the PSS, life events, and somatic symptoms, the General scale had a 
higher correlation with hospitalization status and rectal inflammation in the populations 
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studied.  Thus, the authors concluded that the General scale which assessed stress 'in the 
long run' may be a better predictor of health status. 
Stress and Immunity 
 Theories on how stress is related to immune function have evolved over time.  In 
early models, stress was believed to be broadly immunosuppressive.  Later models 
proposed that acute stress enhanced immune response whereas chronic stress was 
suppressive.  Neither of these theories explained why chronic stress was associated with 
both diseases of inadequate immunity, such as infectious diseases and cancers, and 
diseases characterized by excessive immune response, such as allergies and autoimmune 
diseases.  More recently, models have focused on how chronic stress may induce a shift 
from a Th1 to a Th2 profile.  Chronic stress may actually both enhance and suppress the 
immune system by altering cytokine secretion.  Th1 cytokines may be suppressed while 
production of Th2 cytokines is enhanced without changing overall immune function.  A 
meta-analysis with studies of stress and immune parameters supports this hypothesis 11.  
Thus, this model reconciles the seemly conflicting results of previous work as a shift 
from a Th1 to Th2 profile may increase susceptibility to infectious disease and cancer and 
increase vulnerability to allergies and autoimmune diseases. 
 Segerstrom and Miller (2004)11 conducted a meta-analysis of published studies on 
immune response and stress.  Stress studies were categorized as acute time-limited (brief 
laboratory experiments such as public speaking), brief naturalistic (real-life short term 
challenges such as academic exams), stressful event sequences (a focal event such as 
death of a spouse or natural disaster), chronic stress (circumstances that pervade a 
person's life such as traumatic injury or care giving), distant stress (traumatic events that 
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occurred in the past such as sexual assault or being a prisoner of war), life events 
checklists (number of life events occurring over a specified time frame), and perceived 
stress or intrusive thoughts.   
 Acute time limited stressors were associated with increases in immune 
parameters, particularly number of NK cells and granular lymphocytes.  Brief naturalistic 
stress in healthy adults was associated with functional immune parameters including 
changes in cytokine production indicating a shift from Th1 to Th2 immunity.  Stressful 
event sequences were associated with increased numbers of NK cells and Epstein-Barr 
virus antibodies.  Chronic stress was associated with declines in functional measures of 
immune response, however no reliable changes in immunity were found for chronic 
stressors.  Life events were not significantly associated with immune measures; however 
there was an association with lymphocyte-proliferative responses to PHA and NK cell 
cytotoxictiy in older populations and number of NK cells in participants with HIV/AIDS.  
Stress appraisals were not significantly associated with immune parameters in this 
analysis, however only 3 or 4 studies reported data for each of the immune parameters 
examined and there may have been limited power to detect a significant association.  
Though not significant, modest effect sizes (r of 0.10 to 0.20) were found for number of 
T lymphocytes, T-helper lymphocytes, number of  NK cells and NK cell cytotoxicity. 
 Not only may chronic stress directly influence immunity, but it may also have 
effects on acute stress responses.  Chronically stressed individuals may have greater 
reactivity to acute stress.  Accumulated stress may result in a state where even a minor 
stressor could result in immune changes.  High numbers of daily hassles have been 
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associated with decreases in T cell and NK cell counts during acute experimental stress 
tasks 119. 
 Though significant relationships were not found in the meta-analysis of perceived 
stress and immune parameters, many individual studies have found a significant 
relationship between stress and both immune parameters and clinical outcomes.  Table 
A.2 presents a summary of immune responses and clinical outcomes that have been 
associated with measures of perceived stress.   
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Table A.2. Immune Parameters and Perceived Stress 
             
Immune parameter Study Design N Time frame Exposure Outcome P value Population 
IgG                   
    Theorell 1990120 prospective 49 
12 to 16 
months job strain No significant ass. p>0.05 workers 
    
Söderfeldt 
2000121 
cross-
sectional 103   quantitative job strain No significant ass. p>0.05 workers 
    Söderfeldt 2000 
cross-
sectional 103   emotional job strain No significant ass. p>0.05 workers 
IgA                 
    Yang 2002122 case-control 132 Past 6 months 
Professional Stress 
Scale ↑stress ass. ↓IgA p<0.01 Nurses 
    
Hapuarachchi 
2003123 case-control 43 Past month PSS-14 ↑stress ass. ↓IgA p<0.05 
University 
employees 
  sIgA Stone 1994124 prospective 96 
assessed 
daily for 12 
weeks 
Daily desirable 
events 
↑ desirable events 
ass. ↑ sIgA p<0.05 
men in the 
community 
    Stone 1994 prospective 96 
assessed 
daily for 12 
weeks 
Daily undesirable 
events No significant ass. p>0.05 
men in the 
community 
    Stone 1994 prospective 96 
assessed 
daily for 12 
weeks 
Daily desirable work 
events No significant ass. p>0.05 
men in the 
community 
    Stone 1994 prospective 96 
assessed 
daily for 12 
weeks 
Daily undesirable 
work events 
↑ undesirable 
work events ass. ↓ 
sIgA p<0.01 
men in the 
community 
    Stone 1994 prospective 96 
assessed 
daily for 12 
weeks 
Daily desirable 
leisure events 
↑ desirable events 
ass. ↑ sIgA p<0.01 
men in the 
community 
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    Stone 1994 prospective 96 
assessed 
daily for 12 
weeks 
Daily undesirable 
leisure events 
↑ undesirable 
work events ass. ↓ 
sIgA p>0.05 
men in the 
community 
    Stone 1994 prospective 96 
assessed 
daily for 12 
weeks 
Daily desirable 
friends events No significant ass. p>0.05 
men in the 
community 
    Stone 1994 prospective 96 
assessed 
daily for 12 
weeks 
Daily undesirable 
friends events No significant ass. p>0.05 
men in the 
community 
    Stone 1994 prospective 96 
assessed 
daily for 12 
weeks 
Daily desirable 
spouse events No significant ass. p>0.05 
men in the 
community 
    Stone 1994 prospective 96 
assessed 
daily for 12 
weeks 
Daily undesirable 
spouse events No significant ass. p>0.05 
men in the 
community 
    Stone 1994 prospective 96 
assessed 
daily for 12 
weeks 
Daily desirable 
children events No significant ass. p>0.05 
men in the 
community 
    Stone 1994 prospective 96 
assessed 
daily for 12 
weeks 
Daily undesirable 
children events No significant ass. p>0.05 
men in the 
community 
    Stone 1994 prospective 96 
assessed 
daily for 12 
weeks 
Daily desirable 
household events 
↑ desirable events 
ass. ↑ sIgA p<0.01 
men in the 
community 
    Stone 1994 prospective 96 
assessed 
daily for 12 
weeks 
Daily undesirable 
household events No significant ass. p>0.05 
men in the 
community 
    Stone 1994 prospective 96 
assessed 
daily for 12 
weeks 
Daily desirable 
financial events No significant ass. p>0.05 
men in the 
community 
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    Stone 1994 prospective 96 
assessed 
daily for 12 
weeks 
Daily undesirable 
financial events No significant ass. p>0.05 
men in the 
community 
    Stone 1994 prospective 96 
assessed 
daily for 12 
weeks 
Daily desirable self 
events No significant ass. p>0.05 
men in the 
community 
    Stone 1994 prospective 96 
assessed 
daily for 12 
weeks 
Daily undesirable 
self events No significant ass. p>0.05 
men in the 
community 
Lysozyme secretion                 
    Yang 2002 case-control 132 Past 6 months 
Professional Stress 
Scale 
↑stress ass. 
↓lysozyme p<0.01 Nurses 
IL-1                 
  IL-1RA Song 1999125 prospective 38 43±6 days PSS-14 No significant ass. p>0.05 
students taking 
exams 
IL-2                 
    De Gucht 1999126 
cross-
sectional 60   
Nurse Stress Index 
(high v. low stress) No significant ass. p>0.05 Nurses 
                    
  IL-2 R De Gucht 1999 
cross-
sectional 60   
Nurse Stress Index 
(high v. low stress) No significant ass. p>0.05 Nurses 
  soluble IL-2R Song 1999 prospective 38 43±6 days PSS-14 No significant ass. p>0.05 
students taking 
exams 
IL-6                 
  soluble IL-6R Song 1999 prospective 38 43±6 days PSS-14 No significant ass. p>0.05 
students taking 
exams 
gp 130                 
    Song 1999 prospective 38 43±6 days PSS-14 
↑ high stress group 
compared to low 
stress 0.008 
students taking 
exams 
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CC16                 
    Song 1999 prospective 38 43±6 days PSS-14 No significant ass. p>0.05 
students taking 
exams 
Total T cells                 
  Number 
Kawakami 
1997127 
cross-
sectional 65   job strain index No significant ass. p>0.05 
blue-collar 
workers 
    Maes 1999128  prospective 38 43±6 days PSS-14 
↑ change PSS ↑ 
CD2+ 0.01 
students taking 
exams 
    
Tjemsland 
1997129 
cross-
sectional 98 past 7 days IES intrusion scale ↑ IES ass. ↓T cells p<0.01 
breast cancer 
patients 
    Tjemsland 1997 prospective 98 
1 day before 
to 7 days 
after surgery 
change in IES 
intrusion scale ↑IES ass. ↓T cells p<0.05 
breast cancer 
patients 
  Percentage Kawakami 1997 
cross-
sectional 65   job strain index No significant ass. p>0.05 
blue-collar 
workers 
Leukocytes                 
  Number Maes 1999  prospective 38 43±6 days PSS-14 
↑ change PSS ↑ 
leukocytes 0.003 
students taking 
exams 
    Tjemsland 1997 
cross-
sectional 98 past 7 days IES intrusion scale No significant ass. p>0.05 
breast cancer 
patients 
    Tjemsland 1997 prospective 98 
1 day before 
to 7 days 
after surgery 
change in IES 
intrusion scale No significant ass. p>0.05 
breast cancer 
patients 
Lymphocytes                 
  Number Maes 1999  prospective 38 43±6 days PSS-14 No significant ass. 0.09 
students taking 
exams 
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    Tjemsland 1997 
cross-
sectional 98 past 7 days IES intrusion scale 
↑ IES ass. 
↓lymphocytes p<0.01 
breast cancer 
patients 
    Tjemsland 1997 prospective 98 
1 day before 
to 7 days 
after surgery 
change in IES 
intrusion scale 
↑IES ass. 
↓lymphocytes p<0.05 
breast cancer 
patients 
Neutrophils                 
  Number Maes 1999  prospective 38 43±6 days PSS-14 
↑ change PSS ↑ 
neutorphils 0.002 
students taking 
exams 
Monocytes                 
  Number Maes 1999  prospective 38 43±6 days PSS-14 No significant ass. 0.3 
students taking 
exams 
Leukocyte adhesiveness/aggregation (LAA)             
    Lerman 1999130 case-control 179 Past month 
Shirom-Melamed 
Burnout 
Questionnaire 
↑ burnout ass. 
↑LAA p<0.05 
University 
employees 
CD 14                 
    Song 1999 prospective 38 43±6 days PSS-14 No significant ass. p>0.05 
students taking 
exams 
CD2+CD26+                 
  Number Maes 1999  prospective 38 43±6 days PSS-14 
↑ change PSS ↑ 
CD2+CD26+ 0.01 
students taking 
exams 
CD2+HLA-DR+                 
  Number Maes 1999  prospective 38 43±6 days PSS-14 
↑ change PSS ↑ 
CD2+HLA-DR+ 0.01 
students taking 
exams 
B lymphocytes                 
  Number Maes 1999  prospective 38 43±6 days PSS-14 No significant ass. 0.1 
students taking 
exams 
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    Tjemsland 1997 
cross-
sectional 98 past 7 days IES intrusion scale 
↑ IES ass. ↓ B 
lymphocytes p<0.01 
breast cancer 
patients 
    Tjemsland 1997 prospective 98 
1 day before 
to 7 days 
after surgery 
change in IES 
intrusion scale No significant ass. p>0.05 
breast cancer 
patients 
NK cells (CD3-CD56+ )                 
  Number De Gucht 1999 
cross-
sectional 60   
Nurse Stress Index 
(high v. low stress) No significant ass. p>0.05 Nurses 
    Tjemsland 1997 
cross-
sectional 98 past 7 days IES intrusion scale No significant ass. p>0.05 
breast cancer 
patients 
    Tjemsland 1997 prospective 98 
1 day before 
to 7 days 
after surgery 
change in IES 
intrusion scale No significant ass. p>0.05 
breast cancer 
patients 
  Percentage De Gucht 1999 
cross-
sectional 60   
Nurse Stress Index 
(high v. low stress) 
High stress ass. ↓ 
NK cells p<0.05 Nurses 
CD57-CD16+ (NK subset)               
  Number 
Nakamura 
1999131 
cross-
sectional 42 Past month PSS-14 No significant ass. p>0.05 office workers 
CD57+CD16+ (NK subset)               
  Number Nakamura 1999 
cross-
sectional 42 Past month PSS-14 No significant ass. p>0.05 office workers 
CD57+CD16- (NK subset)               
  Number Nakamura 1999 
cross-
sectional 42 Past month PSS-14 No significant ass. p>0.05 office workers 
NK cell activity Nakamura 1999 
cross-
sectional 42 Past month PSS-14 No significant ass. p>0.05 office workers 
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    Vitaliano 1998132 
cross-
sectional 165 Past month 
Hassles and Uplifts 
scales - Time 1 No significant ass. p>0.05 
dementia 
caregivers, 
cancer 
survivors, and 
controls 
    Vitaliano 1998 
cross-
sectional 165 Past month 
Hassles and Uplifts 
scales - Time 2 No significant ass. p>0.05 
dementia 
caregivers, 
cancer 
survivors, and 
controls 
    Wilcox 2000133 
cross-
sectional 23 Past month PSS-14 No significant ass. p>0.05 
caregivers in 
physical 
activity trial 
                    
CD25+ (activated T cells)               
  Number De Gucht 1999 
cross-
sectional 60   
Nurse Stress Index 
(high v. low stress) 
High stress ass. ↑ 
CD25+ p<0.05 Nurses 
  Percentage De Gucht 1999 
cross-
sectional 60   
Nurse Stress Index 
(high v. low stress) No significant ass. p>0.05 Nurses 
CD3+CD25+ (activated T-cells)               
  Number De Gucht 1999 
cross-
sectional 60   
Nurse Stress Index 
(high v. low stress) No significant ass. p>0.05 Nurses 
  Percentage De Gucht 1999 
cross-
sectional 60   
Nurse Stress Index 
(high v. low stress) No significant ass. p>0.05 Nurses 
CD3+CD16CD56+ (cytotoxic T cells)               
  Number De Gucht 1999 
cross-
sectional 60   
Nurse Stress Index 
(high v. low stress) No significant ass. p>0.05 Nurses 
  Percentage De Gucht 1999 
cross-
sectional 60   
Nurse Stress Index 
(high v. low stress) No significant ass. p>0.05 Nurses 
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Helper T cells (CD4+)                 
  Number De Gucht 1999 
cross-
sectional 60   
Nurse Stress Index 
(high v. low stress) 
High stress ass. ↑ 
CD4+CD25+ p<0.05 Nurses 
    Kawakami 1997 
cross-
sectional 65   job strain index No significant ass. p>0.05 
blue-collar 
workers 
    Scanlan 1998134 
cross-
sectional 168 past month 
Hassles Scale 
(baseline) No significant ass. p>0.05 
older 
caregivers and 
controls 
    Scanlan 1998 prospective 168 
15 to 18 
months Hassles Scale 
↑ hassles ass. ↓ 
CD4 count p<0.05 
older 
caregivers and 
controls 
    Tjemsland 1997 
cross-
sectional 98 past 7 days IES intrusion scale ↑ IES ass. ↓T cells p<0.01 
breast cancer 
patients 
    Tjemsland 1997 prospective 98 
1 day before 
to 7 days 
after surgery 
change in IES 
intrusion scale 
↑IES ass. ↓CD4 T 
cells p<0.05 
breast cancer 
patients 
  Percentage De Gucht 1999 
cross-
sectional 60   
Nurse Stress Index 
(high v. low stress) No significant ass. p>0.05 Nurses 
    Kawakami 1997 
cross-
sectional 65   job strain index No significant ass. p>0.05 
blue-collar 
workers 
    Scanlan 1998 
cross-
sectional 168 past month 
Hassles Scale 
(baseline) No significant ass. p>0.05 
older 
caregivers and 
controls 
    Scanlan 1998 prospective 168 
15 to 18 
months Hassles Scale No significant ass. p>0.05 
older 
caregivers and 
controls 
CD9+CD11b+ (suppressor T cells)               
  Number De Gucht 1999 
cross-
sectional 60   
Nurse Stress Index 
(high v. low stress) No significant ass. p>0.05 Nurses 
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  Percentage De Gucht 1999 
cross-
sectional 60   
Nurse Stress Index 
(high v. low stress) No significant ass. p>0.05 Nurses 
Suppression/cytotoxic T cells (CD8+)               
  Number Kawakami 1997 
cross-
sectional 65   job strain index No significant ass. p>0.05 
blue-collar 
workers 
    Maes 1999  prospective 38 43±6 days PSS-14 No significant ass. 0.08 
students taking 
exams 
    Scanlan 1998 
cross-
sectional 168 past month 
Hassles Scale 
(baseline) 
↑ hassled ass. ↑ 
CD* count (men 
only) p<0.05 
older 
caregivers and 
controls 
    Scanlan 1998 prospective 168 
15 to 18 
months Hassles Scale No significant ass. p>0.05 
older 
caregivers and 
controls 
    Tjemsland 1997 
cross-
sectional 98 past 7 days IES intrusion scale No significant ass. p>0.05 
breast cancer 
patients 
    Tjemsland 1997 prospective 98 
1 day before 
to 7 days 
after surgery 
change in IES 
intrusion scale 
↑IES ass. ↓CD8 T 
cells p<0.01 
breast cancer 
patients 
  Percentage Kawakami 1997 
cross-
sectional 65   job strain index No significant ass. p>0.05 
blue-collar 
workers 
    Scanlan 1998 
cross-
sectional 168 past month 
Hassles Scale 
(baseline) 
↑ hassled ass. ↑ 
CD*8 percent p<0.05 
older 
caregivers and 
controls 
    Scanlan 1998 prospective 168 
15 to 18 
months Hassles Scale No significant ass. p>0.05 
older 
caregivers and 
controls 
  soluble CD8 Song 1999 prospective 38 43±6 days PSS-14 
↑ high stress group 
compared to  low 
stress 0.009 
students taking 
exams 
Helper/inducer T cells (CD4+CD29+)               
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  Number Kawakami 1997 
cross-
sectional 65   job strain index No significant ass. p>0.05 
blue-collar 
workers 
  Percentage Kawakami 1997 
cross-
sectional 65   job strain index 
↑ job strain ↓ % T 
cells p<0.05 
blue-collar 
workers 
Suppressor/inducer T cells (CD4+CD45RA+)               
  Number Kawakami 1997 
cross-
sectional 65   job strain index No significant ass. p>0.05 
blue-collar 
workers 
  Percentage Kawakami 1997 
cross-
sectional 65   job strain index No significant ass. p>0.05 
blue-collar 
workers 
CD4+/CD8+ ratio                 
  Number Maes 1999  prospective 38 43±6 days PSS-14 
↓ change PSS ↑ 
CD4+/CD8+ ratio 0.002 
students taking 
exams 
    Scanlan 1998 
cross-
sectional 168 past month 
Hassles Scale 
(baseline) 
↑ hassled ass. ↑ 
CD4/CD* p<0.05 
older 
caregivers and 
controls 
    Tjemsland 1997 
cross-
sectional 98 past 7 days IES intrusion scale ↑ IES ass. ↓ratio p<0.01 
breast cancer 
patients 
    Tjemsland 1997 prospective 98 
1 day before 
to 7 days 
after surgery 
change in IES 
intrusion scale No significant ass. p>0.05 
breast cancer 
patients 
Clinical Outcomes and Perceived Stress 
Num. URTI episodes                 
    Koh 2002135 case-control 132 Past 6 months 
Professional Stress 
Scale 
↑stress ass. 
↑URTI episodes p<0.01 Nurses 
    Cobb 1996136 prospective 107 15 weeks PSS-10 
↑ stress in those with 
UTTI p<0.001 
Parents in a 
study of stress 
in children 
    Cobb 1996 prospective 107 15 weeks Hassles Scale 
↓ stress in those with 
UTTI p<0.001 
Parents in a 
study of stress 
in children 
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Absence due to URTI                 
    Koh 2002 case-control 132 Past 6 months 
Professional Stress 
Scale 
↑stress ass. 
↑URTI absences p<0.01 Nurses 
URTI (Upper respiratory tract infection) 
(PSS) Perceived stress scale 
IES (Impact of Events Scale) 
sIgA (secretory IgA) 
IL-1RA (interleukin-1 receptor antagonist) 
IL (interleukin) 
IL-2R (IL-2 receptor) 
gp 130 (glycoprotein 130) 
CC16 (Clara cell protein) 
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 Two studies of upper respiratory tract infections (URTI) found that increased job 
or perceived stress were associated with increases in the number of URTIs and work 
absence related to URTIs.  In a case-control study by Koh et al. (2002)135, higher scores 
on the Professional Stress Scale were associated with significant increases in the number 
of URTI episodes and number of absences due to URTI in the past six months.  A 
prospective study by Cobb et al. (1996)136 followed 107 adults participating in a study of 
stress in children for 15 weeks.  Perceived stress and hassles were measured by the 
Hassles Scale and PSS-10 weekly.  Interestingly, daily hassles were lower in participants 
that did not have a clinically verified URTI, whereas perceived stress was significantly 
higher in participants who experienced a URTI during follow-up. 
 Of the numerous immune parameters studied, IgA, lysozyme secretion, gp 130, 
leukocyte number, Neutrophil number, leukocyte adhesiveness/aggregation (LAA), 
CD2+, CD19+, CD25+, NK cells, CD4+, CD8+, and the CD4/CD8 ratio were found to 
be significantly associated with a measure of perceived stress in at least one research 
study.  Many of these studies had small numbers of participants and may lack adequate 
power to detect associations.  Indeed, of the three studies with at least 100 
subjects122,130,134 all had significant findings.  These studies also suggest that perceived 
stress is associated with both immune parameters and occurrence of URTI, however 
further prospective research with adequate sample sizes is needed to examine these 
relationships.   
 While some studies examining the relationship between stress and response to 
immunization have found significant associations with measures of perceived stress, 
stressful life events, and in chronically stressed populations65,137-142, others have not143-145.  
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Though results have from these studies been mixed, they suggest that stress may have a 
negative impact on secondary antibody response (function of antigen-specific T and B 
cells after re-exposure to an antigen), but not primary response (the first time the immune 
system encounters the antigen)146.  The relationship with stress is most pronounced for 
thymus-dependent vaccines and when outcomes are measured an extended time after 
vaccination.  More research is still needed in this area to clarify the suggested effects of 
stress on vaccination responses147. 
 Studies examining immune parameters, clinical outcomes, and responses to 
vaccination all suggest a relationship between psychosocial stress and the immune 
system.  Results reported by Scanlan (1998) suggest that men may be more vulnerable to 
the influence of psychosocial stress on the immune system than women134.  Further 
research is still needed in this area. 
Stress, HPV, and Cervical Cancer 
 If psychosocial factors such as stress can modify the immune response, then such 
factors may influence HPV persistence and progression to cervical precancerous lesions 
and cancers.  Although no published study has evaluated psychosocial variables and HPV 
viral persistence, a cross-sectional study examined perceived stress and stressful life 
events in relation to T-cell proliferative responses to HPV 16 among 74 women with CIN 
I and II.  Stressful life events during the past six months were assessed via a modified and 
shortened version of the Holmes-Rahe Social Readjustment Rating Scale; a checklist of 
12 events.  Perceived stress was measured by the PSS-14.  In a multivariate logistic 
regression including marital status, detection of HPV-16 DNA, and smoking status, 
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higher perceived stress, but not number of life events, was significantly associated with 
non-response to HPV 16, OR=0.91, 95%CI: 0.85-0.98148. 
Chronic stress has been associated with a shift from a Th1 to a Th2 cytokine 
profile148.  Th1 response has been shown to be a factor in HPV persistence and 
progression.  Thus, the stress induced shift from a Th1 to Th2 profile could be the 
biological pathway by which stress can promote HPV persistence and development of 
cervical lesions. 
A search of pubmed including variable combinations of the terms HPV, stress, 
psychosocial, cervical, cervix, lesion, neoplasia, and cancer resulted in the identification 
of eight studies reporting on the association between measures of stress and cervical 
disease.  Of these studies, five found a significant association between psychosocial 
variables and cervical lesions or cancer28-32, whereas three failed to identify a significant 
association149-151.   Only one study measured perceived stress using the PSS-14.   
Controlling for HPV.  Among these studies of psychosocial variables and cervical 
lesions, five controlled for the presence of HPV.  If it is the effect of stress on the 
immune system which leads to decreased immune response and decreased regulation of 
HPV, then these studies could be adjusting for an intermediate factor.  Immune function 
would be important in both clearing the HPV infection and clearing the cervical lesion.  
The studies that controlled for HPV could be looking at the association of stress and 
cervical cancer apart from the effect of stress on immune function in relation to HPV.  
Research that did not control for HPV may be including the effect of psychosocial 
variables on HPV persistence.  Determining at what point stress has an effect in the 
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course of cervical disease may only be possible with a prospective study in which follow-
up begins prior to lesion development.  
 Tiersma et al. (2004)150 did not find a significant relationship in an analysis of 
cervical disease grade and negative life events in the past year among 342 women with 
no CIN, CIN I-CIN III, and invasive carcinoma.  The relevant etiologic time window 
may be different for participants with advanced disease versus low grade disease such as 
CIN I.  Whereas one year is appropriate for lower grade disease, invasive cancers could 
take years to develop and measuring stress for the previous five to ten years may be 
useful in examining these associations.  Interestingly, when not adjusting for birthplace, 
HPV group, age, and hospital site, the p-value for total number of negative life events is 
0.08.   
 Using participants from their previous study who had CIN I or II, Tiersma et al. 
(2005)149 examined the association between number of negatively rated life events and 
time until progression [those who regressed (n=51) or had stable CIN I or II (n=22) 
compared to those who progressed (n=20)] and time until regression (progression or 
stable CIN compared to those who regressed) among 92 women followed for a mean of 
2.25 years.  Including women with stable disease with both those who progressed and 
who regressed may obscure differences between women who progressed compared to 
women who experienced regression.  Comparing each of the three groups may have been 
more informative, although the small sample size may have prevented this. 
 Coker et al. (2003)29 examined differences in the number of stressful life events 
and the number of stressful life events participants reported as very upsetting (high-
impact SLE) during the past 5 years in low-income women with HSIL (n=59) or LSIL 
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(n=163) and controls with normal cytology (n=160).  Both the total SLE score and high-
impact SLE score were associated with SIL among white women, OR=1.20, 95%CI: 
1.04-1.38 and OR=1.30, 95%CI: 1.10-1.55, respectively, but not among African-
American women.  When subscales were examined, only the relationship subscale was 
significantly associated with SIL; the loss, financial, and violence/legal subscales were 
not.  White women had significantly higher total SLE, high impact SLE, and relationship 
subscale scores compared to African American women.  The authors speculate that 
African America women may have been less willing to disclose stressful life events to an 
interviewer they did not know and was not of the same race or socioeconomic status.  
This could result in an underestimation of stress in African Americans and account for 
the null association between SLE and SIL in this group of participants.   
 Two studies were conducted among HIV positive women.  Pereira et al. (2003)30 
abstracted SIL diagnoses at study entry and 1 year later from medical charts of 32 HIV 
infected women.  Women completed a 10-item abbreviated version of the Life 
Experience Survey (LES) which assessed stressful life events in the past year and their 
impact, extremely negative (-3) to extremely positive (+3).  An average impact score for 
negative events in the past 6 months was used in analysis.  Higher negative life stress 
impact scores were associated with progression/persistence of SIL one year later 
adjusting for presence of HPV16/18, decline in CD4+CD3+, and antiretroviral use, 
OR=8.58, 95%CI: 1.07-69.08.   
 Antoni et al. (2008)28 examined the effect of a 10-week Cognitive behavioral 
stress management (CBSM) intervention compared to a 1-day CBSM seminar on cervical 
neoplasia among 39 HIV+ African-American, Caribbean, and Hispanic women with  a 
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history of CIN I.  The intervention group had significantly lower odds of cervical 
neoplasia at 9-month follow-up adjusting for cervical disease at study entry, presence of 
HR-HPV, HIV viral load, CD4+CD3+ cell count decline, and substance use, OR=0.04, 
95%CI: 0.002-0.62.  Differences in cervical neoplasia risk by experimental condition 
were found among the subgroup of women who reported residual life stress at follow-up, 
but not among the subgroup of women who reported no life stress at follow-up.   
 Studies that did not control for HPV.  Goodkin et al (1986)32 found a significant 
correlation between negative life events in the past six months and CIN grade among 73 
women with CIN I-III or invasive cancer and benign illness (leiomyoma).  Although this 
study measured negative life events over 20 years (0 to 6 months, 7 months to 1 year, 1 to 
5 years, 5 years 1 month to 10 years, and 10 years 1 month to 20 years time blocks), the 
correlations were over the same time period for each group of disease grade.   
 In a study of intimate partner violence (IPV), Coker et al. (2000)31 found that ever 
experiencing IPV was significantly associated with self-reported invasive cervical cancer, 
RR=4.28, 95% CI: 1.94-18.39.  Increasing number of years in a violent relationship, IPV-
associated injuries, physical IPV scores, and sexual IPV scores were associated with 
increasing risk of cervical cancer.  Experiencing physical or both physical and sexual IPV 
and a higher number of years in a violent relationship were significantly associated with 
self-reported treatment for an abnormal Pap smear.  All measures in this study were self-
reported and diagnosis was not confirmed with cervical cytology or biopsy results.   
 Recently, Wilkerson et al. (2009)151 reported that among 265 women they found 
no significant association between perceived stress or life events and cervical cytology.  
Cases were patients attending a colposcopy clinic who had a history of abnormal Pap 
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smear.  However, 35% of cases had normal cytology at the time of the interview.  
Including these women who no longer had cervical lesions at the time of the study may 
have obscured associations between women with normal cytology and those with current 
cervical lesions.  Except for age, cervical cancer risk factors and demographic factors 
were also not significantly associated with disease in regression analysis. This study 
measured perceived stress in the past month using the PSS-14.  This may not include the 
relevant etiologic time window as most lesions may take more than 1-2 months to 
progress to CIN II or III.  Failure to identify significant associations may be due to the 
methodological limitations of this study. 
 Comparison of these studies is difficult because they used different study designs, 
measures of stress, control variables, populations, outcomes, and observed participants 
over different time periods.  There is evidence that different types of psychosocial 
variables and stress may impact the immune system differently, with some measures of 
stress showing a significant association with immune outcomes while others do not 
within the same study population152. 
 Overall, these studies indicate that there is an association between cervical lesions 
and psychosocial variables, however well designed prospective studies are needed to 
confirm these associations.  Table A.3 presents a summary of these eight studies. 
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Table A.3. Studies of Cervical Cancer and Stress 
 
 
Cervical Cancer and Stress 
Controlled for HPV 
Study Exposure(s) Assessment Outcome(s) Assessment Study Design Control Variables Methods Results 
Time 
Period Sig 
Antoni et 
al. 200828 
Cognitive 
behavioral 
stress 
management 
(CBSM) 
intervention 
NA 
Life stress 10-item LES 
Clinical 
Trial 
cervical neaoplasia at 
study entry, HR-
HPV infection, HPV 
viral load, decline in 
CD4+ CD3+, 
substance use 
39 HIV+ 
minority women. 
10-week CBSM 
intervention or 1-
day CBSM 
workshop. 9 
month follow-up. 
Intervention group 
reported decreased 
perceived life stress and 
had significantly lower 
odds of cervical 
neoplasia, p=0.03 
9 months Yes Cervical 
neoplasia 
Cervical 
biopsy 
Tiersma 
et al. 
2005149 
Negatively 
rated life 
events 
Life 
Experience 
Survey (LES) 
Distress Profile of Mood States 
Prospective age, HPV HR/LR/-, medical center 
93 patients with 
CIN 1 or 2 
followed 2.25 
years with half-
yearly 
colposcopy and 
cytology. 
Survival 
analysis- time till 
progression 
versus no 
progression and 
time till 
regression versus 
no regression. 
20 progressed, 51 
regressed, and 22 had 
stable disease. No 
association between 
progression or 
regression of CIN and 
negatively-rated life 
events, lack of social 
support, coping style, 
and distress. 
Past year at 
baseline 
and time 
since last 
visit at 
follow- up 
No 
Social support Social Support Questionnaire 
Progression, 
stable disease, 
regression of 
CIN 
Histology 
Coping style Dutch Utrecht Coping List 
Tiersma 
et al. 
2004150 
Total number 
negative life 
events 
Life 
Experience 
Survey (LES) 
CIN grade Biopsy Case-control 
Coping, social 
support, 
socioeconomic 
status, age, HPV 
high/low risk, Dutch 
born 
393 patients 
from two 
teaching 
hospitals 
When adjusted for 
control variables 
p=0.73.  Without 
adjustment p=0.08 
Past year No 
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Coker et 
al. 200329 
Stressful Life 
Events 
17 negative life 
events. SLE 
score=sum of 
number of 
events in past 5 
years. High 
impact 
SLE=sum of 
events 
participants 
reported as 
being very 
upset by the 
event. 
Cases: HSIL 
or LSIL on 
Pap smear  
Pap smear 
with follow-up 
biopsy for 
cases 
Case 
control 
Stratified by race and 
adjusted for age, HR-
HPV+, and lifetime 
number of male sex 
partners 
59 cases of 
HSIL, 163 cases 
of LSIL, and 160 
controls. Among 
whites 101 cases 
and 68 controls 
and among 
African 
Americans 119 
cases and 90 
controls. 
HR-HPV associated 
with higher SLE score, 
OR=1.81, 1.00-3.28. 
SLE score sig. 
associated with SIL 
among whites (SLE 
OR=1.2, 1.04-1.38; 
high impact SLE 
OR=1.3-, 1.1-1.55), but 
not among African 
Americans. Sig. was in 
the relationship stress 
subscale; all 5 questions 
associated with SIL 
among whites. 
Past 5 years Yes 
Controls: 
normal Pap 
smear 
Pereira et 
al. 200330 
Stressful Life 
Events 
10-item version 
of the LES 
developing 
progressive/ 
persistence 
SIL 
Medical chart 
review to 
follow SIL 
diagnosis for 8 
to 16 months 
Prospective 
Presence of HPV 
16/18, decline in 
CD4+CD3+, 
antiretroviral use at 
study entry 
32 HIV-1+ 
women with a 
previous 
abnormal Pap 
smear followed 
for 8 to 16 
months. 
Negative Life events 
sig. associated with 
persistent/progressive 
SIL, OR=8.58, 1.07-
69.08 
Past Year 
at baseline 
with 6 to 18 
month 
follow up 
Yes 
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Did not control for HPV 
Coker et 
al. 200031 
Current or 
recent Physical 
and sexual 
Intimate 
partner 
violence (IPV) 
Index of 
Spouse Abuse-
Physical (12-
item version) 
Self-reported 
cervical 
neoplasia with 
medical record 
review.  Three 
groups: 
cervical cancer 
(n=14), 
cervical 
dysplasia 
(n=234), and 
no reported 
history of 
cervical 
neoplasia or 
other cancer 
controls 
(n=847) 
Modified 
National 
Health 
Interview 
Survey. Asked 
if diagnosed 
with a specific 
cancer and if 
had been 
treated with 
"cryotherapy, 
laser therapy, 
or any other 
treatment for 
abnormal Pap 
smear" 
Cross 
sectional 
Age and pack-years 
of smoking. 
1152 women 
recruited from 
family practice 
clinics. 
Converted OR to 
RR. 
Ever experienced IPV 
associated with 
increased risk of 
cervical cancer, 
adjusted RR=4.47, 
1.07-19.07 and with 
cervical dysplasia 
adjusted RR=1.60, 
1.18-2.15. Dose-
response with years in 
violent relationship. 
Ever 
experienced 
IPV, years 
in violent 
relationship 
Yes 
Battering 
Women's 
Experience 
with Battering 
Past physical, 
sexual, and 
psychological 
IPV 
Abuse 
Assessment 
Screen 
Goodkin 
et al. 
198632 
Negatively 
rated life 
events 
Life 
Experience 
Survey (LES) 
 uterine 
leiomyomas 
control group, 
CIN I, II, III 
and invasive 
cervical cancer 
Surgical 
pathology 
reports and 
colposcopy 
Case-
Control None 
73 women 
recruited from 
UM Jackson 
Department of 
Gynecology 
Significant correlation 
between CIN promotion  
and LES 0-6 months 
0-6mon, 
7mon-1yr, 
1-5yrs, 
5yr1mon-
10yrs, 
10yr1mon- 
20yrs 
Yes 
Wilkerson 
et al. 
2009151 
Perceived 
Stress 
Perceived 
Stress Scale 
Abnormal 
cervical 
cytology 
Cervical 
cytology 
Case-
control Unknown 
Controls: 141 
women with 
normal Pap 
results. Cases: 
124 women 
attending 
colposcopy 
clinic (35% had 
normal Pap at 
time of study) 
No significant 
association between 
disease status and 
perceived stress 
Past month No 
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Sleep 
 Sleep is a physiological state characterized by reduced consciousness, muscle 
movement, and metabolism and alterations in the activity of the central nervous system34.  
It is hypothesized to have a restorative function, but the exact functions of sleep are 
unknown.  Sleep is divided into rapid eye movement (REM) and non-rapid eye 
movement (NREM), which is further divided into S1, S2, S3, and S4.  A 90-minute cycle 
in which sleep cycles through S1-S4 and REM sleep occurs five or six times per night.  
Both quantity and quality of sleep are important.  Chronic sleep loss results in excessive 
drowsiness and diminished psychomotor performance.  Short sleep duration, less than 
five hours per night, and poor sleep quality have been associated with increased risks of 
diabetes, hypertension, coronary heart disease, acute myocardial infarction, and 
mortality34. 
 Previous research suggests that partial sleep deprivation (PSD) increases markers 
of systemic inflammation, TNF-α and IL-1β production, and secretion of IL-6.  The bi-
directional communication between the brain and immune system suggests a route by 
which sleep has the ability to influence the immune system34.  Numerous cytokines and 
other neuroendocrine substances have been associated with the sleep-wake cycle in 
humans and animals.  Studies have found evidence of alterations in several cytokines and 
proliferation of T cells with the sleep-wake cycle12,153.  Not only may sleep influence 
cytokine expression, but cytokines may also influence sleep though a reciprocal 
relationship154.  Studies in both humans and animals have generally found increases in 
sleep duration following infection153.  Shared regulatory molecules between sleep and the 
immune system may explain how sleep influences immunity153. 
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Measurement of Sleep 
 Numerous instruments have been developed to measure sleep quality.  Self-report 
scales include both quantitative (sleep duration, sleep latency, and number of 
awakenings) and qualitative aspects (restfulness, sleep satisfaction, mood, and daytime 
functioning)155.  In a systematic review of instruments used to assess sleep dysfunction in 
adults, Devine et al.(2005)156 identified four domains of sleep that are of general interest 
to measuring sleep: sleep initiation, sleep maintenance, sleep adequacy, and somnolence 
or sleepiness.   
 Six were found to include all four domains (including the commonly used 
Pittsburgh Sleep Quality Index (PSQI)44,156), however all included more than 5 items.  
Four instruments included three of the four domains.  The Jenkins Sleep Problems Scale 
(JSPS) is an extremely brief questionnaire (3 or 4 items) that was developed for 
epidemiological research17.  Though it has not been widely used, it has been shown to be 
reliable and valid156.   
In a study of older adults and college students, Alapin et al.(2000)157 examined 
participants who reported frequency of difficulty in concentrating during the day and how 
distressed they were about their sleep problems on a 10-point scale ranging from not at 
all to very much.  Ability to concentrate during the day significantly differed between 
good and poor sleepers and was significantly correlated with total sleep time, total wake 
time, sleep efficiency, nocturnal tension, and distress about having sleep problems.  The 
single item which assessed ability to concentrate during the day was not stated.  Distress 
was assessed by asking, “How distressed are you by an insomnia problem?”. 
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Sleep and Immunity 
 Sleep has been associated with immune function in both human and animal 
studies.3,154,158-160  Previous research indicates that even small amounts of sleep loss can 
impact immune measures154.  Insufficient sleep can be attributed to inadequate duration 
of sleep or poor qualitative sleep (proportion and duration of sleep stages and number of 
awakenings).  Though there is debate over how much sleep an individual needs, the 
National Sleep Foundation recommends adults get seven to nine hours of sleep per 
day161.  Sleeping for 7 hours has been associated with the lowest rates of morbidity and 
mortality; with both longer or shorter durations associated with increased risk153.  In 
modern society the average sleep duration has been declining.  A study in San Diego 
adults found that the average duration of sleep was only 6.2 hours per night, much less 
than the 8 hour average self-reported duration found in the 1970's162. 
 Experimental sleep deprivation has been used to study the effects of altered sleep 
patterns on immune responses in humans12.  Total sleep deprivation (TSD) or continuous 
wakefulness may have different effects on immune responses than partial sleep 
deprivation (PSD) or a restriction from sleep for only part of the night163.  Because PSD 
may more closely approximate the sleep loss and disruption experienced by many people, 
this review will focus on this type of sleep deprivation.   
 In observational studies of sleep, significant associations between NK cell 
activity35,36 and NK cell number37 have been found (Table 4).  In two experimental 
studies of exposure to rhino virus38,39, sleep efficacy and sleep duration were associated 
with illness.  In experimental studies of PSD, IL-2, IL-6, TNF-α, neutrophils, 
lymphocytes, NK cells, and Lymphokine-activated killer cell activity have been 
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associated with sleep loss.  Table A.4 presents a review of immune parameters and PSD 
studies.  All but the two studies which subjected volunteers to rhino virus had fewer than 
50 subjects and may have been underpowered to detect small to moderate associations.  
Redwine et al. (2000)164 found that the normal increase in IL-6 levels observed during 
baseline sleep was delayed in men deprived of sleep during the early night (until 3 a.m.). 
 Evidence from Shakhar et al. (2007)36 suggests that the association between NK 
cell activity and sleep may be masked by within subject variability in cross-sectional 
studies.  Self-reported sleep duration over the past three nights was assessed at two time 
points.  In cross-sectional analyses, NK cell activity was associated with sleep duration 
the previous night for the second time point, but not the first.  Changes in NK cell activity  
were significantly associated with changes in sleep duration the previous night.  
Therefore some of the reported studies may be limited by their cross-sectional design.  
Table 4 presents a summary of the associations between immune parameters and self- 
reported sleep or experimental PSD. 
 In a study of  immune responses to influenza vaccination, Spiegel (2002)52 
compared 11 healthy men who were subjected to PSD to 14 control subjects.  Men in the 
experimental group were only allowed to sleep from 1-5AM over the first six nights.  The 
morning following the fourth night of PSD they were administered the influenza vaccine. 
After the initial six nights of PSD they were allowed to sleep 12 hours per night. Anti-
influenza IgG antibody titers were assessed before vaccination and at 10 days and 21 to 
30 days post vaccination.  At 10 days post vaccination mean antibody titers in the PSD 
group were significantly lower than the control group (p=0.03).  At 21 to 30 days there 
were no significant differences in antibody titer, indicating that antibody titers may 
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recover after sleep is restored.  This suggests that patients who are chronically sleep 
deprived may have poorer responses to influenza vaccination.  A similar study in 19 
healthy men and women found that one night TSD before administration of Hepatitis A 
vaccine was associated with (p=0.18) lower antibody titers up to 28 days post 
vaccination165. 
Sleep may have an impact on the Th1 to Th2 ratio.  In a study of one night TSD in 
14 healthy men, Dimitrov (2004)166 found that compared to wakefulness, sleep in the 
early part of the night shifted the Th1/Th2 ratio towards increased Th1 responses 
(measured by INF-γ/IL-4 ratio).  This ratio then shifted towards Th2 activity in the later 
part of the night.  None of the PSD or observational studies reported results for the 
Th1/Th2 ratio. 
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Table A.4.  Immune Parameters and Associations with Sleep. 
 
Immune parameter Study Design N 
Time 
frame Exposure Outcome 
P 
value Population 
Partial Sleep Deprivation Experimental  Studies 
IL-2                 
  
Con-A stimulated 
production Irwin 1996167 experimental 42 1 night 
PSD-E 
compared to 
baseline 
↓ compared to 
baseline p<0.01 healthy men 
IL-6                 
  IL-6 concentration Redwine 2000164 experimental 31 1 night 
PSD-E 
compared to 
baseline 
↓ IL-6 
compared to 
baseline p<0.05 healthy men 
  
stimulated 
production of IL-6 Irwin 2010168 experimental 26 1 night 
PSD-E 
compared to 
baseline 
↑ IL-6 
compared to 
baseline p<0.01 healthy adults 
TNF-α                 
  
stimulated 
production of TNF-
α Irwin 2010 experimental 26 1 night 
PSD-E 
compared to 
baseline 
↑ TNF-α 
compared to 
baseline p<0.01 healthy adults 
Total White blood cells                 
    Irwin 1996 experimental 42 1 night 
PSD-E 
compared to 
baseline 
No significant 
ass. p>0.05 healthy men 
Neutrophils                 
  number Irwin 1996 experimental 42 1 night 
PSD-E 
compared to 
baseline 
No significant 
ass. p>0.05 healthy men 
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  percent Irwin 1996 experimental 42 1 night 
PSD-E 
compared to 
baseline 
↓ compared to 
baseline p<0.01 healthy men 
Lymphocytes                 
  number Irwin 1996 experimental 42 1 night 
PSD-E compared 
to baseline 
↑ compared to 
baseline p<0.01 healthy men 
  percent Irwin 1996 experimental 42 1 night 
PSD-E compared 
to baseline 
↑ compared to 
baseline p<0.01 healthy men 
NK cells                 
  Number Irwin 1996 experimental 42 1 night 
PSD-E compared 
to baseline 
↓ compared to 
baseline p<0.01 healthy men 
    Irwin 2008169 experimental 14 1 night 
PSD-E compared 
to baseline No significant ass. p>0.05 
healthy men 
and women 
  Percentage Irwin 1996 experimental 42 1 night 
PSD-E compared 
to baseline 
↓ compared to 
baseline p<0.01 healthy men 
  NK cell activity Irwin 1996 experimental 42 1 night 
PSD-E compared 
to baseline 
↓ compared to 
baseline p<0.05 healthy men 
    Irwin 1994158 experimental 23 1 night 
PSD-L compared 
to baseline 
↓ compared to 
baseline p<0.01 healthy men 
Lymphokine-activated killer cell activity             
    Irwin 1996 experimental 42 1 night 
PSD-E compared 
to baseline 
↓ compared to 
baseline p<0.01 healthy men 
NF-κB activation                 
    Irwin 2008 experimental 14 1 night 
PSD-E compared 
to baseline 
↑ compared to 
baseline p<0.01 
healthy men 
and women 
CD3                 
    Irwin 2008 experimental 14 1 night 
PSD-E compared 
to baseline No significant ass. p>0.05 
healthy men 
and women 
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CD4                 
    Irwin 2008 experimental 
1
4 1 night 
PSD-E compared to 
baseline No significant ass. 
p>0.0
5 
healthy men and 
women 
CD8                 
    Irwin 2008 experimental 
1
4 1 night 
PSD-E compared to 
baseline No significant ass. 
p>0.0
5 
healthy men and 
women 
CD19                 
    Irwin 2008 experimental 
1
4 1 night 
PSD-E compared to 
baseline No significant ass. 
p>0.0
5 
healthy men and 
women 
CD14                 
    Irwin 2008 experimental 
1
4 1 night 
PSD-E compared to 
baseline No significant ass. 
p>0.0
5 
healthy men and 
women 
Observational Studies 
NK cells                 
  
Numbe
r 
Hall 
199837 
cross-
sectional 
2
9 
3 
nights 
Time awake in NREM-
1 
↑time awake ass. 
↓NKC 
p<0.0
5 
Depressed 
patients 
    Hall 1998 
cross-
sectional 
2
9 
3 
nights Sleep quality No significant ass. 
p>0.0
5 
Depressed 
patients 
    Hall 1998 
cross-
sectional 
2
9 
3 
nights sleep latency No significant ass. 
p>0.0
5 
Depressed 
patients 
    Hall 1998 
cross-
sectional 
2
9 
3 
nights REM latency No significant ass. 
p>0.0
5 
Depressed 
patients 
    Hall 1998 
cross-
sectional 
2
9 
3 
nights Total delta NREM-1 No significant ass. 
p>0.0
5 
Depressed 
patients 
    Hall 1998 
cross-
sectional 
2
9 
3 
nights sleep maintenance No significant ass. 
p>0.0
5 
Depressed 
patients 
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    Hall 1998 
cross-
sectional 
2
9 3 nights Total NREM 
No significant 
ass. 
p>0.0
5 
Depressed 
patients 
    Hall 1998 
cross-
sectional 
2
9 3 nights Total delta all night 
No significant 
ass. 
p>0.0
5 
Depressed 
patients 
  NKCA 
Irwin 
199235 
cross-
sectional 
2
3 
1 or 2 
nights Sleep latency 
No significant 
ass. 
p>0.0
5 
depressed 
patients 
    Irwin 1992 
cross-
sectional 
1
7 
1 or 2 
nights Sleep latency 
↑sleep lat. 
↓NKCA 
p<0.0
5 
community 
controls 
    Irwin 1992 
cross-
sectional 
2
3 
1 or 2 
nights Total sleep time 
↑sleep time 
↑NKCA 
p<0.0
1 
depressed 
patients 
    Irwin 1992 
cross-
sectional 
1
7 
1 or 2 
nights Total sleep time 
↑sleep time 
↑NKCA 
p<0.0
5 
community 
controls 
    Irwin 1992 
cross-
sectional 
2
3 
1 or 2 
nights Sleep efficiency 
↑sleep eff. 
↑NKCA 
p<0.0
5 
depressed 
patients 
    Irwin 1992 
cross-
sectional 
1
7 
1 or 2 
nights Sleep efficiency 
↑sleep eff. 
↑NKCA 
p<0.0
5 
community 
controls 
    
Shakhar 
200736 
cross-
sectional 
4
5 3 nights 
Self-reported sleep 
duration over past 3 
nights 
↑sleep time ass. 
↑NKCA (2nd 
time point, but 
not 1st) 
p<0.0
5 healthy women 
    
Shakhar 
2007 prospective 
4
5 1 months 
Self-reported sleep 
duration over past 3 
nights 
↑Δsleep time ass. 
↑ΔNKCA 
p<0.0
5 healthy women 
  
NK % 
lysis Hall 1998 
cross-
sectional 
2
9 3 nights 
Time awake in 
NREM-1 
No significant 
ass. 
p>0.0
5 
Depressed 
patients 
    Hall 1998 
cross-
sectional 
2
9 3 nights Sleep quality 
No significant 
ass. 
p>0.0
5 
Depressed 
patients 
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Table A.4 continued 
 
    Hall 1998 cross-sectional 29 3 nights sleep latency 
No 
significant 
ass. p>0.05 Depressed patients 
    Hall 1998 cross-sectional 29 3 nights REM latency 
No 
significant 
ass. p>0.05 Depressed patients 
    Hall 1998 cross-sectional 29 3 nights Total delta NREM-1 
No 
significant 
ass. p>0.05 Depressed patients 
    Hall 1998 cross-sectional 29 3 nights sleep maintenance 
No 
significant 
ass. p>0.05 Depressed patients 
    Hall 1998 cross-sectional 29 3 nights Total NREM 
No 
significant 
ass. p>0.05 Depressed patients 
    Hall 1998 cross-sectional 29 3 nights Total delta all night 
No 
significant 
ass. p>0.05 Depressed patients 
Occurrence of cold after experimental exposure             
  
Infection 
and illness 
Cohen 
199738 experimental 276 
past 
month Sleep efficacy 
sleep eff. 
≤0.80 ass. 
↑colds 
OR=2.8 
(1.2-4.8) 
healthy men and 
women 
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Table A.4 continued 
 
  
Infection 
and 
objective 
signs of 
illness Cohen 200939 experimental 153 
14 days 
prior to 
baseline Average sleep duration 
<7 hrs 
sleep ass. 
↑ colds 
compared 
to ≥8 hrs 
OR=2.9 
(1.2-7.3) 
healthy men and 
women 
  
Infection 
and 
objective 
signs of 
illness Cohen 2009 experimental 153 
14 days 
prior to 
baseline Sleep efficacy 
sleep eff. 
<0.92 ass. 
↑colds 
compared 
to >0.98 
OR=5.58 
(2.1-
14.5) 
healthy men and 
women 
Note: All tests of significance are of adjusted tests if reported. 
EEG (Electroencephalograph) 
PSD-E (Early night partial sleep deprivation - awake until 0300) 
PSD-L (Late night partial sleep deprivation - awake 0300 to 0700) 
Con A (Concanavalin-A) 
NF-κB (nuclear factor-κB - transcription control pathway of cellular expression of proinflammarotry genes 
NKCA (Natural killer cell activity) 
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 Poor sleep quality and sleep loss are common and the prevalence has been 
increasing162.  Like stress, acute sleep deprivation may actually increase immune 
responses, whereas if sleep loss becomes chronic it can negatively impact immune 
function153.  If chronic partial sleep loss does indeed affect immunity, the public health 
implications are vast, as this is the type of sleep alteration that prevails in modern society 
due to factors such as shift work, pressured lifestyles, and other stresses153.  Despite their 
limitations, these studies provide evidence that sleep can affect the immune system.  The 
effects of sleep deprivation on clinical outcomes requires further research154. 
Sleep and Cervical Cancer 
There are no published studies of sleep and cervical cancer.  One study examined 
sleep quality and depression on immunocompetence in women at risk for cervical cancer.  
Sleep satisfaction was significantly associated with the number and percentage of helper 
T cells and percentage of cytotoxic T cells, even after controlling for depression.3 
Sleep and Stress 
Results of several studies suggest that sleep and stress may interact.  Sleep 
measures have been shown to mediate the relationship between stress and number of NK 
cells37,170.  Among 57 HIV-positive patients, Impact of Events Scale (IES) scores (a 
measure of intrusive and avoidant thoughts) and PSQI scores were significantly 
associated with CD3+CD8+ cell counts.  In a path analysis of IES and PSQI scores, the 
direct association between IES and CD3+CD8+ was no longer significant.  PSQI scores 
remained significant, with 23% of the variance in CD3+CD8+ cells accounted for in the 
full model with IES and PSQI.   
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In a study of 29 patients seeking treatment for bereavement related depression, 
time awake during NREM sleep accounted for 12% of the variance in NK cell number 
while IES accounted for 7%.  When time spent awake during NREM sleep was entered 
into a regression model with IES scores, the association of intrusive thoughts and 
avoidant behaviors was no longer significant.  The small sample size may have limited 
the ability to detect significant effects for IES accounting for sleep37.  In a study of an 
acute laboratory stressor in 39 health women, NK cell mobilization was significantly 
reduced in women with a high amount of time awake after sleep onset171.  Therefore 
including a measure of sleep may be important in assessing the role of stress with regard 
to immune or clinical outcomes. 
Summary 
HPV causes genital warts and is associated with anogenital and oro-pharangeal 
cancers.  Most individuals will be infected with HPV at some point, but will mount an 
effective immune response and clear the infection.  Persistence of HPV infection is an 
important step in the pathway to neoplastic lesions and cancer.  Factors that influence 
persistence of HPV remain to be elucidated.  It is a common belief that high stress and 
sleep loss can cause an increased susceptibility to infection.  Stress and sleep have been 
associated with changes in immune response in many scientific studies.  Specifically, 
stress may induce a shift from a Th1 type immune response towards Th2 type immunity.  
A Th1 type response may be important in successful clearance of HPV.  If stress and 
sleep affect immunity this could have implications for the host's ability to successfully 
respond to an HPV infection.  Since the immune system protects against both infection 
and malignancies, behaviors such as increased stress and decreased sleep duration could 
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affect both the persistence of the HPV infection and the lesions resulting from a persistent 
HPV infection.  Identifying the relationship between stress, sleep and immunity is an 
important public health endeavor. 
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Appendix B. Parent Studies 
 
 
Data for this analysis was drawn from two parent studies conducted at the 
University of South Florida and Moffitt Cancer Center. 
The Natural History of HPV in Men Study 
 The Natural History of HPV in Men (HIM) Study is a prospective natural history 
study of HPV in men.  A convenience sample of over four thousand men ages 18 to 70 
were recruited from the Central Florida area, as well as Sao Paulo, Brazil and the state of 
Morelos, Mexico.  Eligibility criteria for inclusion in the study were: (a) aged 18-70 
years; (b) residents of one of the three sites - central Florida, US, Sao Paulo, Brazil, or 
Morelos, Mexico; (c) no self-reported prior diagnosis of penile or anal cancers;  (d) never 
diagnosed with genital or anal warts; e) have not participated in an HPV vaccine study; f) 
no self-reported prior diagnosis with AIDS or HIV; g) no reported current penile 
discharge or burning during urination; h) not currently being treated for an STI; i) have 
not been imprisoned or homeless during the last 6 months; j) have not been in drug 
treatment during the last 6 months; k) no plan to relocate in the next 4 years; and l) 
willingness to comply with 10 scheduled visits every six months for four years.  The 
proposed research will use data from men in the US cohort. 
Men in the US cohort were recruited from the University of South Florida 
(students, faculty, and staff) and the general population of the greater Tampa 
metropolitan area using multiple strategies including: face-to-face recruitment in 
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classrooms and workplace settings; publicity at mass events through Brochures and 
posters with tear off phone numbers; targeted mailings via e-mail and hard mail; radio 
and newspaper advertisements targeting men; word of mouth; and peer leaders of groups 
with a predominately male membership.  A total of 1,427 men were enrolled into the 
HIM study at the U.S. site. 
 The HIM study protocol includes a total of ten visits: a pre-enrollment run-in visit 
including informed consent, a baseline enrollment visit, and eight follow-up visits 
scheduled every 6 months.  At each visit a sexual history computer-assisted self interview 
(CASI) questionnaire is administered, a visual inspection of the skin and external 
genitalia is conducted, and blood and penile skin samples are collected.  Penile samples 
are collected to detect genital HPV. First, any warts or lesions on the penis are sampled 
by wetting a Dacron applicator with sterile normal saline, swabbing the penis, and 
placing the swab in buffered preservative solution designed to preserve DNA, RNA, and 
protein (Specimen Transport Medium - STM).  After sampling any warts or lesions, a 
new wet swab is used to sweep 360° around the coronal sulcus and then another 360° 
around the glans penis.  This swab is then placed into a separate collection vial with STM 
labeled by anatomic site.  Another wet swab is used to sample the entire skin surface of 
each of the four quadrants of the shaft of the penis (left and right ventral, and left and 
right dorsal) and placed into a vial of STM.  All HPV samples are stored in a –20oC 
freezer until transfer to the University of South Florida laboratory where they are stored 
at  –70 oC until PCR analyses and genotyping is performed.    
 Exfoliated penile cell samples are tested for HPV DNA using polymerase chain 
reaction (PCR) amplification of a fragment of the L1 gene.  To determine specimen 
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adequacy, GH20/PC04 human ß-globin target is co-amplified.  For every 20 samples a 
negative control (H2O) and a positive control (CaSki Cells) are run for accuracy and to 
control for possible contamination. One randomly re-sampled clinical sample is included 
for every 20 samples as a blinded quality control.  HPV genotyping is conducted on all 
samples regardless of results by PCR using the reverse line blot method.  The HPV 
genotype strip contains 40 probe lines, 37 for detecting individual HPV genotypes (6, 11, 
16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51 to 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 
81, 82, 83, 84, IS39, and CP6108) and two concentrations of the ß-globin control probe. 
(Roche Molecular Diagnostics, Alameda, CA). 
 There is no FDA approved test for HPV in men; HPV testing in this study is for 
research purposes only and is not available in regular clinical care.  At every study visit a 
nurse practitioner provides each participant general oral and written materials about 
HPV.  Materials explain that HPV can be sexually transmitted and is associated with 
certain cancers and genital warts.  Participants are told their HPV test results from the 
previous visit at each 6-month follow-up visit and are counseled on what the results mean 
by the nurse practitioner.  They are also reminded that the results are not FDA-approved 
for men and are for research purposes only.   
 Strategies to retain participants in the study for four years include: a pre-
enrollment run-in visit, updating contact information at each visit (phone numbers, e-mail 
addresses, mailing addresses), reminder calls and/or e-mails the day prior to scheduled 
appointments,  monetary compensation of $540 over the ten visits, empathetic and warm 
staff who can establish a rapport with participants to encourage disclosure of sexual 
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conduct and minimize embarrassment during the genital exam, and a retention specialist 
to identify participants who are lost to follow-up. 
The Cognitive and Emotional Responses to an HPV Test Result (CER) Study 
 The Cognitive and Emotional Responses (CER) Study is the behavioral arm of the 
larger HIM Study conducted in the US cohort of men.  This research assesses men’s 
cognitive and emotional responses to receiving an HPV test result.  After completing the 
third HIM visit, the first time they are given HPV test results, all HIM participants are 
invited to participate in the CER study.  After providing informed consent, men complete 
a CASI approximately two to four weeks after they receive their previous HPV test result 
through the HIM study (Figure 1).  At each of the four CER visits, participants complete 
the CER CASI questionnaire on a private computer workstation at the HIM study 
location.  This survey takes approximately 30 minutes to complete.  Instrument items 
assess a range of variables including HPV knowledge, attitudes and beliefs about HPV, 
sexual behavior, sexual partnership status, information-seeking behavior, preventative 
behaviors, emotional responses to receiving HPV test results, perceived threat of genital 
warts and cancers, and HPV vaccine intentions.  Participants are compensated with $130 
for completing four study visits.  The amount of compensation increases with each 
subsequent visit; $25, $30, $35 and $40 at visits 1 though 4, respectively.  A total of 565 
men were recruited into the CER study and completed the first study visit from March 
2007 to March 2010.  An estimated 489 participants will complete the second visit for a 
retention rate of 87% from the first visit to the second.   
 Because the CER study is an ongoing research study examining psychosocial 
factors in a cohort of men tested for HPV every six months, it provides an excellent 
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opportunity to gather data on psychosocial factors which may be associated with 
persistence of an HPV infection.   
Figure B.1. Timeline of HPV in Men (HIM) and Cognitive and Emotional Responses to 
an HPV Result (CER) Studies 
 
 
 
 
 
Associations of HPV and Stress and Sleep (HASS) Study 
 The proposed research will utilize a sub-sample of the CER cohort to examine the 
associations of HPV and stress and sleep (HASS).  Items concerning perceived stress and 
sleep were added to the CER CASI in June 2009, midway through participant 
recruitment.  There were 55 participants who completed their last CER survey prior to 
initiation of the stress and sleep items.  Other participants first received the additional 
items at their first, second, third, or forth CER visit.  Eligibility for inclusion into the 
HASS study will be (a) participants must have completed the stress and sleep items on 
the CER CASI at least one time and (b) participants must have completed the CER CASI 
within 45 days of their previous HIM study visit.  CER study visits which occur after 45 
days following a HIM study visit will be excluded because a longer time window will not 
measure the appropriate time for exposure.  Figure B.2 provides a diagram of the HIM, 
CER, and HASS study structure. 
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Figure B.2. Structure of the HIM, CER, and HASS Studies. 
  
 
  
  
 
     
 138 
 
 
 
 
 
Appendix C. Measures of Stress and Sleep 
 
 
On each CER survey (administered every 6 months), all participants are asked 
about their perceived stress and sleeping habits during the time since they last took the 
survey.  These additional questions were added in June 2009, about mid-way through 
participant recruitment.  Of the 565 men recruited into the CER study, 445 responded to 
the additional items at least one time.  Of the 445 who responded to the additional items, 
426 (96%) completed the survey within 45 days of their most recent HIM study visit.  
There are a total of 997 eligible visits among 426 CER participants. Of the 997 visits, 109 
26% of the men) had 1 eligible visit or approximately 6 months of follow-up, 120 (28%) 
had 2 eligible visits or 12 months of follow-up, 140 (33%) had 3 eligible visits or 18 
months of follow-up, and 57 (13%) had 4 eligible visits or approximately 2 years of 
follow-up time. 
Data from the baseline visit was used in the analysis of HPV prevalence (Aim 1).  
The persistence analysis (Aim 2) was limited to men who tested positive for HPV. There 
were a total of 500 infections among 222 men.  Among HPV positive men, perceived 
stress and sleep problems were compared between those who test negative (clearance) 
and those who continue to test positive for the same HPV type (persistence) at their next 
study visit.  It was hypothesized that perceived stress and sleep will have an impact on 
immune function and this will result in decreased clearance of HPV infection among 
participants with higher stress and sleep problems, Figure C.1.   
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Figure C.1. Hypothesized Interactions between Perceived Stress, Sleep, and HPV 
persistence. 
 
 
 
Stress 
Though there is no gold standard for assessing stress, however perceived stress 
has commonly been assessed by the Perceived Stress Scale developed by Cohen and 
Williamson (1998)16.  All three versions have been found to possess good psychometric 
qualities14, with the 4-item version having a reported reliability coefficient of 0.60117.  
Because the questions are general, the scale can be used in diverse populations114.  The 4-
item version has been suggested for studies where there is time constraints such as in the 
present study117.  These four questions can be completed in just a few minutes114.  
Therefore, this research study uses a modified version of the four-item PSS.  Because 
participants in the HIM study are assessed every 6 months, using the original time frame 
of one month will not measure stress during the entire period between visits and may not 
be predictive of health outcomes.  Therefore, the items in the PSS-4 were modified to 
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assess stress in the past six months as reported in a comparison study of the one month 
and 6 month PSS and a life events scale by Pbert et al. (1992)43.  The General PSQ 
developed by Levenstein et al. (1993)118 had a higher correlation with hospitalization and 
rectal inflammation than the Recent PSQ.  Thus, assessing stress in the past 6 months 
may be a better predictor of HPV status than stress experienced in the past month.  Table 
5 contains a list of the four questions added to the CER CASI. 
Sleep 
Due to time constraints, a very limited number of items could be used to assess 
sleep quality.  No existing sleep questionnaire was both brief and included at least one 
item to measure all aspects of sleep which may be relevant to this research.  The three-
item version of the JSPS, a brief reliable scale17, assess trouble falling asleep, trouble 
staying asleep, and waking up feeling tired.  This three-item scale was included in the 
added items.  However, this scale does not include items which assess the duration or 
quality of sleep.  The Pittsburgh Sleep Quality Index (PSQI) is a validated instrument that 
has been used extensively in the literature, however the entire 19-item scale is too long 
for inclusion in the CER survey156.   Of these19-items encompassing 7 domains44, 
subjective sleep quality and sleep duration, may be associated with immune status and are 
of interest for this research.  Therefore, these two items were included in the questions 
added to the CER survey.  The subjective sleep quality question asks participants to rate 
their sleep quality overall and has four responses ranging from very good to very bad.  
The sleep duration question asks participants how many hours and minutes of sleep they 
get at night.44,156   
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Alapin et al. (2000)157 showed that both the ability to concentrate during the day 
and sleep problem distress may be import aspects of sleep disturbance.  Alapin et al. 
(2000)114 did not report the item used to assess ability to concentrate.  The item used to 
assess distress asked, "How distressed are you by an insomnia problem?".  This question 
was modified as this survey will not be administered in a clinical population.  To assess 
these two aspects of sleep in the CER questionnaire, two four-point likert questions: 
“Does not sleeping affect your ability to concentrate or get things done during the day?” 
and “How bothered are you by your sleep problems?” were included. 
HPV Status 
This analysis will look at the prevalence of HPV in the entire cohort of men and 
subsequent detection of an HPV infection of the same type among participants testing 
positive for any of the 37 types of HPV included in the HIM study.  For HPV prevalence, 
men who are negative for all HPV types will be the comparison group in all analyses.  
HPV clearance will be defined as a negative HPV test result following a positive HPV-
test.  HPV persistence will be defined as HPV infection of the same type detected at two 
or more consecutive clinical visits.  Men will be followed from 6 to 24 months from the 
date of testing positive for HPV. Length of time followed will depend on date of entry 
into the study and date of HPV acquisition. 
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Appendix D. Stratification Brief 
 
 
Abstract 
 Human papillomavirus (HPV) is the most common sexually transmitted infection 
in the US and is associated with genital warts, ano-genital cancers, and oropharyngeal 
cancers. We previously reported associations between HPV prevalence with perceived 
stress and self-reported sleep problems among men. To further investigate these 
associations, we examined the relationships between these factors within subgroups of 
demographic factors. Generalized estimating equations using all 997 study visits among 
426 men were employed to calculate odds ratios (OR) and 95% confidence intervals 
(95% CI). Associations between perceived stress and HPV prevalence differed by age 
category and marital status. Among men aged 50 and older and single men, those with 
high stress were significantly more likely to be infected with oncogenic HPV compared 
to those with low stress, Adjusted OR (AOR)=3.66 (95% CI: 1.25-10.67) and AOR=2.03 
(95% CI: 1.29-3.22). Associations between self-reported sleep problems and HPV 
prevalence differed by age category, education, and marital status. Among men 30 to 49 
participants with low self-reported sleep problems were significantly more likely to be 
infected with any HPV type, AOR=2.34 (95% CI: 1.19-4.62), compared to men with 
moderate sleep problems. Among college educated men, participants with low sleep 
problems were more likely to be infected with any HPV, AOR=1.70 (95% CI: 1.06-2.73), 
and oncogenic HPV, AOR=1.74 (95% CI: 1.04-2.90) and men with high sleep problems 
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were significantly more likely to be infected with oncogenic HPV, AOR=2.44 (95% CI: 
1.32-4.50). Results suggest that associations between perceived stress and sleep problems 
may be moderated by demographic factors. 
Introduction 
 Infection with one or more of the 40 ano-genital types of human papillomavirus 
(HPV) is the most common sexually transmitted infection (STI) in the US 1. A review of 
HPV prevalence in men 172 found that estimates of prevalence ranged from 26% to 65% 
in North American populations. Infection with oncogenic HPV types is associated with 
cervical intraepithelial neoplasia and cervical cancer in women. These types have also 
been associated with other ano-genital cancers, such as penile, anal, and vulvar cancer, as 
well as a portion of oropharyngeal cancers. Infection with non-oncogenic types is 
associated with condylomata (genital warts) 173. 
In a previous publication, we reported associations between perceived stress and self-
reported sleep problems among a sample of men tested for HPV at the baseline study 
visit. In this cross-section study, men with high perceived stress were significantly more 
likely to be infected with any HPV type and any oncogenic HPV type compared to men 
with low perceived stress. Men with high self-reported sleep problems were significantly 
more likely to be infected with any oncogenic HPV type compared to men with moderate 
sleep problems. To further investigate relationships between perceived stress, self-
reported sleep problems, HPV prevalence, and demographic factors, stratified analyses 
were conducted utilizing all study visits.  
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Methods 
Participants 
 Details of this study can be found in Kolar et al. (2013). In brief, men are tested 
for 37 individual HPV genotypes every 6 months as part of a large natural history study 
of HPV in men (the HIM Study) conducted in the US, Mexico, and Brazil 41. A subset of 
these men participating in the US cohort were invited to participate in a behavioral study 
(the CER study) which collected additional behavioral and psychosocial information on 
HIM Study participants 42. 
Men participating in the HIM study were invited to participate in the CER at their third 
HIM study visit. CER study participants completed the additional questionnaire 
approximately 2 to 4 weeks after each 6-month HIM study visit. CER participants 
completed the survey 4 times over 2 years. Midway through CER study recruitment, 
items to assess perceived stress and self-reported sleep problems were added to the 
survey. Men who completed these additional items within 45 days of their corresponding 
HIM study visit were eligible for inclusion in the present analysis. 
Measures 
 
 The 4-item Perceived Stress Scale 16 was modified to assess perceived stress in 
the past 6 months. We previously found that men in the highest quartile of stress scores 
had a higher prevalence of HPV and dichotomized stress as high (highest 25% of stress 
scale scores) and low (lower 75% of stress scale scores.  
 Self-reported sleep problems were assessed with 7 items including the three-item 
version of the Jenkins sleep problems scale (JSPS) which assessed trouble falling asleep, 
trouble staying asleep, and waking up feeling tired 17 and 4 additional items which 
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assessed sleep duration, subjective sleep quality, daytime functioning, and sleep distress. 
All response options were on a 4-point likert scale. Self-reported sleep problems were 
categorized as low (lower 25% of sleep scale scores), moderate (middle 50%), and high 
(top 25%). Men in the moderate category were the reference category because they had 
the lowest prevalence of HPV. 
 Men were considered positive for 'Any HPV' if they tested positive for any of the 
37 HPV genotypes in the study protocol. Men were considered positive for 'Oncogenic 
HPV' if they tested positive for any oncogenic HPV type (regardless of also testing 
positive for a non-oncogenic HPV type) and positive for 'Non-oncogenic HPV' if they 
only tested positive for one or more non-oncogenic HPV genotypes. Men PCR negative 
for the 37 types and men who were only positive for unclassified HPV types were the 
reference group in this analysis.  
Statistical Analysis 
 Population-averaged generalized estimating equation models with an 
autoregressive correlation structure were employed to include all eligible visits 69,174. This 
method allows for the correlation between repeated measures of each subject to be taken 
into account. Analyses were conducted within each category of demographic factors that 
had significant interaction terms with perceived stress and self-reported sleep problems in 
multivariable models. Univariate and adjusted odds ratios (AOR) and 95% confidence 
intervals (95% CI) are reported. The proc genmod procedure in SAS version 9.3 (Cary, 
NC) was used to conduct analyses. 
 Multivariable analyses for perceived stress were adjusted for age, health insurance 
status, education, marital status, and number of vaginal sex partners in the past six 
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months. Multivariable analyses for self-reported sleep problems were adjusted for age, 
health insurance status, education, marital status, lifetime number of sex partners, 
smoking status, and alcohol consumption. We did not further adjust models for both 
perceived stress and self-reported sleep problems because in our previous analysis of 
these factors with HPV prevalence adjustment for the second exposure did not affect 
estimates. The majority of men were white (68%) and were circumcised as determined by 
a HIM study physician (79%). These factors were not significantly associated with HPV 
prevalence in this sample of men, therefore they were not included in multivariable 
models. 
Results 
 
 A total of 997 visits among 426 men were eligible for analysis. Of these visits, 
HPV genotyping was available for 995. Greater than 99% (992) of visit surveys had all 
stress items completed and 98% (974) had all sleep problems items completed. 
Perceived Stress and HPV Prevalence 
 Perceived stress was significantly associated with oncogenic HPV infection in the 
total sample (table D.1), AOR=1.48 (95% CI: 1.06-2.07). Interactions with perceived 
stress were significant for age category and marital status. Among men aged 50 and 
older, those with high stress were significantly more likely to be infected with oncogenic 
HPV, AOR=3.66 (95% CI: 1.25-10.67). Among men 18 to 29 and 30 to 49, differences in 
HPV prevalence were smaller and were not statistically significant. Among men who 
were single, those with high stress were significantly more likely to be infected with 
oncogenic HPV, AOR=2.03 (95% CI: 1.29-3.22).  
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Self-reported Sleep Problems and HPV Prevalence 
 Self-reported sleep problems was associated with infection of any HPV type and 
oncogenic HPV in the total sample, although differences were only significant among 
men with low self-reported sleep problems compared to men with moderate sleep 
problems (table D.2), any HPV AOR=1.42 (95% CI: 1.04-1.94) and oncogenic HPV 
AOR=1.48 (95% CI: 1.08-2.05). Interactions with self-reported sleep problems were 
significant for age category, education, and marital status. Due to small numbers, we 
were unable to estimated adjusted odds ratios for all categories of these demographic 
variables. Among men 30 to 49, men with low self-reported sleep problems were 
significantly more likely to be infected with any HPV type, AOR=2.34 (95% CI: 1.19-
4.62). Differences among men with low sleep problems were significant in univariate 
analysis for non-oncogenic HPV among men 30 to 49, OR=.31 (1.22-4.39), and for any 
HPV type among men 50 and older, OR=2.09 (1.01-4.32). Among men with a college 
degree (2-year, 4-year, or graduate), those with low sleep problems were more likely to 
be infected with any HPV type, AOR=1.70 (95% CI: 1.06-2.73), and oncogenic HPV, 
AOR=1.74 (95% CI: 1.04-2.90) and men with high sleep problems were significantly 
more likely to be infected with oncogenic HPV, AOR=2.44 (95% CI: 1.32-4.50), 
compared to men with moderate sleep problems. Among married men, those with low 
self-reported sleep problems were more likely to be infected with any HPV type, 
OR=2.05 (95% CI: 1.06-3.97) and non-oncogenic HPV, OR=2.25 (95% CI: 1.10-4.59), 
in univariate analyses. 
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Discussion 
 
 This analysis found evidence for effect modification in the relationship between 
HPV prevalence with perceived stress and self-reported sleep problems. Estimates of the 
association between stress and HPV prevalence were higher among men who were older 
or single and estimates of the association between sleep problems and HPV prevalence 
were higher among men who were older, were college educated, or were married.  
 Immune function declines with age and it has been hypothesized that stress may 
result in greater immunological changes among older individuals 64. In a study comparing 
immune response to influenza vaccination among caregivers and controls, Kiecolt-Glaser 
et al. (1996)65 found that differences in antibody titers were greater among participants 
>70 years old. Among men 50 and older in this study, the estimate of the association 
between perceived stress and oncogenic HPV prevalence was higher than for younger 
men. Estimates of the association between self-reported sleep problems with any HPV 
and non-oncogenic HPV were higher for men 30 to 49 and men 50 and older. However, 
the small number of men over 50 in this sample limits the ability to examine the effects 
of older age on perceived stress and self-reported sleep problems with HPV prevalence. 
 There are several limitations other to the present analysis. This was a sample of 
men who were mostly white and were participating in a longitudinal study of HPV 
infection in men, therefore the sample may not be representative of all men with HPV or 
of women with HPV. Measures of stress, sleep problems, and demographic 
characteristics were all self-reported by study participants and information on specific 
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immune parameters, biological indicators of stress, and drug/medication use was not 
available for inclusion into the analysis. 
 This analysis adds to our previous report of the association between perceived 
stress and self-reported sleep problems with HPV prevalence. In this analysis, perceived 
stress was only associated with oncogenic HPV, which are the types of HPV associated 
with cancers of the ano-genital and aerodigestive tracts. Self-reported sleep problems was 
associated with oncogenic and non-oncogenic HPV types. Odds ratios were higher for 
men 50 and older for both perceived stress and sleep problems. These differences by 
demographic factors may be important aspects to consider in future research to ensure 
adequate sample sizes.  
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Table D.1. Odds Ratios comparing prevalence of any HPV Infection, oncogenic HPV infection, and non-oncogenic HPV infection 
among participants with high perceived stress to participants with low perceived stress stratified by demographics and sexual 
behavior. 
 
      Any HPV Type   Any Oncogenic HPV Type   Any Non-oncogenic HPV Type   
      Univariate Multivariablea   Univariate Multivariablea   Univariate Multivariablea   
Perceived stress OR (95% CI) OR (95% CI)   OR (95% CI) OR (95% CI)   OR (95% CI) OR (95% CI)   
Total sample                               
    Low 1.00   1.00     1.00   1.00     1.00   1.00     
    High 1.33 (0.96-1.84) 1.40 (0.99-1.98)   1.40 (1.02-1.93) 1.48 (1.06-2.07)   1.17 (0.80-1.72) 1.14 (0.78-1.68)   
Age                               
  18 to 29                               
    Low 1.00   1.00     1.00   1.00     1.00   1.00     
    High 1.03 (0.70-1.51) 1.06 (0.71-1.57)   1.17 (0.77-1.77) 1.38 (0.88-2.18)   1.06 (0.61-1.84) NE     
  30 to 49                               
    Low 1.00   1.00     1.00   1.00     1.00   1.00     
    High 1.26 (0.76-2.09) 1.26 (0.74-2.16)   1.37 (0.73-2.58) 1.41 (0.73-2.75)   1.21 (0.64-2.28) 1.19 (0.60-2.34)   
  ≥50                               
    Low 1.00   1.00     1.00   1.00     1.00   1.00     
    High 1.74 (0.73-4.14) 1.82 (0.64-5.13)   2.48 (1.03-5.96) 3.66 (1.25-10.67)   1.13 (0.43-3.01) 1.11 (0.36-3.45)   
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Table D.1 continued 
 
Marital Status                               
  Unmarried, Single                               
    Low 1.00   1.00     1.00   1.00     1.00   1.00     
    High 1.38 (0.90-2.11) 1.48 (0.96-2.27)   1.73 (1.11-2.71) 2.03 (1.29-3.22)   1.26 (0.70-2.25) 1.23 (0.68-2.21)   
  Unmarried, living with partner                           
    Low 1.00   1.00     1.00   1.00     1.00   1.00     
    High 0.95 (0.41-2.17) 1.11 (0.41-3.01)   0.56 (0.17-1.81) 0.52 (0.14-1.88)   1.78 (0.63-5.06) 1.55 (0.42-5.70)   
  Married                               
    Low 1.00   1.00     1.00   1.00     1.00   1.00     
    High 0.84 (0.47-1.49) 0.86 (0.45-1.64)   0.81 (0.42-1.56) 0.84 (0.31-2.26)   0.95 (0.49-1.86) 1.00 (0.48-2.08)   
  Separated/ Divorced, widowed                           
    Low 1.00   1.00     1.00   1.00     1.00   1.00     
    High 1.81 (0.95-3.44) 1.76 (1.05-2.93)   1.79 (0.80-4.02) 1.99 (0.96-4.12)   1.40 (0.76-2.57) NE     
aMultivariable model adjusted for age, insurance, education, marital status, number of vaginal sex partners in the past 6 months, and prevalence of HPV infection 
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Table D.2. Odds Ratios comparing prevalence of any HPV Infection, oncogenic HPV infection, and non-oncogenic HPV infection 
among participants with low and high sleep problems compared to those with moderate sleep problems stratified by demographics and 
sexual behavior. 
 
      Any HPV Type   Any Oncogenic HPV Type   Any Non-oncogenic HPV Type   
      Univariate Multivariablea   Univariate Multivariablea   Univariate Multivariablea   
Sleep problems OR (95% CI) OR (95% CI)   OR (95% CI) OR (95% CI)   OR (95% CI) OR (95% CI)   
Total sample                               
    Low 1.29 (0.99-1.68) 1.42 (1.04-1.94)   1.36 (1.04-1.78) 1.48 (1.08-2.05)   1.22 (0.86-1.72) 1.36 (0.89-2.06)   
    Moderate 1.00   1.00     1.00   1.00     1.00   1.00     
    High 1.14 (0.85-1.54) 0.97 (0.69-1.37)   1.37 (0.97-1.94) 1.20 (0.80-1.80)   0.98 (0.65-1.47) 0.82 (0.52-1.29)   
Age                               
  18 to 29                               
    Low 1.01 (0.72-1.41) 1.02 (0.66-1.56)   1.21 (0.87-1.68) 1.11 (0.71-1.75)   0.82 (0.51-1.32) NE     
    Moderate 1.00   1.00     1.00   1.00     1.00         
    High 0.92 (0.61-1.38) 0.71 (0.45-1.10)   1.05 (0.69-1.60) 0.84 (0.49-1.42)   0.86 (0.47-1.56) NE     
  30 to 49                               
    Low 2.00 (1.14-3.51) 2.34 (1.19-4.62)   1.60 (0.91-2.80) 1.67 (0.87-3.18)   2.31 (1.22-4.39) NE     
    Moderate 1.00   1.00     1.00   1.00     1.00         
    High 1.43 (0.77-2.65) 1.48 (0.69-3.17)   1.89 (0.85-4.18) 2.00 (0.72-5.60)   1.11 (0.51-2.41) NE     
  ≥50                               
    Low 2.09 (1.01-4.32) NE     2.28 (0.90-5.77) NE     1.68 (0.74-3.81) NE     
    Moderate 1.00         1.00         1.00         
    High 1.62 (0.81-3.22) NE     1.97 (0.85-4.59) NE     1.12 (0.49-2.56) NE     
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Table D.2 continued 
 
Education                               
  HS Diploma/GED or less                           
    Low 1.48 (0.70-3.16) NE     1.35 (0.53-3.46) NE     1.49 (0.67-3.32) NE     
    Moderate 1.00         1.00         1.00         
    High 1.50 (0.69-3.27) NE     1.12 (0.48-2.60) NE     1.41 (0.52-3.81) NE     
  Some college, no degree                           
    Low 1.11 (0.74-1.65) 1.10 (0.68-1.77)   1.16 (0.76-1.77) 1.12 (0.65-1.93)   1.10 (0.62-1.96) 1.32 (0.69-2.52)   
    Moderate 1.00   1.00     1.00   1.00     1.00   1.00     
    High 0.95 (0.60-1.50) 0.67 (0.41-1.11)   1.04 (0.61-1.75) 0.83 (0.46-1.52)   0.95 (0.47-1.95) 0.59 (0.22-1.55)   
  2-yr/4-yr/Graduate degree                           
    Low 1.57 (1.05-2.35) 1.70 (1.06-2.73)   1.50 (1.01-2.23) 1.74 (1.04-2.90)   1.39 (0.86-2.26) NE     
    Moderate 1.00   1.00     1.00   1.00     1.00         
    High 1.31 (0.82-2.10) 1.39 (0.81-2.41)   2.03 (1.16-3.58) 2.44 (1.32-4.50)   0.91 (0.50-1.66) NE     
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Table D.2 continued 
 
Marital Status                               
  Unmarried, Single                               
    Low 1.20 (0.86-1.69) 1.21 (0.80-1.82)   1.44 (1.07-1.94) 1.40 (0.97-2.02)   0.90 (0.54-1.49) 0.89 (0.48-1.65)   
    Moderate 1.00   1.00     1.00   1.00     1.00   1.00     
    High 1.09 (0.70-1.71) 0.88 (0.54-1.42)   1.30 (0.81-2.07) 1.08 (0.63-1.86)   1.02 (0.53-1.95) 0.86 (0.41-1.80)   
  Unmarried, living with a partner                           
    Low 0.83 (0.36-1.93) 1.23 (0.35-4.25)   0.73 (0.28-1.90) 0.47 (0.10-2.20)   0.70 (0.23-2.09) 1.14 (0.29-4.49)   
    Moderate 1.00   1.00     1.00   1.00     1.00   1.00     
    High 1.48 (0.59-3.74) 1.39 (0.39-4.96)   0.88 (0.34-2.29) 0.32 (0.06-2.06)   1.61 (0.46-5.70) 1.15 (0.15-8.66)   
  Married                               
    Low 2.05 (1.06-3.97) NE     1.57 (0.74-3.32) NE     2.25 (1.10-4.59) NE     
    Moderate 1.00         1.00         1.00         
    High 0.79 (0.39-1.61) NE     1.68 (0.77-3.67) NE     0.43 (0.18-1.03) NE     
  Separated/ Divorced, widowed                           
    Low 1.49 (0.73-3.01) NE     1.45 (0.55-3.82) NE     1.84 (0.79-4.24) NE     
    Moderate 1.00         1.00         1.00         
    High 1.49 (0.72-3.08) NE     1.39 (0.53-3.38) NE     1.87 (0.68-5.14) NE     
aMultivariable model adjusted for age, insurance, education, marital status, smoking status, alcohol consumption, lifetime number of sex partners, and prevalence 
of HPV infection 
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Appendix E. Additional Tables 
 
 
 Tables E.1 and E.2 present the continuous perceived stress and self-reported sleep 
problems scale scores by demographics and sexual behaviors. 
 
Table E.1. Stress and Sleep Scale Scores by Demographic Factors. 
     Stress Scale Sleep Scale 
    N mean (std) p-value N mean (std) p-value 
Marital Status     0.11     0.20 
  Single 249 4.7 (2.6)   246 7.2 (3.8)   
  Unmarried, living with a partner 51 4.9 (2.9)   50 6.9 (4.3)   
  Married 75 4.4 (2.6)   72 7.8 (4.9)   
  Separated/divorced/widowed 49 5.6 (3.1)   48 8.8 (4.9)   
Education     <0.01     0.07 
  HS Diploma/GED or less 49 5.7 (2.3)   45 7.9 (4.7)   
  Some college, no degree 195 4.6 (2.9)   191 6.9 (4.1)   
  2-yr/4-yr/Graduate degree 181 4.7 (2.7)   181 7.9 (4.3)   
Age     0.59     0.11 
  18 to 20 93 4.3 (2.4)   93 6.4 (3.0)   
  21 to 22 81 4.6 (2.6)   80 7.3 (3.7)   
  23 to 31 94 4.9 (2.7)   93 7.2 (4.1)   
  32 to 49 99 5.0 (3.0)   96 8.6 (5.0)   
  ≥50 58 5.0 (3.1)   55 7.8 (5.3)   
Health insurance     0.78     0.72 
  No 108 4.9 (3.0)   107 7.5 (4.7)   
  Yes 312 4.7 (2.7)   305 7.5 (4.1)   
Race     0.58     <0.01 
  Non-white 138 4.8 (2.8)   133 6.8 (4.7)   
  White 287 4.7 (2.7)   284 7.7 (4.0)   
Ethnicity     0.85     0.91 
  Non-Hispanic 346 4.7 (2.8)   337 7.4 (4.3)   
  Hispanic 74 4.7 (2.5)   75 7.3 (3.8)   
Main sex partner     0.42     0.70 
  No 169 4.8 (2.9)   166 7.6 (4.2)   
  Yes 250 4.6 (2.6)   246 7.4 (4.3)   
Physician determined circumcision     0.90     0.14 
  No 90 4.7 (2.8)   90 6.8 (3.9)   
  Yes 328 4.8 (2.7)   320 7.7 (4.4)   
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Table E.1 continued 
 
Alcohol     0.23     0.03 
  No alcohol 76 4.7 (2.6)   70 6.4 (3.9)   
  ≤1 drink per day 172 4.9 (2.7)   170 7.4 (4.6)   
  >1 drink per day 164 4.5 (2.8)   163 7.9 (4.1)   
Smoking status     0.03     <0.01 
  Never 243 4.5 (2.7)   238 6.9 (4.1)   
  Former 94 4.8 (2.6)   94 8.1 (3.8)   
  Current 87 5.3 (2.8)   84 8.2 (4.9)   
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Table E.2. Stress and Sleep Scale Scores by Sexual Behavior Factors. 
 
     Stress Scale Sleep Scale 
    N mean (std) p-value N mean (std) p-value 
Age at first sexual intercourse     0.18     0.13 
  ≤15 101 4.8 (2.8)   99 8.1 (4.7)   
  16-17 141 4.4 (2.7)   140 7.0 (3.8)   
  18-19 94 5.1 (2.8)   92 7.9 (4.4)   
  ≥20 51 4.3 (2.8)   50 6.7 (4.2)   
Lifetime number of sex partners     0.48     <0.01 
  0 22 5.2 (2.1)   21 5.7 (3.9)   
  1-3 100 4.7 (2.5)   100 6.9 (4.0)   
  4-9 97 4.6 (2.8)   96 7.0 (3.8)   
  10-20 101 4.5 (2.5)   100 7.5 (4.2)   
  ≥21 88 5.0 (3.3)   84 9.2 (4.9)   
  Decline to answer 17 5.5 (2.5)   16 6.1 (3.4)   
Any sex past 6 months     0.11     0.94 
  No 100 5.0 (2.6)   97 7.6 (4.6)   
  Yes 323 4.7 (2.8)   318 7.4 (4.2)   
Vaginal sex past 6 months     0.08     0.87 
  No 120 5.0 (2.6)   116 7.6 (4.4)   
  Yes 304 4.6 (2.8)   300 7.4 (4.2)   
Performed oral sex past 6 months     0.08     0.47 
  No 167 5.0 (2.9)   161 7.3 (4.3)   
  Yes 254 4.6 (2.7)   252 7.6 (4.3)   
Received oral sex past 6 months     0.22     0.61 
  No 134 4.9 (2.9)   130 7.3 (4.5)   
  Yes 276 4.6 (2.7)   274 7.5 (4.1)   
Insertive anal sex past 6 months     0.20     0.14 
  No 366 4.8 (2.8)   358 7.6 (4.3)   
  Yes 51 4.3 (2.4)   51 6.6 (4.1)   
Number of female sex partner past 6 months   0.47     0.77 
  0 120 4.9 (2.6)   115 7.6 (4.5)   
  1 193 4.8 (2.9)   190 7.2 (4.3)   
  ≥2 103 4.5 (2.6)   103 7.6 (4.1)   
Condom use during vaginal sex past 6 months   0.81     0.70 
  Never 115 4.7 (2.8)   113 7.8 (4.7)   
  < 1/2 time, 1/2 time, > 1/2 time 124 4.7 (2.5)   125 7.1 (3.8)   
  Always 68 4.6 (3.2)   65 7.3 (4.0)   
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 For the baseline prevalence analysis PRs were calculated comparing quartiles of 
perceived stress and sleep problems. Results did not differ from the categorized analysis. 
 
Table E.3. Associations between quartiles of perceived stress and sleep problems with 
prevalence of any HPV type, any oncogenic HPV type, and any non-oncogenic HPV 
type. 
   
    Any HPV Type 
    Univariate Multivariable 1 Multivariable 2   
    PR (95% CI) PR (95% CI) PR (95% CI)   
Perceived Stress Score Quartiles         
  1st 1.00 1.00 1.00   
  2nd 1.09 (0.80-1.49) 1.08 (0.80-1.46) 1.11 (0.82-1.50)   
  3rd 0.92 (0.65-1.29) 0.94 (0.67-1.32) 0.96 (0.68-1.35)   
  4th 1.32 (0.98-1.79) 1.38 (1.03-1.86) 1.37 (1.01-1.87)   
Self-reported Sleep Problems quartiles       
  1st 1.30 (0.94-1.81) 1.37 (1.01-1.86) 1.36 (1.01-1.84)   
  2nd 1.00 1.00 1.00   
  3rd 1.12 (0.79-1.58) 1.16 (0.84-1.58) 1.13 (0.83-1.55)   
  4th 1.49 (1.08-2.06) 1.31 (0.97-1.77) 1.25 (0.91-1.70)   
    Any Oncogenic HPV Type 
    Univariate Multivariable 1 Multivariable 2   
    PR (95% CI) PR (95% CI) PR (95% CI)   
Perceived Stress Score Quartiles         
  1st 1.00 1.00 1.00   
  2nd 0.98 (0.61-1.55) 0.96 (0.61-1.50) 1.00 (0.62-1.60)   
  3rd 0.74 (0.44-1.25) 0.69 (0.40-1.18) 0.72 (0.42-1.24)   
  4th 1.31 (0.84-2.05) 1.40 (0.90-2.19) 1.38 (0.84-2.26)   
Self-reported Sleep Problems quartiles       
  1st 1.45 (0.87-2.44) 1.66 (1.02-2.70) 1.66 (1.02-2.70)   
  2nd 1.00 1.00 1.00   
  3rd 1.00 (0.57-1.77) 1.16 (0.68-1.97) 1.11 (0.65-1.89)   
  4th 1.89 (1.16-3.09) 1.73 (1.07-2.79) 1.58 (0.97-2.59)   
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Table E.3 continued 
 
    Any Non-oncogenic HPV Type 
    Univariate Multivariable 1 Multivariable 2   
    PR (95% CI) PR (95% CI) PR (95% CI)   
Perceived Stress Score Quartiles         
  1st 1.00 1.00 1.00   
  2nd 1.34 (0.78-2.32) 1.31 (0.78-2.19) 1.33 (0.80-2.22)   
  3rd 1.14 (0.64-2.02) 1.18 (0.67-2.06) 1.2 (0.68-2.10)   
  4th 1.64 (0.95-2.84) 1.65 (0.98-2.79) 1.66 (0.97-2.84)   
Self-reported Sleep Problems quartiles       
  1st 1.35 (0.79-2.29) 1.34 (0.81-2.20) 1.31 (0.80-2.16)   
  2nd 1.00 1.00 1.00   
  3rd 1.29 (0.76-2.17) 1.25 (0.77-2.01) 1.22 (0.76-1.97)   
  4th 1.43 (0.83-2.46) 1.08 (0.64-1.83) 1.01 (0.59-1.75)   
aMultivariable 1 model adjusted for age, insurance, education, marital status, and number 
of vaginal sex partners in the past 6 months, Multivariable 2 model additionally adjusted 
for sleep category 
bMultivariable 1 model adjusted for age, insurance, education, marital status, smoking 
status, alcohol consumption and lifetime number of sex partners, Multivariable 2 model 
additionally adjusted for perceived stress category 
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 An additional table of perceived stress by category of sleep problems and sleep problems by category of perceived stress was 
also calculated for the baseline prevalence analysis. 
 
Table E.4. Unadjusted Odds Ratios comparing prevalence of any HPV Infection, oncogenic HPV infection, and non-oncogenic HPV 
infection among participants with high perceived stress to participants with low perceived stress stratified by age category and sexual 
behavior. 
 
    Any HPV   Oncogenic HPV   Non-Oncogenic HPV 
    Perceived   Univariate   Multivariate   Perceived Univariate   Perceived   Univariate 
    Stress N PR (95% CI)   PR (95% CI)   Stress PR (95% CI)   Stress   PR (95% CI) 
Sleep Category                                 
  Low Low   1.00   1.00   Low 1.00   Low   1.00 
    High   1.15 (0.67-1.98)   1.36 (0.79-2.36)   High 1.01 (0.38-2.70)   High   1.42 (0.61-3.31) 
  Moderate Low   1.00   1.00   Low 1.00   Low   1.00 
    High   1.32 (0.91-1.90)   1.45 (1.003-2.10)   High 1.43 (0.75-2.70)   High   1.41 (0.80-2.46) 
  High Low   1.00   1.00   Low 1.00   Low   1.00 
    High   1.24 (0.87-1.76)   1.23 (0.86-1.76)   High 1.32 (0.79-2.21)   High   1.36 (0.68-2.74) 
    Sleep   Univariate         Sleep Univariate   Sleep   Univariate 
        PR (95% CI)           PR (95% CI)       PR (95% CI) 
Perceived Stress Category                               
  Low Low   1.26 (0.94-1.69)   1.32 (1.004-1.72)   Low 1.56 (0.99-2.47)   Low   1.15 (0.72-1.85) 
    Moderate   1.00   1.00   Moderate 1.00   Moderate   1.00 
    High   1.35 (0.97-1.87)   1.25 (0.93-1.67)   High 1.79 (1.09-2.96)   High   1.15 (0.65-2.06) 
  High Low   1.10 (0.61-2.00)   0.97 (0.60-1.56)   Low 1.11 (0.38-3.25)   Low   1.16 (0.47-2.85) 
    Moderate   1.00   1.00   Moderate 1.00   Moderate   1.00 
    High   1.27 (0.86-1.88)   1.07 (0.62-1.84)   High 1.67 (0.87-3.18)   High   1.12 (0.57-2.21) 
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 Full tables of stress and sleep stratified by all variables included in multivariable models for the gee prevalence analysis were 
also created. 
 
Table E.5. Odds Ratios comparing prevalence of any HPV Infection, oncogenic HPV infection, and non-oncogenic HPV infection 
among participants with high perceived stress to participants with low perceived stress stratified by demographics and sexual 
behavior. 
 
      Any HPV Type   Any Oncogenic HPV Type   Any Non-oncogenic HPV Type   
      Univariate Multivariablea   Univariate Multivariablea   Univariate Multivariablea   
Perceived stress OR (95% CI) OR (95% CI)   OR (95% CI) OR (95% CI)   OR (95% CI) OR (95% CI)   
Total sample                               
    Low 1.00   1.00     1.00   1.00     1.00   1.00     
    High 1.33 (0.96-1.84) 1.40 (0.99-1.98)   1.40 (1.02-1.93) 1.48 (1.06-2.07)   1.17 (0.80-1.72) 1.14 (0.78-1.68)   
Ageb                               
  18 to 29                               
    Low 1.00   1.00     1.00   1.00     1.00   1.00     
    High 1.03 (0.70-1.51) 1.06 (0.71-1.57)   1.17 (0.77-1.77) 1.38 (0.88-2.18)   1.06 (0.61-1.84) NE     
  30 to 49                               
    Low 1.00   1.00     1.00   1.00     1.00   1.00     
    High 1.26 (0.76-2.09) 1.26 (0.74-2.16)   1.37 (0.73-2.58) 1.41 (0.73-2.75)   1.21 (0.64-2.28) 1.19 (0.60-2.34)   
  ≥50                               
    Low 1.00   1.00     1.00   1.00     1.00   1.00     
    High 1.74 (0.73-4.14) 1.82 (0.64-5.13)   2.48 (1.03-5.96) 3.66 (1.25-10.67)   1.13 (0.43-3.01) 1.11 (0.36-3.45)   
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Table E.5 continued 
 
Education                               
  HS Diploma/GED or less                             
    Low 1.00   1.00     1.00   1.00     1.00   1.00     
    High 1.54 (0.61-3.90) 1.42 (0.50-4.04)   1.46 (0.47-4.50) 1.20 (0.34-4.25)   1.28 (0.41-3.99) 1.08 (0.27-4.28)   
  Some college, no degree                             
    Low 1.00   1.00     1.00   1.00     1.00   1.00     
    High 0.91 (0.63-1.33) 0.90 (0.60-1.36)   1.18 (0.74-1.87) 1.26 (0.74-2.13)   0.77 (0.44-1.34) 0.72 (0.41-1.29)   
  2-yr/4-yr/Graduate degree                             
    Low 1.00   1.00     1.00   1.00     1.00   1.00     
    High 1.55 (0.97-2.47) 1.66 (1.03-2.67)   1.44 (0.99-2.08) 1.60 (1.01-2.52)   1.73 (0.96-3.13) 1.70 (0.94-3.09)   
Health insurance                               
  No                               
    Low 1.00   1.00     1.00   1.00     1.00   1.00     
    High 1.20 (0.64-2.24) 1.28 (0.66-2.50)   1.45 (0.66-3.23) 2.03 (0.87-4.74)   1.00 (0.49-2.05) 0.98 (0.47-2.04)   
  Yes                               
    Low 1.00   1.00     1.00   1.00     1.00   1.00     
    High 1.30 (0.96-1.76) 1.32 (0.97-1.81)   1.42 (1.01-1.99) 1.51 (1.05-2.17)   1.25 (0.83-1.89) 1.22 (0.81-1.86)   
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Table E.5 continued 
 
Marital Statusb                               
  Unmarried, Single                               
    Low 1.00   1.00     1.00   1.00     1.00   1.00     
    High 1.38 (0.90-2.11) 1.48 (0.96-2.27)   1.73 (1.11-2.71) 2.03 (1.29-3.22)   1.26 (0.70-2.25) 1.23 (0.68-2.21)   
  Unmarried, living with partner                           
    Low 1.00   1.00     1.00   1.00     1.00   1.00     
    High 0.95 (0.41-2.17) 1.11 (0.41-3.01)   0.56 (0.17-1.81) 0.52 (0.14-1.88)   1.78 (0.63-5.06) 1.55 (0.42-5.70)   
  Married                               
    Low 1.00   1.00     1.00   1.00     1.00   1.00     
    High 0.84 (0.47-1.49) 0.86 (0.45-1.64)   0.81 (0.42-1.56) 0.84 (0.31-2.26)   0.95 (0.49-1.86) 1.00 (0.48-2.08)   
  Separated/ Divorced, widowed                           
    Low 1.00   1.00     1.00   1.00     1.00   1.00     
    High 1.81 (0.95-3.44) 1.76 (1.05-2.93)   1.79 (0.80-4.02) 1.99 (0.96-4.12)   1.40 (0.76-2.57) NE     
Number of vaginal sex partners in the past 6 months                       
  0                               
    Low 1.00   1.00     1.00   1.00     1.00   1.00     
    High 1.67 (0.92-3.03) 1.48 (0.77-2.83)   1.99 (1.06-3.73) 1.98 (0.98-4.01)   1.60 (0.71-3.60) 1.08 (0.44-2.65)   
  1                               
    Low 1.00   1.00     1.00   1.00     1.00   1.00     
    High 1.15 (0.81-1.65) 1.12 (0.76-1.64)   1.45 (0.94-2.22) 1.44 (0.91-2.27)   1.07 (0.69-1.66) 0.99 (0.63-1.56)   
  ≥2                               
    Low 1.00   1.00     1.00   1.00     1.00   1.00     
    High 1.63 (0.81-3.27) 1.71 (0.85-3.45)   1.49 (0.74-3.01) 1.55 (0.76-3.18)   2.00 (0.83-4.81) 2.17 (0.4-5.62)   
aMultivariable model adjusted for age, insurance, education, marital status, smoking status, alcohol consumption, lifetime number of sex partners, and prevalence of HPV infection 
bInteraction with stress significant in multivariable model for any HPV, oncogenic HPV, or non-oncogenic HPV model 
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Table E.6. Odds Ratios comparing prevalence of any HPV Infection, oncogenic HPV infection, and non-oncogenic HPV infection 
among participants with low and high sleep problems compared to those with moderate sleep problems stratified by demographics and 
sexual behavior. 
 
      Any HPV Type   Any Oncogenic HPV Type   Any Non-oncogenic HPV Type   
      Univariate Multivariablea   Univariate Multivariablea   Univariate Multivariablea   
Sleep problems OR (95% CI) OR (95% CI)   OR (95% CI) OR (95% CI)   OR (95% CI) OR (95% CI)   
Total sample                               
    Low 1.29 (0.99-1.68) 1.42 (1.04-1.94)   1.36 (1.04-1.78) 1.48 (1.08-2.05)   1.22 (0.86-1.72) 1.36 (0.89-2.06)   
    Moderate 1.00   1.00     1.00   1.00     1.00   1.00     
    High 1.14 (0.85-1.54) 0.97 (0.69-1.37)   1.37 (0.97-1.94) 1.20 (0.80-1.80)   0.98 (0.65-1.47) 0.82 (0.52-1.29)   
Ageb                               
  18 to 29                               
    Low 1.01 (0.72-1.41) 1.02 (0.66-1.56)   1.21 (0.87-1.68) 1.11 (0.71-1.75)   0.82 (0.51-1.32) NE     
    Moderate 1.00   1.00     1.00   1.00     1.00         
    High 0.92 (0.61-1.38) 0.71 (0.45-1.10)   1.05 (0.69-1.60) 0.84 (0.49-1.42)   0.86 (0.47-1.56) NE     
  30 to 49                               
    Low 2.00 (1.14-3.51) 2.34 (1.19-4.62)   1.60 (0.91-2.80) 1.67 (0.87-3.18)   2.31 (1.22-4.39) NE     
    Moderate 1.00   1.00     1.00   1.00     1.00         
    High 1.43 (0.77-2.65) 1.48 (0.69-3.17)   1.89 (0.85-4.18) 2.00 (0.72-5.60)   1.11 (0.51-2.41) NE     
  ≥50                               
    Low 2.09 (1.01-4.32) NE     2.28 (0.90-5.77) NE     1.68 (0.74-3.81) NE     
    Moderate 1.00         1.00         1.00         
    High 1.62 (0.81-3.22) NE     1.97 (0.85-4.59) NE     1.12 (0.49-2.56) NE     
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Table E.6 continued 
 
Educationb                               
  HS Diploma/GED or less                             
    Low 1.48 (0.70-3.16) NE     1.35 (0.53-3.46) NE     1.49 (0.67-3.32) NE     
    Moderate 1.00         1.00         1.00         
    High 1.50 (0.69-3.27) NE     1.12 (0.48-2.60) NE     1.41 (0.52-3.81) NE     
  Some college, no degree                             
    Low 1.11 (0.74-1.65) 1.10 (0.68-1.77)   1.16 (0.76-1.77) 1.12 (0.65-1.93)   1.10 (0.62-1.96) 1.32 (0.69-2.52)   
    Moderate 1.00   1.00     1.00   1.00     1.00   1.00     
    High 0.95 (0.60-1.50) 0.67 (0.41-1.11)   1.04 (0.61-1.75) 0.83 (0.46-1.52)   0.95 (0.47-1.95) 0.59 (0.22-1.55)   
  2-yr/4-yr/Graduate degree                           
    Low 1.57 (1.05-2.35) 1.70 (1.06-2.73)   1.50 (1.01-2.23) 1.74 (1.04-2.90)   1.39 (0.86-2.26) NE     
    Moderate 1.00   1.00     1.00   1.00     1.00         
    High 1.31 (0.82-2.10) 1.39 (0.81-2.41)   2.03 (1.16-3.58) 2.44 (1.32-4.50)   0.91 (0.50-1.66) NE     
Health insurance                               
  No                               
    Low 1.69 (0.97-2.94) 1.88 (0.87-4.05)   1.43 (0.79-2.61) 1.56 (0.67-3.61)   1.70 (0.89-3.25) NE     
    Moderate 1.00   1.00     1.00   1.00     1.00         
    High 1.59 (0.91-2.78) 1.13 (0.54-2.34)   1.47 (0.70-3.09) 1.11 (0.42-2.97)   1.24 (0.64-2.40) NE     
  Yes                               
    Low 1.07 (0.79-1.46) 1.19 (0.83-1.71)   1.17 (0.87-1.58) 1.30 (0.90-1.89(   1.05 (0.67-1.64) 1.13 (0.67-1.91)   
    Moderate 1.00   1.00     1.00   1.00     1.00   1.00     
    High 1.01 (0.70-1.46) 0.89 (0.59-1.34)   1.33 (0.90-1.95) 1.27 (0.81-1.97)   0.87 (0.50-1.53) 0.74 (0.40-1.38)   
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Table E.6 continued 
 
Marital Statusb                               
  Unmarried, Single                               
    Low 1.20 (0.86-1.69) 1.21 (0.80-1.82)   1.44 (1.07-1.94) 1.40 (0.97-2.02)   0.90 (0.54-1.49) 0.89 (0.48-1.65)   
    Moderate 1.00   1.00     1.00   1.00     1.00   1.00     
    High 1.09 (0.70-1.71) 0.88 (0.54-1.42)   1.30 (0.81-2.07) 1.08 (0.63-1.86)   1.02 (0.53-1.95) 0.86 (0.41-1.80)   
  Unmarried, living with a partner                           
    Low 0.83 (0.36-1.93) 1.23 (0.35-4.25)   0.73 (0.28-1.90) 0.47 (0.10-2.20)   0.70 (0.23-2.09) 1.14 (0.29-4.49)   
    Moderate 1.00   1.00     1.00   1.00     1.00   1.00     
    High 1.48 (0.59-3.74) 1.39 (0.39-4.96)   0.88 (0.34-2.29) 0.32 (0.06-2.06)   1.61 (0.46-5.70) 1.15 (0.15-8.66)   
  Married                               
    Low 2.05 (1.06-3.97) NE     1.57 (0.74-3.32) NE     2.25 (1.10-4.59) NE     
    Moderate 1.00         1.00         1.00         
    High 0.79 (0.39-1.61) NE     1.68 (0.77-3.67) NE     0.43 (0.18-1.03) NE     
  Separated/ Divorced, widowed                           
    Low 1.49 (0.73-3.01) NE     1.45 (0.55-3.82) NE     1.84 (0.79-4.24) NE     
    Moderate 1.00         1.00         1.00         
    High 1.49 (0.72-3.08) NE     1.39 (0.53-3.38) NE     1.87 (0.68-5.14) NE     
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Table E.6 continued 
 
Lifetime number of sex partners                           
0                               
    Low 3.65 (0.58-22.94) NE     NE   NE     1.92 (0.10-38.17) NE     
    Moderate 1.00                   1.00         
    High 3.94 (0.30-52.20) NE     NE   NE     9.31 (0.39-223.47) NE     
  1 to 3                               
    Low 1.01 (0.49-2.10) NE     2.02 (0.74-5.56) NE     NE   NE     
    Moderate 1.00         1.00                   
    High 0.13 (0.01-1.32) NE     0.53 (0.08-3.56) NE     NE   NE     
  4 to 9                               
    Low 1.09 (0.64-1.85) 1.10 (0.61-1.97)   1.08 (0.63-1.86) NE     1.02 (0.46-2.28) NE     
    Moderate 1.00   1.00     1.00         1.00         
    High 1.02 (0.58-1.81) 1.10 (0.65-1.84)   1.09 (0.57-2.08) NE     1.37 (0.56-3.40) NE     
  10 to 20                               
    Low 1.18 (0.66-2.09) 1.26 (0.68-2.34)   1.15 (0.66-1.98) 1.22 (0.68-2.20)   1.31 (0.64-2.69) 1.23 (0.55-2.77)   
    Moderate 1.00   1.00     1.00   1.00     1.00   1.00     
    High 1.20 (0.68-2.12) 1.18 (0.62-2.22)   1.33 (0.69-2.57) 1.44 (0.74-2.79)   0.83 (0.44-1.57) 0.60 (0.27-1.33)   
  ≥21                               
    Low 2.31 (1.01-5.31) 2.03 (0.80-5.16)   1.78 (0.79-4.00) 1.22 (0.52-2.86)   2.46 (0.87-6.94) 2.45 (0.78-7.72)   
    Moderate 1.00   1.00     1.00   1.00     1.00   1.00     
    High 0.94 (0.50-1.78) 0.88 (0.44-1.74)   1.08 (0.52-2.26) 0.90 (0.39-2.09)   0.83 (0.36-1.92) 0.96 (0.41-2.22)   
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Table E.6 continued 
 
Smoking status                               
  Never                               
    Low 1.29 (0.90-1.85) 1.39 (0.91-2.13)   1.46 (1.02-2.09) 1.61 (1.03-2.51)   1.07 (0.69-1.68) NE     
    Moderate 1.00   1.00     1.00   1.00     1.00         
    High 1.11 (0.71-1.73) 1.00 (0.61-1.65)   1.44 (0.85-2.43) 1.34 (0.72-2.47)   0.83 (0.49-1.39) NE     
  Former                               
    Low 1.14 (0.65-2.02) 1.03 (0.54-1.97)   1.05 (0.55-2.01) 0.97 (0.45-2.07)   1.27 (0.59-2.77) NE     
    Moderate 1.00   1.00     1.00   1.00     1.00         
    High 1.10 (0.60-2.00) 0.87 (0.44-1.71)   1.17 (0.61-2.26) 1.42 (0.67-3.02)   1.00 (0.39-2.52) NE     
  Current                               
    Low 1.65 (0.77-3.56) NE     1.53 (0.71-3.32) NE     1.81 (0.72-4.57) NE     
    Moderate 1.00         1.00         1.00         
    High 1.28 (0.69-2.37) NE     1.42 (0.66-3.09) NE     1.15 (0.53-2.47) NE     
Alcohol                               
  No alcohol                               
    Low 0.85 (0.47-1.55) NE     0.77 (0.51-1.19) NE     0.91 (0.39-2.10) NE     
    Moderate 1.00         1.00         1.00         
    High 1.24 (0.81-1.91) NE     1.28 (0.78-2.09) NE     1.20 (0.67-2.18) NE     
  ≤1 drink per day                               
    Low 1.23 (0.81-1.88) 1.14 (0.71-1.82)   1.38 (0.88-2.17) NE     1.05 (0.66-1.66) 0.91 (0.47-1.77)   
    Moderate 1.00   1.00     1.00         1.00   1.00     
    High 1.24 (0.80-1.93) 0.91 (0.52-1.58)   1.49 (0.86-2.59) NE     1.01 (0.61-1.66) 0.66 (0.34-1.27)   
  >1 drink per day                               
    Low 1.51 (0.94-2.43) 2.05 (1.19-3.52)   1.55 (0.90-2.69) 2.13 (1.14-3.96)   1.43 (0.77-2.66) NE     
    Moderate 1.00   1.00     1.00   1.00     1.00         
    High 0.96 (0.56-1.63) 0.94 (0.51-1.72)   1.25 (0.68-2.30) 1.25 (0.64-2.43)   0.69 (0.32-1.50) NE     
aMultivariable model adjusted for age, insurance, education, marital status, smoking status, alcohol consumption, lifetime number of sex partners, and prevalence of HPV infection 
bInteraction with stress significant in multivariable model for any HPV, oncogenic HPV, or non-oncogenic HPV model 
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 Associations between self-reported sleep problems were further examined by 
categorizing sleep problems the same as perceived stress with the top 25% as high and 
the bottom 75% as low. Results were similar when 3 categories are used, although only 
multivariable model 2 for any HPV type and any oncogenic HPV type was significant. 
 
Table E.7. Associations between HPV clearance and self-reported sleep problems 
categorized as high and low. 
 
    Univariate Multivariable 1 Multivariable 2 
    HR (95% CI) HR (95% CI) HR (95% CI) 
Any HPV type 
Sleep problemsb             
  Low 1.00   1.00   1.00   
  High 0.84 (0.63-1.10) 0.78 (0.57-1.06) 0.68 (0.50-0.93) 
Any Oncogenic HPV type 
Sleep problemsb             
  Low 1.00   1.00   1.00   
  High 0.95 (0.75-1.22) 0.65 (0.40-1.05) 0.56 (0.32-0.99) 
Any Non-oncogenic HPV type 
Sleep problemsb             
  Low 1.00   1.00   1.00   
  High 0.91 (0.64-1.30) 0.87 (0.60-1.27) 0.75 (0.49-1.15) 
aMultivariable 1 model adjusted for age, insurance, education, marital status, number of 
vaginal sex partners in the past 6 months, and prevalence of HPV infection, Multivariable 
2 model additionally adjusted for sleep category 
bMultivariable 1 model adjusted for age, insurance, education, marital status, smoking 
status, alcohol consumption, lifetime number of sex partners, and prevalence of HPV 
infection, Multivariable 2 model additionally adjusted for perceived stress category 
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 Associations between perceived stress and self-reported sleep problems with 
incidence of HPV infection are presented below. Per infection incidence was analyzed, 
therefore men can contribute multiple infections to the analysis. 
Table E.8 . Associations between perceived stress and self-reported sleep problems with 
incidence of any HPV type, any oncogenic HPV type, and any non-oncogenic HPV type 
among men tested for HPV every 6 months. 
 
Any HPV Type (n=336) 
    Univariate Multivariable 1 Multivariable 2 
    HR (95% CI) HR (95% CI) HR (95% CI) 
Perceived Stressa             
  Low 1.00   1.00   1.00   
  High 0.95 (0.68-1.33) 1.01 (0.72-1.41) 1.02 (0.74-1.42) 
Sleep problemsb           
  Low 0.97 (0.67-1.39) 0.96 (0.67-1.36) 0.96 (0.67-1.38) 
  Moderate 1.00   1.00   1.00   
  High 0.85 (0.57-1.28) 0.75 (0.49-1.16) 0.74 (0.49-1.13) 
Oncogenic HPV (n=156) 
    Univariate Multivariable 1 Multivariable 2 
    HR (95% CI) HR (95% CI) HR (95% CI) 
Perceived Stressa             
  Low 1.00   1.00   1.00   
  High 0.86 (0.56-1.34) 0.97 (0.62-1.50) 0.90 (0.57-1.43) 
Sleep problemsb           
  Low 0.91 (0.57-1.46) 0.80 (0.49-1.31) 0.81 (0.49-1.32) 
  Moderate 1.00   1.00   1.00   
  High 1.07 (0.66-1.72) 0.90 (0.55-1.46) 0.91 (0.56-1.47) 
Non-oncogenic HPV (n=180) 
    Univariate Multivariable 1 Multivariable 2 
    HR (95% CI) HR (95% CI) HR (95% CI) 
Perceived Stressa             
  Low 1.00   1.00   1.00   
  High 1.01 (0.69-1.49) 1.04 (0.71-1.53) 1.11 (0.76-1.62) 
Sleep problemsb           
  Low 1.01 (0.65-1.56) 1.05 (0.70-1.59) 1.05 (0.69-1.61) 
  Moderate 1.00   1.00   1.00   
  High 0.71 (0.45-1.13) 0.65 (0.39-1.07) 0.63 (0.39-1.02) 
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Table E.8 continued 
 
aMultivariable 1 model adjusted for age, insurance, education, marital status, number of 
vaginal sex partners in the past 6 months, and prevalence of HPV infection, Multivariable 
2 model additionally adjusted for sleep category 
bMultivariable 1 model adjusted for age, insurance, education, marital status, smoking 
status, alcohol consumption, lifetime number of sex partners, and prevalence of HPV 
infection, Multivariable 2 model additionally adjusted for perceived stress category 
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Table E.9. Associations of categorized sleep duration with HPV prevalence in the total sample and HPV clearance among HPV-positive men. 
 
 
Any HPV Type Any Oncogenic HPV Type Any Non-oncogenic HPV Type 
GEE Analysis 
    Univariate Multivariablea   Univariate Multivariablea   Univariate Multivariablea 
    OR (95% CI) OR (95% CI)   OR (95% CI) OR (95% CI)   OR (95% CI) OR (95% CI) 
Sleep time category                           
  Less than 5 hours 1.35 (0.72-2.55) 1.31 (0.65-2.64)   1.49 (0.66-3.34) 1.09 (0.48-2.49)   1.31 (0.61-2.80) 1.06 (0.45-2.53) 
  5 to 6 hours 0.97 (0.63-1.50) 1.53 (0.998-2.35)   0.95 (0.56-1.62) 0.82 (0.47-1.45)   0.98 (0.58-1.67) 0.78 (0.42-1.46) 
  6 to 7 hours 1.31 (0.99-1.71) 1.23 (0.76-2.00)   1.24 (0.91-1.68) 1.18 (0.81-1.70)   1.40 (0.98-2.01) 1.31 (0.87-1.96) 
  7 to 9 hours 1.00   1.00     1.00   1.00     1.00   1.00   
  9 or more hours 1.28 (0.70-2.33) 1.40 (0.66-3.00)   1.10 (0.58-2.10) 0.96 (0.49-1.91)   1.34 (0.63-2.88) 1.04 (0.42-2.54) 
Clearance Analysis 
    Univariate Multivariable   Univariate Multivariable   Univariate Multivariable 
    HR (95% CI) HR (95% CI)   HR (95% CI) HR (95% CI)   HR (95% CI) HR (95% CI) 
Sleep time category                           
  Less than 5 hours 0.95 (0.48-1.89) 1.03 (0.50-2.10)   0.92 (0.23-3.71) 1.31 (0.25-6.90)   0.92 (0.42-2.01) 0.84 ((0.39-1.80) 
  5 to 6 hours 0.88 (0.54-1.42) 0.84 (0.51-1.38)   1.06 (0.60-1.88) 1.18 (0.62-2.26)   0.77 (0.41-1.44) 0.65 (0.36-1.16) 
  6 to 7 hours 0.93 (0.69-1.27) 0.79 (0.57-1.09)   1.18 (0.79-1.76) 1.40 (0.88-2.23)   0.79 (0.54-1.16) 0.49 (0.32-0.75) 
  7 to 9 hours 1.00   1.00     1.00   1.00     1.00   1.00   
  9 or more hours 0.83 (0.49-1.41) 0.76 (0.43-1.36)   1.20 (0.63-2.28)_ 1.12 (0.45-2.78)   0.60 (0.28-1.29) 0.42 (0.19-0.95) 
aMultivariable model adjusted for age, insurance, education, marital status, smoking status, alcohol consumption, lifetime number of sex partners, and prevalence 
of HPV infection. 
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